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Abstract 
This thesis explores abnormalities in the multiple sclerosis (MS) spinal cord and 
their relationship with physical disability through the use of conventional and 
quantitative magnetic resonance imaging (MRI). 
Firstly, an hypothesis was tested that spinal cord atrophy would be associated 
with disability, independently from brain atrophy and lesion load, in long disease 
duration MS. The results presented confirm that cord atrophy is significantly 
associated with higher levels of physical disability after more than twenty years 
of MS. 
Following this observation, the next experiment investigated whether a 
combination of an active surface model (ASM) and high resolution axial images, 
would provide a more reproducible measure of spinal cord cross-sectional area; 
compared to previously described methodologies. The results presented show 
the superior reproducibility of the ASM combined with axial images for the 
measurement of cord area in MS, which may be of relevance to future clinical 
trials utilising cord atrophy as an outcome measure. 
The pathology of MS in the spinal cord was also explored in several ways using 
MRI. Firstly, spinal cord lesion morphology was studied, to investigate whether 
focal lesions, that traversed two or more spinal cord columns and involved the 
grey matter, would be associated with progressive MS. The results presented 
confirm this association and also that diffuse abnormalities are more frequently 
seen in progressive disease. 
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Secondly, spinal cord lesion load was measured quantitatively on axial images, to 
investigate if this measure would be associated with disability independently 
from cord atrophy. The functional importance of focal lesions in MS is 
highlighted by demonstrating an independent association between lesion load 
and disability. 
Thirdly, magnetisation transfer ratio (MTR) measures of the outer spinal cord 
were obtained, in an area expected to contain the pia mater and subpial tissue, to 
investigate whether outer cord abnormalities could be seen in MS compared to 
healthy controls and if such abnormalities would be associated with cord 
atrophy. The results presented show that significant decreases in MTR occur in 
the outer cord early in the disease course, prior to the development of cord 
atrophy and further decreases in MTR were seen in progressive MS. 
Furthermore, an independent association is presented between outer cord MTR 
and cord atrophy, suggesting that spinal cord meningeal inflammation may be 
associated with axonal loss in MS. 
Lastly, diffusion tensor imaging was used in the spinal cord grey matter, in order 
to investigate whether microstructural abnormalities in this structure would be 
associated with physical disability. The results of this study identified an 
association between grey matter radial diffusivity and disability, independently 
from cord atrophy, suggesting a significant contribution of spinal cord grey 
matter pathology to clinical dysfunction. 
In summary, this thesis shows that MS spinal cord abnormalities may be 
visualised and quantified using high field MRI, and are significantly associated 
with disability. The observations presented may of relevance to future MRI 
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studies and clinical trials in MS that aim to understand and potentially prevent 
the pathological processes underlying irreversible physical disability. 
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Chapter 1- The spinal cord and multiple sclerosis 
1.1 The spinal cord 
1.1.1 External structure 
The spinal cord (medulla spinalis) extends from the medulla oblongata to the 
conus medullaris. It extends from cranial border of the atlas to the second 
lumbar vertebra, although the caudal termination of the cord is variable (Jit et al. 
1959). Three layers cover the cord: dura, arachnoid and pia, with the 
cerebrospinal fluid (CSF) contained in the subarachnoid space. The width of the 
spinal cord depends on the level with enlargements at the cervical and lumbar 
levels corresponding to the spinal nerves innervating the limbs.  
The anterior surface of the spinal cord is marked by the anterior median fissure, 
which contains perforating blood vessels and dorsally by the posterior median 
and lateral sulci. The white substance contained between the two posterior sulci 
is known as the posterior funiculus. The region between the posterolateral 
sulcus and the anterior median fissure is the anterolateral funiculus. Inferiorly 
the filum teminale descends to leave the subarachoid space and extends to the 
tip of the coccyx. 
Along the length of the cord are paired dorsal and ventral roots of spinal nerves, 
which join in the vertebral foramena to form a spinal nerve. Caudally the spinal 
nerve roots form a bundle known as the cauda equina. 
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1.1.2 Internal structure 
The spinal cord is divided in cross sections into laminae which contain grey and 
white matter, with the grey matter forming a central ‘H’ shaped arrangement, 
surrounded by the white matter (Schoenen 1973). The white matter is divided 
into anterior, posterior and lateral columns connected by a central commissure, 
which contains the central canal. The grey matter contains nerve cells supplying 
the limbs. The white matter is coloured by myelin, which coats the nerve fibres. 
The white matter contains the ascending and descending tracts of the spinal cord.  
The descending tracts include: corticospinal, vestibulospinal, tectospinal, 
olivospinal, reticulospinal and rubrospinal (Williams 1980). The ascending tracts 
include: spinothalamic, dorsal columns and spinocerebellar tracts. Cajal first 
described the histology of spinal cord motor neurons (Cajal 1908), using Golgi 
silver stains.  
1.1.3 Physiology 
The cell bodies of motor neurons that innervate the muscles, that are located in 
the grey matter in longitudinal columns, and receive both afferent and efferent 
input. The most important tract for movement and motor control is the 
corticospinal tract, originating in the precentral gyrus of the frontal lobe. This 
tract is also known as the pyramidal tract, as the fibres cross at the medulla they 
are said to form pyramids. 
Injury to the spinal cord may result in sphincter and sensory dysfunction, and 
spastic paraplegia associated with injury to the corticospinal tract. 
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Many different conditions can result in spinal cord injury including, trauma, 
tumours and multiple sclerosis (MS). 
 
1.2 Multiple sclerosis 
The name multiple sclerosis (MS) is due to the pathological appearance of white 
matter lesions in the CNS that become sclerotic as they age. MS is potentially the 
most common cause of neurological disability in young adults (Compston and 
Coles 2002); it is thought to be the result of infiltration of the central nervous 
system (CNS) by inflammatory cells in a genetically predisposed individual due 
to an unknown environmental antigen (Compston and Coles 2008). The result of 
inflammation of the CNS is a host of neurological symptoms and signs ranging 
from cognitive impairment to paraplegia depending on the site affected by the 
disease. 
The result of migration of inflammatory cells into the CNS is dysfunction of the 
oligodendrocytes as well as activation of other inflammatory cells. The 
oligodendrocyte is responsible for myelination or coating the axons in the CNS, 
allowing saltatory conduction to occur along the length of the axon. It is 
estimated that each oligodendrocyte myelinates 30 to 50 axons (Compston et al., 
2006). In MS demyelination occurs, resulting in impaired conduction along the 
axon; this may be manifested as slowing of conduction (where conduction is still 
possible through sodium channels being distributed along the axonal 
membrane) or conduction block. Demyelinated axons are susceptible to a rise in 
temperature (e.g. Uhtoff’s phenomenon) and positive phenomena (e.g. tonic 
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spasms) can also result from transmission between neighbouring axons 
(Compston and Coles 2002).  
The symptoms and signs produced by demyelination often become apparent 
when a clinically eloquent site, such as the spinal cord, is involved. The 
involvement of the spinal cord can result in weakness, spasms, stiffness, bladder 
dysfunction, sexual dysfunction, paraplegia, constipation and sensory 
dysfunction. 
 
1.2.1 Natural history 
MS affects women twice as commonly as it does men and has a lifetime risk of 
one in 400 in the UK (Compston and Coles 2002). MS typically presents between 
the ages of 20 and 40, as a relapsing remitting condition (RRMS), where a relapse 
is defined as ‘the rapid appearance of new symptoms or the sudden worsening of 
old symptoms, lasting longer than 24 hours and occurring at least one month 
after the preceding relapse’ (Confavreux et al., 1980). RRMS is the initial course 
in about 85% of patients (Compston and Coles. 2002); the remaining 15% have a 
slowly progressive onset of symptoms and disability and is known as primary 
progressive MS. The main clinically recognised forms of the disease have been 
defined by a National Multiple Sclerosis Society of the USA Advisory Committee 
(Lublin and Reingold 1996): Relapsing remitting MS (RRMS), secondary 
progressive MS (SPMS), primary progressive MS (PPMS) and progressive 
relapsing MS (PRMS). 
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These definitions have recently been modified (Lublin et al., 2014), with the 
inclusion of two new disease courses: clinically isolated syndrome (CIS) and 
radiologically isolated syndrome (RIS), which is an incidental imaging finding 
suggestive of demyelination without a corresponding history or physical 
examination findings typical for MS. The PRMS disease subtype has also been 
redefined in the modified criteria as PPMS with accompanying disease activity. 
RRMS as described consists of relapses with a course exhibiting partial or 
complete recovery from the relapse-acquired deficit. About two-thirds to four-
fifths of cases of RRMS will at some time enter a secondary progressive phase 
(Weinshenker et al., 1989), which consists of a gradual and progressive increase 
in symptoms and disability, with or without occasional relapses, but without a 
significant reversal of the underlying disability. The mean age of onset of RRMS 
is about 30 years and there is a 2:1 female to male predominance. 
This differs from PPMS where the mean age of onset is about 40 years and equal 
numbers of males and females are affected. PPMS is often described as a ‘chronic 
progressive myelopathy’, since spinal cord involvement, with walking 
impairment, is the predominant manifestation in 80% of cases. Typically it 
progresses to quadriparesis with autonomic dysfunction and a substantially 
worse prognosis than RRMS (Noseworthy et al., 2000), although the course of 
SPMS (once established) and PPMS are quite similar in their evolution. PRMS 
differs slightly from PPMS, where although there is progressive disease from 
onset, there are also superimposed relapses, with or without full recovery. PRMS 
is less common than PPMS. 
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As RRMS is the most common subtype it has been extensively studied in natural 
history studies of MS. Initial symptoms in RRMS consist of: optic neuritis, 
sensory symptoms, motor deficit of acute or insidious onset, diploplia, vertigo or 
balance difficulty (Weinshenker et al., 1989). Confavreux et al. estimated from a 
natural history study that the annual relapse frequency is approximately one per 
year (Confavreux et al., 1980). It was found that more than half of the RRMS 
cases in this study were severely disabled within fifteen years. The percentage of 
patients who convert to a progressive form increases steadily with duration of 
disease.  
Given the potential for intervention during the RRMS phase, studies have also 
focused on what factors determine long-term disability following the initial 
phase, as there is a disparity between the suppression of relapses and 
accumulation of disability in clinical trials in MS (Beutler et al., 1996; Coles et al., 
1999). Being able to predict the course from an early stage would also be 
invaluable in counselling patients. Factors that influence disease outcome 
including frequency of relapses in first two years, interval between relapses and 
interval between first and second relapse were assessed longitudinally by 
Weinshenker et al. (1989(2)). It was found that the median interval between first 
and second relapse was two years in an untreated population. High numbers of 
relapses in the first two years following onset of MS correlated with long-term 
disability. This study was then extended to 28 years of follow up (Scalfari et al., 
2010), where the effect of relapses was revaluated. It was found that 80% of 
patients developed SPMS with a median time to progression of 15 years. There 
was also found to be a variable interval between the first and second relapse, and 
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patients who had frequent relapses in the first two years were found to be more 
likely to develop SPMS. A longer interval correlated with a lower probability of 
developing SPMS. The frequency and the interval of relapses were both found to 
be important factors in the first two years of the disease. However over the 
course of the disease the overall number of relapses and location of relapse do 
not appear to correlate with progression to SPMS (Kremenchtzky et al., 2006).  
Given the apparent importance of relapse frequency in the initial phase of the 
disease and its effect on long-term outcomes investigators have looked at what 
are possible reasons for an increase in relapse frequency. As MS has a female 
predominance (Compston et al., 2002) the effect of pregnancy on the course of 
MS has been assessed in the Pregnancy in Multiple Sclerosis (PRIMS) study 
(Confavreux et al., 1998). The investigators studied 254 pregnant women with 
MS and found no increased risk of relapse with breast-feeding or epidural. The 
relapse rate was affected by pregnancy with a decrease during pregnancy and an 
increase in the first three months post-partum followed by a return to baseline 
number of relapses. It was also found that the overall progression in level of 
disability was not affected by pregnancy, despite the post-partum increase in 
relapse rate. 
Other factors that have been studied to influence relapse rate include vaccination 
status, as earlier reports suggested a potential link between vaccination and 
onset of MS. In an observational study, it was shown that commonly 
administered vaccines do not increase the risk of relapse in patients with MS and 
some possibly lowered the risk of relapse, including tetanus, poliomyelitis or 
diphtheria (Confavreux et al., 2001).  
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1.2.2 Environmental factors 
MS has been noted for several years to have a clear distribution based on latitude 
(Kurtzke 1975). In this study Kurtzke divided areas into: high, medium and low 
risk, which correlated with latitude. It was noted that there were virtually no 
cases of MS in the tropics and high-risk zones were identified in northern Europe 
and USA. Based on other epidemiological studies the effect of migration from 
high to low risk has shown a reduction in MS risk (Dean 1967). However, the 
opposite does not appear to be true with migration from Asia to Northern 
Europe (Dean et al., 1976). In more recent studies the prevalence and incidence 
of MS has been increasing and in some countries the female to male ratio of MS 
has also been increasing (Orton et al., 2006). 
A number of different hypotheses have arisen from this geographical 
distribution of what is believed to be an autoimmune disease. The first known as 
the “poliomyelitis hypothesis” is based on the idea that higher risk is associated 
with late childhood infection with an unknown virus, whereas infantile infection 
confers immunity (Poskanzer et al., 1976). The second hypothesis is based on 
Kurtzke’s studies of British troops and their effect on the prevalence of MS in the 
Faroe Islands; he concluded that MS is caused by a pathogen (Kurtzke 1993). The 
third hypothesis is known as the ‘hygiene hypothesis’ based on observations in 
Israel on sanitation (Leibowitz et al., 1966) and is substantiated by the fact that 
MS appears to be more prevalent among higher socio-economic groups. 
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Based on his observations including apparent clustering of MS in areas, Kurtzke 
concluded that MS is a ‘rare late outcome of a specific but unknown infectious 
disease of adolescence and young adulthood and that this infection could be 
caused by a thus-far-unidentified virus’ (Kurtzke 1993). 
A number of different proposed viruses have been suggested as the ‘unidentified 
virus’, the most frequently cited being Epstein-Barr virus (EBV). EBV is a 
ubiquitous virus that infects 90% of the adult population worldwide, this 
normally occurs asymptomatically in the first decade of life, however in 
industrialised countries later infection also occurs and may result in infectious 
mononucleosis. EBV is implicated in the pathogenesis of a number of different 
diseases including: Burkitt’s lymphoma, nasopharyngeal carcinoma and EBV-
related Hodgkin’s disease (Crawford 2001).  
Similarities have been noted between the epidemiology of MS and EBV, EBV 
related diseases have a known geographic distribution (Ascherio et al., 2007). 
Epidemiological evidence also suggests that there is a greater risk conferred of 
developing MS in those who had previously been exposed to EBV, whereas the 
risk of developing MS in seronegative subjects is extremely low (Thacker et al., 
2006). EBV has been suggested to be a necessary cofactor for the development of 
MS with serological levels of immunoglobulin G (IgG) correlating with activity on 
neuroimaging and progression of disability (Farrell et al., 2009). The basis for 
EBV as a putative agent in the pathogenesis of MS is strengthened by the fact that 
T cells derived from MS patients cross react with EBV based on shared epitopes 
between myelin basic protein and EBV DNA (Lang et al., 2002). 
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However a number of counter arguments are proposed that EBV may be simply a 
confounder in epidemiological studies, rather than a causative agent in MS. 
Firstly EBV is a ubiquitous virus with the majority of the adult population being 
exposed, while MS is a relatively rare disease (Ascherio et al., 2007). Secondly 
antibody titres to EBV and other viruses are raised in MS, which may be a 
reflection of immune dysregulation rather than being causative factors (Hunter 
et al., 2000). Furthermore, in a study of acute and chronic MS plaques and CSF, 
EBV was not found in the B lymphocytes or plasma cells and no intrathecal EBV 
antibody production was found (Sargsyan et al., 2010). It has therefore been 
suggested that EBV may combine with other risk factors such as smoking that 
may increase risk of MS by modulating EBV infection or the host’s response to 
EBV (Simon et al., 2010). 
Smoking has also been extensively studied as a contributory factor in the 
development of MS. It has been shown that cigarette smoking accelerates the 
transition to SPMS (Hernan et al., 2005); smoking can aggravate MS symptoms 
(Emre 1992), and an association has been established between age of onset of 
MS and smoking (Ghadirian et al., 2001). In three large epidemiological studies 
in women there was found to be an increase in the relative risk of developing MS 
in those who smoked (Villard-Mackintosh et al., 1993; Thorogood et al., 1998; 
Hernàn et al., 2001). The mechanisms by which smoking might increase MS risk 
are uncertain at present but may include neurotoxicity of compounds in 
cigarettes (Smith et al., 1963), immunomodulatory effects (Sopori et al., 1998) or 
the increased risk of respiratory infections, which are some researchers suggest 
may be linked to MS risk (Graham 1990). 
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The other major environmental factor investigated has been the role of vitamin 
D in MS. For most people the major source of vitamin D is sunlight (Holick 2004). 
However for people living beyond the 40th parallels north or South the level of 
sunshine is seasonally low for almost four months of the year with a 
corresponding reduction in vitamin D levels (Webb et al., 1988). The areas that 
experience limited amounts of sunshine include Canada, the Northern half of the 
USA, Northern Europe, Russia, New Zealand and Tasmania (Pierrot-Deseilligny 
and Souberbielle 2010). These regions are also those with a higher prevalence of 
MS (Goodin 2009). This association was first noted by Goldberg (Goldberg 1974) 
and more recent studies have suggested that the month of birth is important in 
MS risk determination as this determines maternal vitamin D levels during the 
pregnancy. Births in November have the lowest risk of MS and births in May 
have the highest risk (Willer CJ et al., 2004).  
In experimental autoimmune encephalomyelitis (EAE), mouse model of MS, 
injection of vitamin D has been shown to prevent pathological signs of disease 
(Cantorna et al., 1996) and its onset can be delayed by providing vitamin D 
supplements (Spach et al., 2005). It has also been shown that macrophages and B 
and T cells contain vitamin D receptors (von Essen et al., 2010), which play a role 
in autoimmunity in conditions such as MS. In some studies the intake of vitamin 
D supplements was found to be associated with a lower risk of MS (Kampman 
and Brustad 2008). Serum vitamin D levels are also found to be low in patients 
RRMS (Soilu-Hänninen et al., 2008). 
It is unlikely that vitamin D alone is responsible for MS alone, as with the other 
potential environmental factors listed above, none of which appear to be solely 
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responsible, it is more likely that a complex interaction between these and 
genetic factors contribute to the pathogenesis of MS. 
 
1.2.3 Genetics 
15 to 20% of patients with MS have a family history of the disease: it is said that 
this figure is greater than would be expected by chance (Compston and Coles 
2002). In twin studies it has been found that there is a higher rate of 
concordance of MS in monozygotic twins compared to dizygotic twins (~25% vs. 
2-3%: Mumford et al., 1994). In those who were adopted early in life and later 
developed MS, the new family did not incur any extra risk of MS, however the 
biological parents were found to be at increased risk (Ebers et al., 1995). Equally 
children of parents, who both have MS, are at greater risk of developing MS, than 
if just one parent is affected (Robertson et al., 1997). It has been also found that 
the risk of a relative developing MS increases with the degree with which they 
are related to them (Dyment et al., 2006). Based on these and other observations 
in families with two or three affected individuals, no clear mode of inheritance is 
apparent in MS, however it is clear that genes play a definite role its 
pathogenesis (Compston et al., 2006).  
Initial studies identified the link between MS and major histocompatibility 
complex (MHC) (Compston et al., 1976). The genes for the Human Leukocyte 
Antigen (HLA) lie within the MHC, an area that contains extreme levels of 
polymorphism (Horton et al., 2004). A number of HLA genes have been identified 
in association with MS including: DRB*1501, DRB5*0101, DQA180102 and 
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DQB2*0602 (Olerup and Hilbert 1991).  Since the association was proven with 
MHCs and MS a number of other potential candidate genes have been studied but 
with limited success. 
Whole genome screens have been done for linkage to MS in the UK, US and 
Canada, however none of these studies found any significant linkages even when 
meta-analysis was used (Sawcer 2008). Later genomewide association studies 
(GWAS) were performed. The International Multiple Sclerosis Genetics 
Consortium studied 931 family trios, testing them for association by analysing 
single nucleotide polymorphisms (SNPs) in 2692 samples (IMSGC 2007). Two 
significant associations in SNPs were found in genes encoding IL2R and IL7R 
chains. These were deemed to be of importance as IL2R gene has been 
implicated in a number of other autoimmune diseases (Vella et al., 2005; Brand 
et al., 2007) and IL7 has been shown to be important in the generation of 
autoreactive T cells in MS, particularly in the early stages of the disease 
(Bielekova et al., 1999). The Welcome Trust Case Control Consortium (WTCCC) 
performed the second GWAS analysing potential associations with MS (Burton et 
al., 2007). This study analysed 12 374 SNPs, however no significant associations 
were found with MS. 
Other GWAS studies have been performed, which have been followed by 
replication studies to assess the more frequently identified abnormalities. The 
Gene Associations in Multiple Sclerosis in 2009 identified a number of potential 
candidate loci, each of which had a modest effect, including: glypican 
proteoglucan 5 (GPC5) genes, which may be involved in sequestering pro-
inflammatory cytokines. PARK2 or Parkin, already identified as playing a role in 
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autosomal recessive Parkinson’s due to proteasomal degradation. Its role in MS 
is believed to be due to mitochondrial dysfunction and apoptosis of neuronal 
cells. Reelin (RELN) was also found to be associated with age of onset of MS 
(Baranzini et al., 2009).  
In the same year a GWAS study was published by the Australia and New Zealand 
Multiple Sclerosis Genetics Consortium (ANZgene 2009). Two previously 
unidentified MS susceptibility loci were identified on chromosome 12 and 20. 
Methyltransferase-like protein 1 (METTL1) and cyclin-dependent kinase 4 
(CDK4), which is down regulated in T cells in Japanese MS cases. Both loci are 
associated with other autoimmune diseases. 
A meta-analysis of MS susceptibility loci was performed in the same year as the 
ANZgene study (De Jager et al., 2009). Three previously unreported associations 
were identified: tumour necrosis factor receptor superfamily member 1A 
(TNFRSF1A), interferon response factor 8 (IRF8) and CD6 loci. TNFRSF1A had 
previously been implicated in disorders of tumour necrosis factor (TNF) and 
IRF8 is implicated in the response to type I interferons and is involved in 
macrophage cell function. CD6 is believed to be involved in T-cell stimulation 
and differentiation and may have a role in inflammatory conditions where T cells 
are implicated in pathogenesis.  
The two GWAS studies identified STAT3 gene, a risk allele for Crohn’s disease 
(Jakkula et al., 2010) and CBLB gene that regulates B and T cell activity and mice 
deficient in this gene are more susceptible to experimental autoimmune 
encephalomyelitis (EAE) (Sanna et al., 2010). A more recent genetic study in MS 
has identified 48 new susceptibility variants (IMSG 2013), including associations 
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with SNPs encoding proteins related to inflammatory B and T cell activity, 
contiguous with the inflammatory hypothesis of the disease. 
However there are a number of limitations to genetic analysis in MS. Firstly MS is 
not a common disease in the whole population, so huge population based studies 
are required to estimate epidemiological parameters (Sawcer 2008). Secondly 
MS is a heterogeneous disorder with a wide spectrum of phenotypes making 
genetic analysis a greater challenge (Compston et al., 2006). Thirdly even the 
associations found to date such as variation in the allele for IL7 occur in up to 
72% of white Europeans, the vast majority of who will never develop MS 
(Sawcer 2008). As with environmental factors in MS there is substantial 
evidence for a genetic component but its study remains challenging. 
1.2.4 Pathology 
The pathology of MS was first described by Carswell and Cruveilhier (Carswell 
1838; Cruveilher 1841) and later summarised by Frommann and Charcot 
(Frommann 1878; Charcot 1880). Since first described the sclerotic plaque has 
been appreciated to be one of the most important findings in MS. The plaque 
results from a complex process of inflammation, demyelination and repair 
accompanied by variable axonal loss (Compston and Coles 2008).  
Oligodendrocytes in the CNS manufacture myelin and the development of these 
cells is regulated by growth factors (Barres 1992). The sections of the axon in 
between the myelin are known as nodes, containing sodium channels, which 
facilitate saltatory conduction along the axon (Compston et al., 2006). In MS the 
oligodendrocytes are damaged by activated inflammatory T lymphocytes. It is 
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believed that these T lymphocytes are not regulated in MS, which allows the 
immune dysregulation to occur (Compston and Coles 2008).  
During the stage of myelin destruction microglial cells are also activated 
immunologically (Ulvestad et al., 1994). These activated microglial cells 
contribute to inflammation with myelin damage and also to repair by removal of 
myelin debris and promotion of remyelination. Due to a combination of a failure 
of remyelination and axonal loss, saltatory conduction is altered along the axon. 
This results in a redistribution of ion channels (Compston and Coles 2008). 
As this process is hypothesised to be driven by T cells their role in the pathology 
of MS has been studied extensively. The evidence for T cells is based on the EAE 
model of MS and similar immune mediated molecules are seen in viral infections 
of the CNS (Lassman 1999). Interleukin 17, regulated by interleukin 23 is 
believed to be secreted by T lymphocytes (Langrish et al., 2005). A combination 
of interleukin 17 and 22 disrupt the blood brain barrier, which allows migration 
of Th17 cells into the CNS (Kebir 2007). A combination of B and T lymphocytes 
and other immune cells activate the microglia, culminating in myelin loss 
through cell surface bound tumour necrosis factor  (Zajicek et al., 1992). The 
plaque itself is then surrounded by undifferentiated oligodendrocytes, 
macrophages and other cells and can be seen on gross specimens. 
However demyelination alone does not seem to be responsible for disease 
progression in MS. Axonal loss in a neurodegenerative manner almost certainly 
results in disease progression (Compston et al., 2006). It has been suggested that 
both inflammation and non-inflammatory processes may initiate axonal loss and 
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sometimes inflammation and axonal loss occur simultaneously. Axonal loss may 
be marked pathologically (Compston and Coles 2008). 
The plaques in MS are readily seen in the white matter of the CNS; however, MS 
is not exclusively a disease of white matter and grey matter has long been 
recognised as being involved (Dawson 1916). Clinico-pathological correlation in 
MS with white matter lesions does not seem to account for all the potential 
deficits seen such as: cognitive impairment, memory impairment, attention 
deficits and reduced mental processing. However the process of axonal loss and 
demyelination in the CNS grey matter has not been clearly elucidated to date, 
although some have suggested it may be secondary to white matter 
inflammation (Geurts and Barkhof 2008). The pathology of grey matter does 
differ from white matter lesions, as inflammatory cells or disruption in blood 
brain barrier are not readily detected in grey matter lesions (Bö et al., 2003). 
Grey matter lesions exhibit marked cellular loss and have been reported to be 
associated with progressive MS (Kutzelnigg et al., 2005). 
Pathological studies have given an insight into the disease mechanisms in MS 
and the wide range of symptoms experienced by the patient. Although pathology 
can provide a definitive diagnosis of MS, particularly in atypical presentations 
(Phadke and Best 1983), it is not a practical way to diagnose those suspected of 
having MS in life, therefore a number of different diagnostic criteria have been 
drawn up based on clinical and laboratory (especially magnetic resonance 
imaging [MRI]) findings. 
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1.2.5 Diagnosis  
Since MS was first described the diagnosis was based solely on clinical findings. 
With the advent of clinical trials and disease modifying therapy, more stringent 
criteria have been developed to exclude other possibilities and confirm a 
diagnosis of MS. A number of different criteria have been published, 
incorporating laboratory data as well as magnetic resonance imaging (MRI); the 
more frequently cited criteria are summarised below. 
One of the first proposed diagnostic criteria were written by Schumacher et al. 
on the basis that there were at that time no clear guidelines for enrolling patients 
into therapeutic trials (Schumacher et al., 1965). A number of difficulties with 
clinical trials, some of which still exist today, are highlighted by the authors 
including: difficulty with diagnosis, unpredictable course of MS and lack of 
biological markers. At the time of writing the guidelines were based on the 
concept of dissemination in time and space with objective abnormalities on 
neurological examination. Each attack was defined as lasting for more than 24 
hours and by definition had to be more than a month from the preceding event. 
The authors recommended routine laboratory tests, in an effort to exclude 
alternate conditions and a lumbar puncture was also included, to look for an 
increase in CSF gamma globulin and mononuclear cells. Schumacher and 
colleagues also recommended that progressive presentations over the course of 
six months or more should be excluded: this will be addressed again later. It was 
also suggested that ‘no better explanation’ is possible to account for the 
symptoms or signs, an observation that is also reflected in more recent criteria.  
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Following on from the Schumacher criteria, Poser et al (Poser et al., 1983) 
incorporated the use of supportive laboratory data in making a definitive MS 
diagnosis, however accepting that the diagnosis does remain a clinical one. As in 
earlier criteria clinical definitions such as what constitutes an attack and 
remission are defined and again the basis is that of dissemination in time and 
space of lesions, with objective findings on neurological examination and CSF. 
The main purpose of the lumbar puncture is to determine if unmatched 
oligoclonal bands (OCBs) are present in the CSF but not in the serum. These 
consist of intrathecal IgG bands detected on electrophoresis and are suggestive 
of an immunological process in the CNS. Their presence is supportive of MS 
diagnosis; however, they may be present in other CNS inflammatory conditions 
such as sarcoid, syphilis, subacute sclerosing pancencepahilitis (SSPE) and 
systemic lupus erythematosus (SLE). 
There are restrictions given of ages between 10 and 59 years and again 
progressive onset of disease is excluded from making an MS diagnosis. With the 
aforementioned caveats, Poser et al. proposed the following categories: clinically 
definite MS, laboratory supported definite MS, clinically probable MS, laboratory 
supported probable MS. 
With the advent of MRI and its widespread use in MS and other neurological 
diseases its contribution was reflected in diagnostic criteria for the disease. MRI 
findings in MS are a reflection of the pathology seen, e.g. with callosal 
involvement (Dawson 1916), and early post mortem studies showed that MRI T2 
high signal lesions corresponded with plaques of demyelination (Ormerod et al., 
1987). Paty et al. wrote a set of criteria that included MRI as well as other 
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paraclinical parameters for a diagnosis of MS (Paty et al., 1988). The use of MRI 
was based on the fact that previous studies had shown clear abnormalities using 
this modality of imaging in MS (Robertson et al., 1985). The other parameters 
assessed were CT, OCBs, visual evoked potentials and somatosensory evoked 
potentials (SSEP). 
Visual evoked potentials (VEPs) involve the use of a chequer board pattern of 
black and white flashing squares as a stimulus. The visual evoked potential 
response is then recorded from the occipital scalp region and can be compared 
to mean values. SSEP involves electrical stimulation of median or posterior tibial 
nerves; again the response is recorded over the scalp. Both of these assessments 
of evoked potentials (visual and somatosensory) may be delayed, although not 
exclusively, in demyelinating diseases such as MS. 
The criteria developed by Paty et al. included abnormalities in the above named 
parameters as well as a history of dissemination in time and space. Whether the 
MRI was strongly suggestive of, possible or not MS was based on the number of 
lesions seen. The authors recommended the following: an MRI strongly 
suggestive of MS has four lesions or three one of which is periventricular; for 
possible MS two lesions must be present or one lesion in a periventricular 
location. If there is one lesion or none, then another diagnosis should be 
considered. The authors also introduced the concept that a single appropriate 
lesion could be used to demonstrate dissemination in space. However given the 
increase in non specific lesions seen with advancing age it is was also 
recommended that OCBs are a prerequisite for a diagnosis for those over 40. 
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The issue of MRI abnormalities with advancing age was then addressed by 
Fazekas et al. to improve specificity of MRI for MS (Fazekas et al., 1988). As 
alluded to in previous criteria again the use of MRI lesions on T2-weighted 
images was incorporated as evidence of dissemination in space. The 
investigators compared T2-weighted lesions in healthy volunteers to those seen 
in MS patients and suggested at least two of the three following MRI criteria for a 
diagnosis of MS: lesion size greater than 6mm, lesions abutting the body of the 
lateral ventricle, infratentorial lesion. When these criteria were applied to 
elderly volunteers with non-specific high signal changes none of them were 
attributed with an incorrect MS diagnosis. It is also noted that MS remains a 
clinical diagnosis. 
Several potential MRI features for supporting a diagnosis of MS were then 
applied to a cohort of subjects with a clinically isolated syndrome (CIS) 
suggestive of MS, and then development of clinically definite MS (i.e. further 
clinical relapse in a different CNS location) during follow up was used to evaluate 
their performance (Barkhof et al., 1997). As new T2 lesions had previously been 
shown to be representative of dissemination in time (Paty et al., 1988), the 
introduction of contrast in MRI led to the concept of enhancing lesions with non-
enhancing lesions on MRI representing dissemination in time and space (Heun et 
al., 1988). The presence of enhancing lesions was incorporated into the new 
diagnostic criteria following a logistic regression analysis of the previous criteria 
(Fazekas et al., 1988; Paty et al., 1988) in CIS patients. The recommendations 
from the study were as follows: presence of at least one enhancing lesion or nine 
T2 weighted lesions: one juxtacortical, one infratentorial and three 
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periventricular (Barkhof et al., 1997). It was found that the diagnostic accuracy 
increased from 69 to 80% when the number of lesions was increased from four 
to nine.  
Tintoré et al later addressed the criteria recommended by Barkhof et al. (1997), 
in a further study on CIS patients (Tintoré et al., 2000). This study was done on 
the basis that a diagnosis of MS cannot be made in those with CIS, as they do not 
fulfil the criteria of dissemination in time. Again it was found that the Barkhof 
criteria were superior to earlier proposed criteria; however, it was 
recommended that at least three out of the four criteria be fulfilled to optimise 
the accuracy in diagnosis.  
A meeting of the NMSS-supported International Panel on MS Diagnosis then 
presented what later became known as the McDonald criteria (McDonald et al., 
2001). These criteria integrated MRI into the diagnosis as well as: evidence of 
dissemination in time (DIT) and space (DIS), objective clinical signs, CSF analysis, 
visual evoked potentials. Importantly for the first time the McDonald criteria 
made provisions for the subset of patients with progressive forms of MS and 
include this in the criteria.  
The MRI criteria were based on those of Barkhof and Tintoré (Barkhof et al., 
1997; Tintoré et al., 2000); three of the four of the following were required: one 
gadolinium enhancing lesion or nine T2 hyperintense lesions, at least one 
infratentorial lesion, at least one juxtacortical lesion, at least three 
periventricular lesions. These initial McDonald criteria also included, to a limited 
extent, the presence of spinal cord abnormalities on MRI. Dissemination of 
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lesions in time was satisfied by the presence of gadolinium (Gd) enhancing or a 
new T2 weighted lesion in an MRI at least three months from the initial event.  
The McDonald Criteria were then revised in 2005 following a meeting of the 
International Panel on the Diagnosis of Multiple Sclerosis (Polman et al., 2005). 
The Panel reviewed all literature published on the original McDonald criteria 
and recognised the potential for misdiagnosis of MS in conditions that are not 
typical of adult onset MS in a Western adult population. The modified criteria 
again incorporate CSF analysis, VEPs and clinical findings as well as three of the 
MRI criteria as outlined in the 2001 criteria with some modifications. Any 
number of cord T2 lesions could substitute for a brain lesion (whereas only one 
could in 2001 criteria) and a cord lesion was recognised as having the same 
significance as an infratentorial lesion. The other modification was in the 
definition of DIT: the originally proposed time period of three months for DIT 
was altered to one month for a new T2 lesion to satisfy DIT or detection of Gd 
enhancement at least three months after the onset of the clinical event. 
The European multicentre collaborative research network that studies MRI in 
MS (MAGNIMS) (Montalban et al. 2010) proposed criteria for MS based on a 
single scan. The proposed MRI criteria are as follows: (i) one or more lesion(s) in 
at least two of 4 locations considered characteristic for MS (juxtacortical, 
periventricular, infratentorial and spinal cord), as outlined before, to satisfy 
dissemination in space, and (ii) simultaneous presence of Gd enhancing and non 
enhancing lesions or a new enhancing lesion or T2 weighted lesion on any follow 
up scan to satisfy dissemination in time. 
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These MAGNIMS criteria were subsequently appraised and encorporated into 
the 2010 revisions to the McDonald criteria (Polman et al., 2011). DIS again was 
defined as one or more T2 lesions in at least two of four characteristic areas of 
the CNS (Periventricular, juxtacortical, infratentorial, spinal cord). However, 
symptomatic lesions in the brainstem or spinal cord are excluded and Gd 
enhancement is not required to demonstrate DIS. DIT has been defined as a new 
T2 or Gd enhancing lesion on a follow up MRI scan, with reference to the original 
scan or presence of Gd enhancing and non Gd enhancing lesions. The criteria for 
a diagnosis of PPMS are also given whereby patients must have one year of 
progression with two of the following: Evidence of DIS in the brain (≥1 T2 lesion 
in following locations: periventricular, juxtacortical or infratentorial), evidence 
of DIS in the spinal cord, based on ≥2 T2 lesions in the cord, positive unmatched 
OCBS. The issues of ethnic heterogeneity and differential diagnosis are discussed 
(discussed in detail below). Again, however it is emphasised that these criteria 
must be applied in an appropriate clinical context with objective signs on clinical 
examination. These updated criteria differ substantially from previous iterations 
of the McDonald criteria because it is now possible to confirm a diagnosis of MS 
at the first presentation suggestive of demyelination. 
In presenting any new criteria, it is generally acknowledged that MS is highly 
heterogeneous condition with a large number of conditions that can mimic it 
clinically and/or on imaging (Charil et al., 2006; Miller et al., 2008); no criterion 
is entirely reliable on its own, and expert clinical evaluation by an experienced 
neurologist remains at the centre of an effective diagnostic process. It is also 
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essential that the specificity and sensitivity of each proposed new set of criteria 
are rigorously scrutinised to reduce the chance of a misdiagnosis of MS. 
 
1.2.6 Differential diagnosis 
MS has a number of ‘typical’ presentations such as optic neuritis, partial myelitis 
or brain stem syndromes, however these presentation may have numerous other 
causes to consider in the differential diagnosis, and furthermore, a number of 
atypical or unusual presentations of MS are possible such as: psychosis 
(Felgenhauer 1990), behavioural or intellectual changes (Young et al., 1976), 
aphasia (Lacour et al., 2004) hemianopia or seizures (Striano et al., 2003). Given 
the diverse range of symptoms and signs possible MS often enters the 
differential diagnosis of unexplained neurological symptoms and equally a 
number of other varied conditions can mimic MS, which may result in 
misdiagnosis. 
The differential diagnosis of MS is highlighted in the McDonald criteria 
(McDonald et al., 2001), listing a number of different potential mimics. The 
clinical presentation and the characteristic imaging findings in MS can be caused 
by ischaemic changes due to conditions such as antiphospholipid antibody 
syndrome, CADASIL, and systemic lupus erythematosis (SLE) (Compston et al., 
2006). A number of genetic disorders such as leukodystrophies can produce 
white matter changes on MRI. 
Given the relapsing nature of MS a number of CNS infections can present in a 
similar fashion, such as CNS Lyme disease and neurosyphilis. Possible infective 
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aetiologies can often be elucidated by CSF analysis, which is alluded to in early 
diagnostic criteria for MS (Schumacher et al., 1965). 
Other disorders such as acute disseminated encephalomyelitis (ADEM) or 
neuromyelitis optica (NMO) are more closely related to MS and can pose 
diagnostic dilemas. However with recently discovered antibody for NMO 
(Lennon et al., 2004), the distinction between MS and NMO is possible in 
suspected cases. 
Miller et al. addressed the issue of differential diagnosis and ‘red flags’ in the 
diagnosis of MS (Miller et al., 2008). There were 79 red flags identified, which 
were classified as: major, intermediate or minor. The authors provided a 
diagnostic algorithm to eliminate alternative diagnoses and to confirm a 
diagnosis of CIS or MS. CIS is further defined as being monofocal or multifocal 
based on clinical or radiological features. 
The issue of differentiation between NMO and MS is also addressed based on: 
differences in response to immunomodulatory therapy, predilection in NMO for 
severe optic neuritis and myelitis with T2 weighted spinal cord lesions on MRI 
extending over three or more spinal segments, expression of aquaporin 4 
antibodies (seen in ~70% with NMO) and OCBs are less likely to be present (10-
20% of NMO cases vs. 70-90% MS). NMO can be excluded with biopsy evidence 
of sarcoidosis or vasculitis although seropositivity for antinuclear antibodies 
(ANA) or Sjögren’s (SSA/SSB) does not exclude an NMO diagnosis. 
The diagnosis of ADEM and its differential diagnosis are also outlined. ADEM 
typically presents as a subacute encephalopathy over one week to three months 
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and may have improvement or recovery; it may follow an infectious illness. MRI 
brain in ADEM typically shows symmetrical or large multifocal brain lesions 
(Kesselring et al.,1990), however it has been proposed that no clinical or MRI 
criteria reliably distinguishes fulminant episodes of MS from ADEM (Banwell et 
al., 2007) and the diagnosis of ADEM is often revised to that of MS after 
continued surveillance (de Seze et al., 2007). 
Following a meeting of the MAGNIMS (Magnetic Resonance Network in Multiple 
Sclerosis) a list of imaging red flags for MRI were compiled for images atypical 
for MS where another diagnosis is more likely (Charil et al., 2006). The imaging 
characteristics of NMO, with minimal cerebral lesions, ADEM, with symmetrically 
defined lesions and poorly defined lesion margins are discussed as well as the 
findings in a number of other conditions such as CADASIL, abscesses and 
progressive multifocal leucoencephalopathy (PML). 
In summary, it is clear that a wide spectrum of disorders can mimic MS 
highlighting the importance of investigations and imaging when suspicious of an 
MS mimic. MRI clearly plays a key role in the diagnosis of MS as outlined above; 
an introduction to MRI is given in chapter two. 
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Chapter 2 - Magnetic resonance imaging 
 
2.1 Magnetic resonance imaging principles 
The human body is composed of a number of different tissue types, each with 
varying amounts of water present. Each water molecule is composed of 
hydrogen and oxygen atoms, which contain: protons, neutrons and electrons. It 
is the nucleus of the hydrogen atom that is of particular interest in MRI as this 
contains a proton, which has a net charge and spin on its own axis. These protons 
have a magnetic moment and can align with an external magnetic field. 
When an external magnetic field (B0) is applied to a hydrogen nucleus the 
magnetic moment of the nucleus will align in either the same direction (parallel), 
or in the opposite direction (anti-parallel). The net moment of the hydrogen 
nuclei is known as the net magnetisation vector (NMV), which is initially 
longitudinal i.e. along the z-axis. When the B0 is applied, an additional rotatory 
movement occurs around the applied field, this movement is known as 
precession. The frequency of procession is called the Larmor frequency and is 
governed by the magnetic field strength and gyromagnetic ratio. 
Resonance occurs when an applied force matches the natural frequency of an 
object, giving rise to an increase in the amplitude oscillations that occur. The 
same principle of resonance applies to protons, when an external force matches 
the precessional frequency of the nucleus. If a radio frequency (RF) pulse is 
applied with a frequency equal to the Larmor frequency that causes resonance to 
occur, this resulting process is known as excitation. 
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The application of the RF pulse flips the NMV towards the transverse plane i.e. 
along x-y axis from the original z-axis. In the special case of a 90° the NMV is 
entirely orientated in the transverse plane. The phase and magnitude of the NMV 
in plane is measured by the receiver coil.  
2.2 T1 – longitudinal relaxation 
Immediately after excitation, the NMV returns to the original longitudinal vector, 
which is known as the longitudinal or T1 relaxation (shown in Figure 2.1). 
 
Figure 2.1 T1 relaxation of brain grey and white matter (image from 
www.mcauslander.sc.edu) 
The removal of the RF pulse causes the NMV magnitude of the protons to spiral 
back to their original processional position around the static magnetic field from 
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the transverse plane during the application of the RF pulse. T1 is defined as the 
time required for longitudinal magnetisation to restore to 63% of its final value. 
2.3 T2 – transverse relaxation 
During the application of the RF pulse, a large number of protons precess with 
the same phase in the transverse plane. Due to spin-spin interactions (T2 
relaxation) and field inhomogeneities (T2* relaxation), less and less protons 
precess in phase, which combined result in transverse relaxation. T2 relaxation 
is shown in Figure 2.2. 
 
Figure 2.2 T2 (transverse relaxation) of grey matter, white matter, blood and 
CSF (image from www.mcauslander.sc.edu) 
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As a result of magnetic field inhomogeneities, the process of decay known as T2* 
decay also occurs and represent the reduction in the induced signal. 
T2 is defined as a time required for a decrement, from the transverse 
magnetisation value to decrease to a value of 37%. 
2.4 Pulse sequences 
Pulse sequences are designed to take advantage of different relaxation times in 
tissues and are constructed through the use of different combinations of RF 
pulses and gradients. The main parameters of a pulse sequence are the echo time 
(TE) and the repetition time (TR). TR is the time between subsequent excitations. 
The time from the RF pulse to the acquisition is known as the TE. 
2.5 Spin Echo sequences 
If a transverse magnetisation is produced by an RF pulse, a transient MR signal 
occurs at the Larmor frequency, which decays with a characteristic T1 and T2*. 
This decay is known as the free induction decay. However, the re-appearance of 
the NMR signal can occur after this point, as a consequence of the effective 
reversal, or rephasing, of the dephasing spins by a specific 180° RF pulse in a 
spin echo (SE) sequence. 
The fast spin echo sequence differs slightly from the conventional SE, as multiple 
180° RF pulses are applied and this produces a series of echoes with a resultant 
reduction in total acquisition time. Fast spin echo sequences are usually T2 
weighted and the use of this sequence in MS is discussed later in relation to its 
use in the spinal cord (Kidd et al., 1993). 
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2.6 Gradient echo sequences 
Gradient echo sequences are an alternative means rephase the spins compared 
to SE sequences, as they are usually faster and allow shorter echo times. No 180° 
pulse is applied, in contrast to SE sequences and which facilitates the short TE 
and TR. 
A commonly used gradient echo sequence in investigation of multiple sclerosis is 
the T1 weighted magnetically prepared rapid acquisition gradient echo sequence 
(MP-RAGE) (Mugler and Brookeman 1990). T1 MPRAGE sequences have also 
been used for evaluation of spinal cord atrophy (Lin et al., 2003) and its use will 
be discussed further later. 
2.7 Image contrast 
Contrast is of importance in MRI so that abnormalities in normal appearing 
tissue can be readily determined, such as demyelination in the CNS in MS. 
Different tissues in the body have intrinsic contrast parameters that are fixed, 
however by altering parameters such as TR and TE, amongst others, extrinsic 
contrast can be changed. When viewing the image areas of high signal appear 
brighter and low signal are darker. 
 
2.7.1 T1-weighted imaging 
T1 recovery is dependent on the intrinsic properties of the tissue type that is 
being examined. Fat has a short T1 time whereas water’s T1 time is prolonged as 
a result of its molecular structure. Since fat has a short T1 it appears bright on a 
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T1-weighted image and water or CSF appears have a longer T1 and as a result 
appear dark. The amount of T1-weighting is determined by TR, which is short for 
a T1-weighted spin echo sequence to maximize the contrast between different 
tissues e.g. grey matter, white matter and CSF in the brain. Therefore a T1-
weighted image is created by using a short TR and short TE. 
In addition to the contrast produced by different MRI weighting, paramagnetic 
substances can be injected intravenously such as gadolinium (Gd) chelates, 
which act as enhancement agents in MRI. Gadolinium shortens the T1 of effected 
tissue by altering the local magnetic field. In imaging the brain in MS, Gd 
enhancement is thought to reflect areas of acute inflammation with disruption of 
the blood-brain barrier (Nesbit et al., 1991). 
T1-weighted images and in particular Gd enhanced T1 weighted images are of 
importance in MS. The onset of a relapse in MS is often accompanied by Gd 
enhancing lesions on MRI (Miller et al., 1993). Equally, some hypo-intense 
lesions can be seen on T1-weighted images in MS and these are termed black 
holes, which, when persistent, have been shown to correlate with axonal loss on 
histopathology (Bruck et al., 1997). When acute contrast enhancing lesions are 
analysed 80% appear hypointense (van Waesberghe JH et al., 1998). In a four 
year follow up study, it was found that approximately 60% of these so-called 
‘acute’ black holes evolve into permanent ones and that the persistence of black 
holes correlated with the duration of enhancement (Bagnato et al., 2003). 
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2.7.2 T2-weighted imaging 
As with T1, T2 imaging decay varies according to the tissue being imaged as 
decay is determined by the result of magnetic fields of nuclei interacting with 
each other. Fat has a short T2 time and water has a long T2, due to slower 
dephasing of water molecules. Water therefore appears as high signal on T2-
weighted imaging and fat appears dark. The degree of T2-weighting is varied by 
changing the TE; T2-weighted images typically have a long TR (to minimise T1 
contrast) and long TE, to maximise the differences in T2 decay as seen in Figure 
2.2. 
T2-weighted images have also been evaluated in the context of MS as a measure 
of inflammatory disease burden and net changes in the brain T2 lesion volume 
have been used as endpoints in clinical trials (Paty et al., 1993). The net change 
of T2 weighted lesion volume in a serial MRI study reflects the volume of new or 
enlarging and resolved or shrinking lesions (Willoughby et al., 1989). 
2.6.3 Proton density imaging 
The number of protons in the tissue being examined determines the proton 
density. The signal is determined in proton density (PD) weighted image by the 
number of protons present, high signal is produced by greater number of 
protons by an increase in the transverse component of magnetisation. If the 
effects of T1 and T2 are decreased, this results in increased proton density 
weighting on an image. Typically this is achieved by using a long TR and short TE. 
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Proton density-weighted sequences may be of particular value in MS for imaging 
lesions in the posterior fossa. In one study assessing the MRI findings in patients 
with a known internuclear opthalmoplegia, a common finding in MS, it was 
found that proton density-weighted imaging was superior to other sequences in 
detecting lesions in the medial longitudinal fasiculus (Frohman et al., 2001). 
 57 
 
Chapter 3 - Spinal cord magnetic resonance imaging in multiple sclerosis 
 
3.1 Introduction 
In clinically definite MS, spinal cord lesions are detected in up to 85% of patients 
and if atrophic changes are included then up to 90% of patients will have an 
abnormal MRI of the spinal cord (Lycklama et al., 1998). This degree of 
involvement of the cord, a clinically eloquent site, is likely to be a contributory 
factor to the physical disability experienced by MS patients. 
As MS has been proven in post mortem studies to involve all of the central 
nervous system (CNS) it is desirable to image it in its entirety. However, MRI of 
the spinal cord poses a number of technical difficulties as the cord itself is a small, 
mobile structure (Mikulis et al., 1994), which is also susceptible to motion 
artefacts from respiration, cardiac contraction and cerebrospinal fluid (CSF) flow 
artefact (Bronskill et al., 1988; Curtin et al. 1989; Czervionke et al., 1988; Hinks 
et al., 1988; Levy et al., 1988). These technical difficulties can be addressed by 
several approaches including cardiac gating, presaturation slabs and fast imaging 
techniques. 
Due to these technical limitations earlier MR studies had difficulty detecting 
smaller and more chronic lesions, particularly in the thoracic cord whereas 
larger more acute lesions were more easily identified (Miller et al., 1987; Turano 
et al., 1991). Furthermore, the duration of image acquisition was prolonged in 
early studies in order to obtain diagnostic quality images for detection of lesions 
using conventional T2-weighted spin echo images. The issues of length of time 
and image quality were addressed using multi-array coils and T2-weighted fast 
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spin echo sequencing (Kidd et al., 1993). This new imaging technique was also 
able to give an indication of cord atrophy, which correlated with the level of 
disability experienced by the patient. 
Routine clinical assessment of the spinal cord in suspected or confirmed MS, 
typically involves both sagittal and axial T2-weighted images. Fluid attenuated 
inversion recovery (FLAIR), unlike in the brain, has not proven useful in the 
assessment of cord lesions (Keiper et al., 1993), nor has T1-weighted imaging 
(Lycklama et al., 2003). This may be due to the organisation of tissue in the cord. 
However, T1-weighted imaging can be used for the evaluation of cord atrophy 
(Lycklama et al., 1998). Axial T2-weighted images are also of use in the detection 
of MS lesions (Stevenson et al., 1998); they may confirm an equivocal 
abnormality seen on a sagittal image as well as localising the lesion more 
accurately within the cord. 
MRI is an important marker of disease activity in MS as the administration of 
gadolinium (Gd) contrast can demonstrate activity despite absence of clinical 
manifestations of the disease (Bastianello et al., 1990; Harris et al., 1991; Miller 
et al., 1998; Thompson et al., 1991; Barkhof et al., 1992; Capra et al., 1992; 
McFarland et al., 1992). In a study examining serial Gd enhanced MRI of the brain 
and spinal cord (Thorpe et al., 1996); it was found that 10% of the enhancing 
lesions found were in the spinal cord. It was also found that 31% of the 
enhancing spinal cord lesions cause symptoms, in comparison with the much 
larger number of enhancing lesions in the brain with a very low number of 
corresponding relapses. New enhancing brain lesions are more likely to be found 
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than in the cord and simultaneous enhancement of brain and cord lesions is 
often found. 
To assess the MRI abnormalities in the MS spinal cord, investigators have 
compared pathological findings directly with the post mortem images obtained 
from MRI. This allows complete imaging of the spinal cord without any flow or 
movement artefacts and permits a direct comparison. In one study, the spinal 
cords of 19 patients and three controls were examined histologically and 
radiologically using 1.0T MRI with 1mm pixel resolution (Lycklama et al., 2001). 
In this study the sensitivity of MRI was found to be high when compared to 
histology and there was also a good correlation with the subtype of MS. It was 
found that high signal change on MRI corresponded with demyelination and 
changes extended into grey matter in some patients and the distribution of 
lesions were similar to previous studies (Oppenheimer 1978; Fog 1950). It was 
also noted when the MRI was reviewed concurrently with the histology that mild 
signal increase corresponded to partial demyelination. In the PPMS group more 
extensive abnormalities consisted of diffuse signal change on proton density 
weighted spin echo sequences. 
In a separate study a comparison was made between 1.5T, 4.7T MRI and the 
histopathology in spinal cords of seven MS cases (Bergers et al., 2002). The 
findings were similar however the authors point out that; sagittal views on MRI 
underestimate the number and extensiveness of spinal cord lesions, as well as 
diffuse abnormalities in the MS spinal cord. 
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3.1.1 Spinal cord imaging in clinically isolated syndrome 
MRI has been used to assess the number of asymptomatic lesions in the spinal 
cord, in patients with a clinically isolated syndrome (CIS), a presumed 
inflammatory demyelinating event, which often heralds the onset of MS 
(O’Riordan et al., 1998). It was found that there was a high frequency of 
asymptomatic cord lesions found, irrespective of the clinical syndrome. The 
lesions found were predominantly in the cervical and thoracic cord with no 
lumbar lesions found. These findings correlated with previous neurophysiologic 
studies on the cord in CIS (Hume et al., 1988). O’Riordan et al. argue that spinal 
cord MRI may assist in the diagnosis of demyelination in patients over 50, where 
high signal changes in the brain are likely to be seen due to ischaemia, whereas 
abnormalities of the cord are less likely. 
The role of spinal cord imaging in patients who presented with an optic neuritis 
has been assessed (Dalton et al., 2003); it was found that 27% of patients with 
optic neuritis had spinal cord lesions at presentation. Using diagnostic criteria 
(McDonald et al., 2001) for MS spinal cord imaging was felt to be of limited value 
in this study. Other studies however, have shown that the frequency of 
developing MS, has been found to be higher in patients with both brain and 
spinal cord lesions at baseline, than brain lesions alone (Brex et al., 1999). 
In a more recent study of 100 patients with optic neuritis, followed up for six 
years, it was found that asymptomatic cord lesions were seen in 26% of patients 
(Swanton et al., 2009). It was found in those with cord lesions at presentation 
there was an increased odds of higher disability at six years and that this effect 
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was independent of brain lesion load. Swanton et al. argue that there may be a 
role for spinal cord imaging in patients with optic neuritis in assessing the risk 
for future disability.  
In a multicentre retrospective study 282 patients with CIS were assessed to 
investigate the performance of the McDonald criteria in those who developed 
CDMS (Swanton et al., 2007). T2-weighted spinal cord images were available for 
130 patients, with abnormalities detected in 45 patients and five had normal 
brain imaging. It was found that spinal cord MRI increased the sensitivity and 
specificity of the McDonald criteria by up to 3%.  
As not all those with a CIS will convert to clinically definite MS (CDMS), other 
studies have assessed spinal cord imaging in recently diagnosed MS (Bot et al., 
2004). The presenting feature often determines whether the spinal cord is 
imaged or not in CIS. In this study of 104 patients with early MS 82.7% had an 
abnormal MRI of the spinal cord. The fact that not all patients with CIS convert to 
MS may account for the disparity in the percentage of abnormal spinal cord 
images obtained in CIS patients compared to recently diagnosed MS patients in 
this study. The spinal cord MRI obtained in this cohort allowed a diagnosis of MS 
in three patients who did not fulfil the Paty criteria and in 28 patients who did 
not fulfil the Barkhof/Tintoré criteria. It was also found that with substitution of 
a spinal cord lesion for a brain lesion to determine dissemination in space the 
sensitivity of the McDonald criteria reached 84.6%. 
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3.2 Utility of spinal cord MRI in diagnosis 
The diagnosis of multiple sclerosis is based on diagnostic criteria; following a 
meeting of an International Panel on the diagnosis of MS the McDonald criteria 
were established (McDonald et al., 2001 Tables 3.1 and 3.2). The original criteria 
were to be applied to patients in whom there was a clinical suspicion of 
demyelinating disease and no other explanation could account for the symptoms. 
The criteria were based largely on brain MRI that contained: one Gd enhancing 
lesion or nine T2 enhancing lesions if there is no Gd enhancing lesion, at least 
one infratentorial lesion, at least one juxtacortical lesion, or at least three 
periventricular lesions. However it was recommended that one spinal cord 
lesion could be substituted for one brain lesion. 
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Table 3.1 McDonald MRI criteria to demonstrate dissemination of lesions in 
time: 
Original McDonald Criterion 2005 Revisions 
1. If a first scan occurs 3 months or 
more after the onset of the clinical 
event, the presence of a Gd-enhancing 
lesion is sufficient to demonstrate 
dissemination in time, provided that it 
is not at the site implicated in the 
original clinical event. If there is no 
enhancing lesion at this time, a follow 
up scan is required. The timing of this 
follow up scan is not crucial, but 3 
months is recommended. A new T2- or 
Gd-enhancing lesion at this time fulfils 
the criterion for dissemination in time 
1. There are two ways to show 
dissemination in time using imaging: 
 a. Detection of Gd enhancement at 
least 3 months after the onset of the 
initial clinical event, if not at the site 
corresponding to the initial event 
b. Detection of a new T2 lesion if it 
appears at any time compared with a 
reference scan at least 30 days after 
the onset of the initial clinical event 
2. If the first scan is performed less 
than 3 months after the onset of the 
clinical event, a second scan done 3 
months or longer after the clinical 
event showing a new Gd-enhancing 
lesion provides sufficient evidence for 
dissemination in time. However, if no 
enhancing lesion is seen at this second 
scan, a further scan not less than 3 
months after the first scan that shows a 
new T2 lesion or an enhancing lesion 
will suffice. 
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Table 3.2 McDonald MRI Criteria to demonstrate brain abnormalities and 
demonstration of dissemination in space: 
Original McDonald Criteria 2005 Revisions 
Three of the following: 
1. At least one Gd Enhancing 
lesion or nine T2 hypertintense 
lesions if there is no Gd-
enhancing lesion 
2. At least one infratentorial lesion 
3. At least one juxtacortical lesion 
4. At least three periventricular 
lesions 
Three of the following: 
1. At least one Gd-enhancing 
lesion or nine T2 hyperintense 
lesion if there is no Gd-
enhancing lesion 
2. At least one infratentorial lesion 
3. At least one juxtacortical lesion 
4. At least three periventricular 
lesions 
NOTE: One spinal cord lesion can 
substitute for one brain lesion 
NOTE: A spinal cord lesion can be 
considered equivalent to a brain 
infratentorial lesion: an enhancing 
spinal cord lesion is considered to be 
equivalent to an enhancing brain lesion 
and individual spinal cord lesions can 
contribute together with individual 
brain lesions to reach the required 
number of T2 lesions 
Criteria reproduced from Polman et al. 2005 
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Following a further meeting of the International Panel a number of conclusions 
were reached regarding spinal cord MRI in suspected MS, which are reflected in 
the 2005 revisions to the McDonald Criteria (Polman et al., 2005, Table 3.1 and 
3.2). The Panel recognised the use of spinal cord imaging in excluding an 
alternative diagnosis, such as a compressive lesion (e.g. tumour or intervertebral 
disc), and also that intrinsic cord lesions are unlikely to occur in a healthy person 
with aging as brain white matter lesions do (Kidd et al., 1993; Lycklama et al., 
2003). Thus cord lesions provide more specificity, especially in older adults, 
when brain imaging is less specific. It was also recommended that spinal cord 
imaging could be used to determine dissemination in space, if this is not found 
on brain imaging in suspected MS. The cord lesion can substitute for an 
infratentorial lesion but not for a periventricular or juxtacortical lesion. It was 
recommended that spinal cord lesions should be focal and clearly delineated on 
T2-weighted imaging. 
The presence of spinal cord lesions are also included in the 2010 revisions to the 
McDonald criteria and may provide evidence of DIS in MS or in the context of 
PPMS if there are more than two spinal cord lesions this may serve as evidence 
of DIS in the spinal cord (Table 3.3). 
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Table 3.3 The 2010 McDonald criteria for diagnosis of multiple sclerosis 
Clinical Presentation Additional Data Needed for MS 
Diagnosis 
≥2 attacks; objective clinical evidence 
of ≥2 lesions or objective clinical 
evidence of 1 lesion with reasonable 
historical evidence of a prior attack 
None 
≥2 attacks; objective clinical evidence 
of 1 lesion 
DIS, demonstrated by: ≥1 T2 lesion in 
at least 2 of 4 MS-typical regions of the 
CNS (periventricular, juxtacortical, 
infratentorial, or spinal cord); or await 
a further clinical attack implicating a 
different CNS site 
1 attack; objective clinical evidence of 
≥2 lesions 
DIT, demonstrated by: Simultaneous 
presence of asymptomatic Gd-
enhancing and non enhancing lesions 
at any time; or a new T2 and/or Gd-
enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with 
reference to a baseline scan; or await a 
second clinical attack 
1 attack; objective clinical evidence of 
1 lesion (clinically isolated syndrome) 
DIS and DIT, demonstrated by: For DIS: 
≥1 T2 lesions in at least 2 of 4 MS-
typical regions of the CNS 
(periventricular, juxtacortical, 
infratentorial, or spinal cord); or await 
a second clinical attack implicating a 
different CNS site; and for DIT: 
Simultaneous presence of 
asymptomatic Gd-enhancing and non 
enhancing lesions at any time; or a new 
T2 and/or Gd-enhancing lesion(s) on 
follow-up MRI, irrespective of its 
timing with reference to a baseline 
scan; or await a second clinical attack 
Insidious neurological progression 
suggestive of MS (PPMS) 
1 year of disease progression 
(retrospectively or prospectively 
determined) plus 2 of 3 of the 
following criteria: 
1.Evidence for DIS in the brain based 
on ≥1 T2 lesions in the MS-
characteristic (periventricular, 
juxtacortical or infratentorial) regions 
2.Evidence for DIS in the spinal cord 
based on ≥2 T2 lesions in the cord 
3.Positive CSF (isolelectric focusing 
evidence of oligoclonal bands and/or 
elevated IgG index) 
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In two long-term follow-up studies (Beck et al., 2003; Fisniku et al., 2008), it was 
found that MS developed in up to 86% of those with an abnormal brain MRI with 
a CIS. In order to provide an early diagnosis of MS the European multicentre 
collaborative research network that studies MRI in MS (MAGNIMS) drew up 
diagnostic criteria (Montalban et al., 2010), which can provide an MS diagnosis 
in the earliest stage of the disease. These criteria also reflect the importance of 
spinal cord imaging as in the McDonald criteria. 
Spinal cord MRI has been recommended both for early diagnosis and may also be 
useful in determining clinical subtypes (Lycklama et al., 1998). It has also been 
recommended in differentiating MS from other inflammatory disorders affecting 
the spinal cord. Autoimmune conditions, such as systemic lupus erythematosus, 
Sjögren disease, sarcoidosis and small vessel ischaemic changes can mimic the 
T2-weighted signal changes of MS in an MRI of the brain. Thus the sensitivity of 
brain MRI in MS is higher than its specificity (Ormerod et al., 1987). The result is 
that patients with neurological symptoms and an abnormal MRI brain could be 
potentially inappropriately diagnosed as having MS. As spinal cord abnormalities 
in MS have been well defined radiologically as either focal lesions or atrophic 
changes these findings rarely are found in the spinal cord in a healthy population. 
Inflammatory conditions can cause changes in the spinal cord but these often 
differ from MS (Provenzale et al., 1994; Junger et al., 1993). In one study of 
patients with various autoimmune neurological conditions, who had a brain MRI 
mimicking MS, no cervical cord lesions were seen (Rovaris et al., 2000). It has 
been suggested that MS can be confirmed with a positive predictive value of 85% 
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when the spinal cord MRI is abnormal and when the spinal cord is normal; the 
exclusion of MS has a negative predictive value of 97% (Bot et al., 2002).  
Typically spinal cord lesions in MS are detected in the sagittal plane using T2 or 
PD-weighted images and are then confirmed on axial images. The lesions are 
usually less than one vertebral segment in length, most commonly in the cervical 
cord, however diffuse involvement of the spinal cord can also be seen (Lycklama 
et al., 2003). The lesions involve the lateral and posterior white matter and also 
involve the grey matter with a wedge shaped appearance on axial images 
(Tartaglino et al., 1995). Acutely, MS plaques can cause swelling of the cord and 
can enhance with Gd contrast, longstanding lesions can merge to form diffuse 
areas of signal change. Focal or generalised atrophy may also occur. In some 
instances only diffuse changes are seen without the appearance of demarcated 
focal lesions and are associated with progressive forms of the disease (Lycklama 
et al., 1997). 
Although spinal cord MRI is useful when MS is a differential diagnosis based on 
brain imaging, it is also useful when there is a high clinical suspicion of MS but 
the patient has a normal MRI brain, as is the case in a minority of patients with 
MS (Allen et al., 1981). MRI excludes an alternate diagnosis for the symptoms 
attributed to the cord, such as a compressive cause, and increases the sensitivity 
and specificity of imaging for an MS diagnosis (Thorpe et al., 1996). In the same 
study it was commented that cord imaging is particularly helpful in progressive 
forms of MS where there may be a limited number of lesions on the brain and a 
high proportion of cord lesions.  
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Figure 3.1 Sagittal T2-weighted T2 MRI of cervical cord with MS lesion indicated 
by the yellow arrow 
 
Figure 3.2 Axial T2-weighted MRI of the cervical spinal cord with MS lesion, 
indicated by the yellow arrow as a hyper-intense abnormality 
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3.3 Spinal cord atrophy on MRI 
The abnormalities found in spinal cord imaging have been evaluated to 
determine if they correlate with the subtype of MS: RR or progressive forms of 
the disease (Lycklama et al., 1998). There was a correlation found between the 
number of brain T1 lesions and number of focal spinal T2 lesions. There was also 
found to be a correlation between spinal cord atrophy and expanded disability 
status scores (EDSS) (Kurtzke 1983) in all groups. However, a difference in the 
degree of atrophy of the cord was noted between RRMS and progressive forms of 
the disease (PPMS, SPMS). This study was of importance as earlier studies 
(Filippi et al., 1995) evaluating the correlation between brain MRI abnormalities 
and disability were disappointing. These findings were emphasised in a further 
study evaluating dimensions of the cervical spinal cord in benign MS and SPMS 
compared to controls (Filippi et al., 1996). There was found to be an inverse 
association between cord atrophy and disability and cord dimensions in benign 
MS were similar to healthy controls. However a comparison of the T2-weighted 
lesions on brain MRI did not correlate with disease subtype or degree of 
disability. 
As earlier studies had shown a variable relationship between cord atrophy and 
disability (Kidd et al., 1993; Filippi et al., 1995), a new reproducible method of 
measuring cord atrophy was developed by Losseff et al. (1996). In this study a 
1.5T MRI was performed on sixty patients with various forms of MS. From this 
scan five axial 3mm slices were used at the level of C2/C3 intervertebral disc. 
This level was chosen for three reasons: the CSF space is wide so that the cord 
lies centrally (maximising cord/CSF contrast); there is little variability of cross 
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sectional area at this level; and it is an uncommon site for disc protrusion. A 
semi-automated technique was used, the accuracy of which was determined by 
calculating the area of resin rods in fluid to simulate spinal cord measurement. 
From these images a region of interest was drawn around the cord in the top 
slice and then around the cord and CSF space. The technique provided a measure 
of cord cross-sectional area with a coefficient of variation of 0.8%, indicating its 
reproducibility. A strong correlation was found between EDSS score and cord 
area and a correlation between reductions in cord area compared to controls 
with increasing levels of disability. The functional system scores of the EDSS 
were also found to correlate with cord area using this technique.  
Cord atrophy has been found to occur independently of focal lesions (Bergers et 
al., 2002) and these findings have correlated with pathological studies (Ganter et 
al., 1999). The axonal loss and increase in axonal diameter noted pathologically 
was confirmed to occur in normal appearing spinal cord as well as totally and 
partially demyelinated areas. This study provided further evidence for the lack of 
correlation between T2-weighted lesions and physical disability as measured by 
the EDSS. As pathological studies indicated axonal loss from early in the course 
of the disease, radiological studies have also examined possible axonal loss in 
patients with a CIS using atrophy as a surrogate marker of this pathology (Brex 
et al., 2001). Those patients with an abnormal brain MRI were found to have a 
more atrophic spinal cord than those with a normal brain MRI compared to 
controls. Spinal cord syndromes accounted for 12% of those studied, suggesting 
that axonal loss occurs in the spinal cord irrespective of clinical presentation. 
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The investigators also reported atrophic changes found in the brain in the early 
stages of MS following CIS (Brex et al., 2000). 
 
Figure 3.3 Sagittal 3D T1-weighted cervical spine MRI: used in calculating spinal 
cord area in MS. 
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3.4 Association between spinal cord MRI abnormalities and disability 
 
The EDSS, developed by Kurtzke (1983), remains one of the most frequently 
used measures of disability in MS in clinical trials and studies of MS. A number of 
criticisms have been made of the EDSS since it was developed: insensitivity to 
small changes, poor intra-rater and inter-rater variability and its focus on 
ambulatory function without all measures of disability being taken into account 
(Hobart et al., 2000). Spinal cord cross sectional area on MRI, however, has been 
shown to correlate with EDSS and functional system scores (FSS) (Losseff et al., 
1996) and given the lack of correlation between T2-weighted lesions on brain 
MRI and disability, a number of investigators have assessed the use of spinal 
cord MRI parameters as an objective and reproducible measure of disability.  
The abnormalities found on spinal cord MRI appear to correlate with the subtype 
of MS (Lycklama et al., 1997). As there had been no correlation found between 
the number of focal lesions and disability (Bergers et al., 2002) Lycklama et al. 
investigated whether diffuse changes seen on proton density-weighted images, 
rather than focal T2 hyperintense lesions could account for disability in the 
subgroups of MS assessed. Sixty patients with RRMS, SPMS and PPMS were 
imaged and examined using the EDSS (Kutrzke 1983) and also the Functional 
Systems Score (Kurtzke 1961). It was found that the presence of diffuse 
abnormalities was associated with progressive forms of MS and higher scores on 
the EDSS and Functional Systems Score.  
As there has been an established link between cord atrophy and disability 
(Losseff et al., 1996), studies have determined whether this is a reliable MRI 
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parameter for assessment of physical disability in long-term follow up studies 
(Stevenson et al., 1998; Losseff et al., 1996). 
 By using a volume acquired inversion-prepared fast spoiled gradient echo 
(FSPGR) acquisition the problem of reproducibility was addressed by Stevenson 
et al. (Stevenson et al., 1998). The cord area was measured at C2/C3 in 28 
patients with MS. Intra-rater reproducibility was improved at 0.51% compared 
to 0.73% in the assessment by Losseff et al. (Losseff et al., 1996). Again there was 
a strong correlation between EDSS scores, however the MRI parameters were 
found to be reproducible in this long-term follow up study. 
MRI of the brain in PPMS often shows limited abnormalities (Thompson et al., 
1991); with the result that prediction of disability was limited in this progressive 
form of the disease based on this modality of imaging alone. In a long term follow 
up study of PPMS (Sastre-Garriga et al., 2005), it was found that cord atrophy 
over two years predicted clinical outcome on long-term follow up. 
In a ten-year follow up study of 101 patients with PPMS, patients were assessed 
using 10m metre timed walking test (TWT), nine hole peg test (9-HPT), EDSS 
and T1 and T2-weighted MRI of the brain and spinal cord at baseline one and 
two years (Khaleeli et al., 2008). Cervical cord cross sectional area was 
calculated using the technique described by Losseff et al. (Losseff et al., 1996). 
Changes in the EDSS score as well as other parameters were recorded. Although 
spinal cord cross sectional area predicted disability at five years it did not do so 
at ten years. The strongest predictor of long term disability in PPMS was TWT at 
baseline. 
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Earlier studies (Stevenson et al., 1998; Losseff et al., 1998; Losseff et al., 1995) 
focused on cord atrophy as a marker of disability however this has not been the 
only MRI parameter assessed in relation to disability, more recent studies have 
used quantitative MRI measures as a means of assessing the cord and correlation 
with disability. 
 
3.5 Inversion recovery MRI in the spinal cord 
Inversion recovery MRI techniques invert the magnetisation in a T1 sequence by 
applying a pulse, resulting in a strong contrast between tissues with different T1 
relaxation times and can also suppress signal from fluid or fat. Inversion 
recovery sequences can also provide greater sensitivity for Gd enhancement (Lee 
et al., 2000). A number of different inversion recovery techniques have been 
employed imaging multiple sclerosis: short T1 inversion recovery (STIR), phase 
sensitive inversion recovery (PSIR) and double inversion recovery (DIR).  
 
3.5.1 Short T1 inversion recovery 
Imaging the cord in the sagittal plane in MS is useful as it can give anatomical 
level of lesions seen along the length of the cord, this can be done using a number 
of different sequences including short T1 inversion recovery (STIR). Enhanced 
T1 and T2 contrast are obtained by shortening the inversion time (Bydder et al., 
1985). The signal change due to increase in T1 and T2 is of importance as this is 
commonly seen in spinal cord lesions, such as in MS; the sequence also has less 
susceptibility to motion artefacts and enhanced fat suppression (Mascalchi et al., 
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1992). This technique was first employed in the spinal cord in 48 patients with 
varied spinal cord syndromes, not exclusively demyelinating. The STIR sequence 
was found to be superior to cardiac gated spin echo images; however, there was 
a lower signal to noise ratio (SNR) with STIR (Mascalchi et al., 1992).  
This technique was then employed to evaluate exclusively patients with MS who 
had symptoms or signs suggestive of spinal cord pathology (Thorpe et al., 1994). 
The STIR sequences obtained on the spinal cord were compared to FSE 
sequences. More lesions were seen on the STIR sequence; however, there was 
poorer anatomic definition and again a lower SNR. Using a combination of STIR 
and FSE the overall number of lesions detected increased by 25% and the 
authors recommend using a combination of both sequences. 
Rocca et al. compared the use of STIR with gradient echo (GE) and T2-weighted 
FSE in a study of 56 patients with MS (Rocca et al., 1999). Both GE and STIR 
sequences increased the number of lesions detected when compared to FSE, with 
STIR having the best sensitivity of the three sequences and also the greatest 
number of lesions was detected with STIR. In a separate study the STIR sequence 
was compared to conventional spin echo sequence (CSE) in a cohort of patients 
with secondary progressive MS (Bot et al., 2000). The STIR sequence showed 
33% more lesions, including smaller focal lesions, and with a higher contrast to 
noise ratio (CNR). STIR was recommended as an adjunct in detecting 
abnormalities in the spinal cord in MS. 
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Figure 3.4 Sagittal STIR image of cervical spine showing MS lesion in the cervical 
cord 
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3.5.2 Phase sensitive inversion recovery imaging 
As with other inversion recovery techniques, phase sensitive inversion recovery 
(PSIR) can provide strong contrast between tissues with different T1 relaxation 
times by estimating and removing background phase and retrieving correct 
polarity information. PSIR has shown to be effective in cortical grey matter 
lesion detection with clear lesion delineation (Hou et al., 2005; Nelson et al., 
2007, Sethi et al., 2012; Sethi et al., 2013). PSIR has been prospectively compared 
with FSE and STIR imaging in the spinal cord in MS (Poonawalla et al., 2008). 
Contrast between lesions was compared using the different sequences with FSE 
as the reference. The highest lesion to cord contrast was seen with the PSIR 
sequences and both this sequence and the STIR improved lesion detection 
compared to FSE. The authors recommend that STIR alone is not sufficient for 
lesion detection. 
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Figure 3.5 Axial PSIR of healthy cervical spinal cord at the level of C2/C3 
 
Figure 3.6 Axial PSIR of MS cervical spinal cord with lesion visible (highlighted 
by yellow arrow) in the lateral column of the white matter 
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3.5.3 Double inversion recovery imaging 
Double inversion recovery imaging (DIR) suppresses signal from white matter 
and CSF, which allows easier identification of lesions (Bedell et al., 1998). DIR 
has been utilised for detection of cortical lesions in MS that may not be visible on 
conventional MRI (Geurts et al., 2005).  This sequence has its limitations 
however as it is susceptible to flow artefacts, it also has a low SNR and has poor 
definition of lesion borders. However, use of DIR in combination with PSIR may 
improve the identification of cortical lesions in MS (Nelson et al., 2007). DIR 
imaging has been used for identification of cortical lesions in MS by several 
investigators (Calabrese et al., 2007; Geurts et al., 2005; Nelson et al., 2007; 
Wattjes et al., 2007); however there is limited information as yet on using this 
technique in the spinal cord in MS. 
 
3.6 Quantitative spinal cord MRI 
The importance of MRI in the diagnosis of MS has been reflected by its inclusion 
in all of the most recent diagnostic guidelines for this disease (McDonald et al., 
2001; Polman et al., 2005; Montalban et al., 2010). It has also been used as an 
objective marker of disease activity in a number of clinical trials for treatments 
in MS (Rovaris et al., 1999). However conventional MRI has its limitations in 
detecting the nature and extent of damage in T2-weighted lesions (Kappos et al., 
1999; Molyneux et al., 2001). A number of quantitative measures have been 
developed to elucidate the pathology of MS, which include: Magnetisation-
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transfer MRI, diffusion-weighted MRI, functional MRI and magnetic-resonance 
spectroscopy. 
 
3.6.1 Magnetic resonance spectroscopy 
In normal brain tissue four main metabolites are detected from in vivo proton 
magnetic resonance spectroscopy using long TEs: choline containing compounds, 
creatine/phosphocreatine, N-acetylaspartate (NAA) and lactate. Spectroscopy of 
acute MS lesions reveals a change in the normal values with increases in choline 
and lactate in the acute phase and a decrease in NAA (Davie et al., 1994; 
DeStefano et al., 1995). NAA is located in neurones and axons only and reduced 
NAA levels are thought to reflect axonal damage. NAA is synthesised in the 
mitochondria together with adenosine triphosphate and oxygen consumption 
(Bates et al., 1996) and although its exact function is unclear it is known to be the 
second most abundant amino acid in the CNS (Simmons et al., 1991). 
NAA is of particular importance in assessing spectra as its level is a reflection of 
axonal integrity, it can be permanently decreased reflecting axonal loss or there 
can be a reversible component suggesting axonal dysfunction in an acute lesion 
(Davie et al., 1994). Decreases in NAA can precede visible abnormalities on MRI 
by several months (Pan et al., 2001) and levels are correlated with disability and 
cognitive dysfunction (Bjartmar et al., 2000; Kendi et al., 2004). 
In a study by Bjartmar et al (2007) the NAA levels in the post-mortem spinal 
cords of five disabled patients with MS were measured. Spinal cord area, axonal 
loss and NAA levels were measured on the pathological specimens. It was shown 
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that axonal loss was correlated with decreased NAA in both myelinated and 
demyelinated axons. These data support the use of decreased NAA levels in MR 
spectroscopy (MRS) as a marker of axonal loss and consequently disability in MS. 
Studies initially focused on MRS in the brain of patients with MS, however more 
recently a number of studies involving the spinal cord have been done. The first 
such study was carried out by Kendi et al (2004), comparing MRS in the cervical 
cord of nine patients with MS and twelve healthy controls. In keeping with 
histopathological findings (Bjartmar et al., 2000) there was a prominent 
decrease in NAA levels in the spinal cord of MS patients, with all other 
metabolites unchanged from controls. The same technique was investigated in a 
separate study with 11 patients with MS and 11 controls (Blamire et al., 2007). 
Again it was found that NAA levels were substantially reduced in the spinal cord 
compared to controls and there was significant cord atrophy on conventional 
MRI sequences in MS cases. However, no significant correlation was found 
between NAA levels and EDSS scores, the authors point out that this may be due 
to the small sample size or the heterogeneity of cases used. The decrease in NAA 
was also found to be greater than compared to normal appearing white matter in 
the brain it is hypothesised that this disparity may be due to axonal damage, 
Wallerian degeneration or transection of the cord but not in the brain. 
MRS has also been employed as a method of understanding the mechanism of 
spinal cord repair following an acute relapse (Ciccarelli et al., 2010). Fourteen 
patients with a diagnosis of MS and a spinal cord syndrome localised to the 
cervical cord clinically and radiologically were recruited and imaged at three 
monthly intervals following their initial presentation. It was found that the 
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patients who did not improve had an overall decrease in NAA over time across 
the three time points (1, 3 and 6 months). In comparison with those who 
recovered, where there was an increase in NAA from one month to six months, 
and those with a better recovery had a corresponding greater increase. It was 
found that a longer disease duration was associated with a smaller increase in 
NAA after one month and both those who recovered and those who didn’t had an 
overall decrease in cord area over time. It is hypothesised that the increase in 
NAA may reflect enhanced mitochondrial activity, which is a proposed 
mechanism for recovery following demyelination. 
In a similar study by the same group (Ciccarelli et al., 2007) acute disability was 
assessed, following a cervical cord relapse, in 14 patients with MS, using spinal 
cord spectroscopy and diffusion based tractography. Radiological parameters 
were compared with the EDSS, 9-hole peg test (9-HPT) (Goodkin et al., 1988) 
and 25-foot walk test (TWT) (Cutter et al., 1999). It was found that NAA, 
although significantly lower than controls, did not correlate with EDSS or TWT 
but there was a correlation with 9-HPT.  
Myo-inositol, is a further metabolite that may be analysed from MRS and is a 
potential marker of glial cell function (Brand et al., 1993) and also may be 
increased in the normal appearing white matter in the MS brain (Fernando et al., 
2004). The authors found that myo-inositol correlated with the EDSS and 
creatine levels correlated with 9-HPT. 
More recently, myo-inositol in the cervical cord has been reported to be useful in 
distinguishing neuromyelitis optica (NMO) spectrum disorders from MS 
(Ciccarelli et al., 2013). The lower myo-inositol levels seen in this study in NMO 
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are thought to reflect astrocytic necrosis, which is a prominent feature 
pathologically in this disorder. This may have implications for future studies that 
aim to investigate biomarkers capable of distinguishing NMO from MS. 
3.6.2 Magnetisation-transfer imaging 
Magnetisation transfer involves transfer of magnetisation from the hydrogen 
nuclei of protons (including macromolecular protons e.g. in myelin and 
membranes) that have restricted movement to those that are unrestricted or 
free. The hydrogen nuclei in the water molecules are usually referred to as 
protons. Proton movement differs depending on their location whether they are 
in fluid, with free movement, or in tissue, where movement is more restricted 
(Woff et al., 1989). The free protons have fewer interactions with the 
environment and a longer T2 time compared to the protons that interact with 
the local structures and have a shorter T2. Magnetisation transfer is a 
measurement of the interaction between these two pools of protons and from 
this the magnetisation transfer ratio (MTR) can be calculated. It is of significance 
in MS because a low MTR indicates damage to macromolecular structures 
including myelin and other neuronal structures. A substantial reduction of MTR 
indicates severe tissue damage (van Wasenberghe et al., 1999). 
As with other modalities of quantitative MRI, initial studies were done on the 
brain, with subsequent work done on the spinal cord, including a comparison of 
magnetisation transfer imaging to histopathology in the spinal cord (Bot et al., 
2004). In this study the cervical cords from 11 patients with MS and two controls 
were imaged using 4.7T MRI and examined histologically. Conventional MRI 
sequences were performed as well as quantitative measures; axonal number, 
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diameter and myelin content were then established from the histology. 
Quantitative MR findings were compared with conventional MRI and it was 
found that total cord area measurement showed a prolonged T1 relaxation time, 
which was increased in MS cases. This finding was replicated with T2 
measurements and a reduced MTR compared to controls. There was a strong 
correlation found between MTR and demyelination but not axonal features. 
However the authors indicate that a number of factors may have influenced this 
lack of correlation: length of disease, varying degrees of gliosis of the cord, 
formalin fixation and high field strength. 
In a similar post mortem study on the spinal cord, using 7T MRI, Mottershead et 
al. evaluated a number of different MRI parameters, including MTR, with 
pathological samples (Mottorshead et al., 2003). It was found that there was a 
strong correlation between MTR and axonal density as well as myelin content. 
The change in MTR values were felt to be due to a reduction in bound protons, 
due to axonal loss, with a corresponding increase in free protons. This study 
supports the use of MTR to quantify both myelin and axonal loss.  
In vivo studies have also examined the use of quantitative MRI measures, 
including the examination of sensorimotor dysfunction and its correlation with 
spinal column damage in MS (Zackowski et al., 2009). Images were obtained on a 
3T MRI using cerebrospinal-fluid-normalised magnetisation transfer (MTCSF), 
which allowed evaluation of spinal columns or grey matter. MTCSF uses CSF as 
an internal intensity standard, allowing inter-individual comparison of MT data 
without the need for a reference scan. It allows for quantitative measures of 
specific spinal columns. MTCSF was calculated in lateral columns and dorsal 
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columns and grey matter volume were assessed from C2/C3. Measures of 
impairment, reflecting damage in these structures were calculated using 
vibratory sense, postural sway, ankle dorsiflexion and walking velocity. It was 
found that EDSS scores correlated with MTCSF results there were significant 
correlations between vibration and dorsal columns and dorsiflexion and walking 
velocity with lateral columns. This study demonstrated that MTCSF could be 
used as a measure of disability in the spinal cord column being assessed. It was 
also noted that grey matter volume MTCSF was significantly correlated with 
disability. The fact that MT imaging is specific for demyelination, as seen in post-
mortem studies (Bot et al., 2004), could indicate that demyelination plays an 
important role in disability, as evidenced by this study. 
Other studies have focused more on the correlation between grey matter and 
disability using MTR (Agosta et al., 2007). MS lesions are found on pathological 
studies on the grey matter of the spinal cord, however, the position of lesions 
with respect to grey and white matter is not easily determined on conventional 
MRI (Lycklama et al., 2001; Gilmore et al., 2006). The cervical cord grey matter of 
18 patients with RRMS was assessed by MTR and findings were correlated with 
EDSS scores (Agosta et al., 2007). Findings were compared to healthy controls. 
RRMS patients were found to have significantly lower MTR in the cervical cord 
grey matter. MTR was also found to correlate with the EDSS score.  
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Figure 3.7 MTR imaging in healthy cervical spinal cord. A) MT ‘on’ B) MT ‘off’ C) 
MTR map 
 
3.6.3 Diffusion weighted imaging 
Diffusion MRI is an alternate means of assessing the motion of water molecules, 
as an apparent diffusion coefficient (ADC). The structure that contains the water 
molecules alters the direction of movement, such as myelin in the brain. During a 
diffusion weighted MRI scan, diffusion sensitising gradients encode the diffusion 
properties of the tissue being investigated; this facilitates the sensitivity of the 
MR signal to the diffusion behaviour spins of the protons in the tissue. By 
measuring the ADC diffusion MRI is thereby able to give information about the 
microstructure of tissue along a diffusion-sensitised direction (Filippi et al., 
2003). The water molecules in the structure are defined as having anisotropy, 
which is the property of being directionally dependent. Anisotropy results in 
variation of diffusivity with direction of measurement (Le Bihan et al., 1991). By 
acquiring a number of different diffusion directions a diffusion tensor (DT) can 
be reconstructed as an ellipsoid construct. The full direction of a molecule’s 
diffusion can be plotted along one of the three orthogonal axes (x, y, z), which are 
known as eigenvectors. The measure of length of each eigenvector provides an 
eigenvaluie, from which quantitative measures can be calculated, including the 
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mean diffusivity (average of ADCs in three orthogonal directions). These values 
can be characterised using a 3 x 3 matrix known as tensor (Piperpaoli et al., 
1996), from which fractional anisotropy (which is a scalar value between zero 
and one that describes the degree of anisotropy of a diffusion process) and radial 
diffusivity (index of diffusivity perpendicular to the main axis of DT i.e. 
perpendicular to the main fibre direction) can be evaluated (Basser et al., 1996). 
Studies have shown abnormal values of ADC, mean diffusivity ([MD] i.e. the 
average magnitude of molecular displacement by diffusion) and FA in T2 lesions 
in MS, with more abnormal values when the lesion is hypointense on T1 (Rovaris 
et al., 2005). 
Diffusion tensor imaging (DTI) has been possible in the spinal cord and has been 
shown to be possible in healthy volunteers including tractography (Smith et al., 
2010). The technique involves advanced protocols and had been applied to study 
MS in the spinal cord. 
A technique known as zonally oblique multislice (ZOOM) technique had 
previously been developed (Wheeler-Kingshott et al., 2002); the same technique 
was extended to establish DTI in the spinal cord. However, this technique was 
limited by the fact that a slice gap was required, which precluded the acquisition 
of contiguous slices. A method of obtaining contiguous slices was then developed 
(CO-ZOOM) which was used in both the optic nerve and spinal cord (Agosta et al., 
2007). The technique used was later employed for spinal cord tractography in 
MS (Ciccarelli et al., 2007), as it had been shown to reduce distortions due to 
susceptibility variations and allows for study of axonal damage where nerve 
fibre tracking is performed.   
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Clark et al. (2000) have examined the use of diffusion imaging in multiple 
sclerosis in three patients with significant locomotor impairment (mean EDSS 
score of 6) compared to four healthy controls. MD was significantly higher in MS 
cord lesions than in controls, with a correspondingly reduced anisotropy 
although this was not found to be statistically significant. Both values were found 
to have a high standard deviation, which may represent the heterogeneity of the 
lesions. The abnormal values were attributed to demyelination and axonal loss 
and in acute lesions to vasogenic oedema. These findings were based on the 
assumption that the spinal cord has cylindrical symmetry.  
DT MRI has been shown in cross sectional studies to correlate with the level of 
disability associated to demyelinating and degenerative conditions in the spinal 
cord (Valsasina et al., 2005; Valsasina et al., 2007). Following these studies a 
longitudinal study was performed on 42 patients with varied MS subtypes 
(Agosta et al., 2007). FA and MD values were calculated in the cervical cord as 
well as routine MRI studies, which allowed calculation of cross sectional area. 
The decrease in FA over time was found to be associated with patients’ age and 
clinical phenotype, higher in PPMS than other groups. However no significant 
correlation was found with longitudinal change in cord atrophy, or T2-weighted 
lesions with changes in FA or MD. This study demonstrated that not just cord 
atrophy changes over time but also the intrinsic tissues of the cord as reflected 
by DTI changes. It was also shown that the intrinsic abnormalities precede the 
development of atrophy reflected on MRI imaging. Furthermore, the changes in 
FA of the cervical cord were associated with EDSS scores at baseline and with the 
accrual of disability over time. 
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It has been shown that axonal damage in the spinal cord occurs independent of 
T2-weighted lesions in the spinal cord (Bergers et al., 2002) and that T2-
weighted lesions in the brain do not correlate with disability (Filippi et al., 1995). 
Applying the same principles to DTI imaging, Van Hecke et al. assessed the spinal 
cord diffusion properties in MS patients with and without T2 weighted lesions in 
the spinal cord (Van Hecke et al., 2009). In each patient the following parameters 
were calculated: FA, MD, axial (longitudinal) diffusivity (||), radial (transverse) 
diffusivity () and the ratio of axial to radial diffusivity (||/). Regions of 
interest (ROI) were manually placed on axial images to avoid volume averaging 
by inclusion of CSF. Diffusion tractography was also performed on the spinal 
cord. It was found that FA and the ratio of longitudinal and transverse diffusivity 
(||/) were both significantly reduced in the spinal cord of patients with and 
without any lesions and no statistical difference between the subgroups of 
patients. MD values were found to be increased, but not found to be statistically 
significant. Other authors have suggested that normalisation of the MD value can 
occur due to astrocytic proliferation, cell debris, fibrillary gliosis and 
inflammatory infiltrates (Agosta et al., 2005). Such findings suggest that FA and 
||/ are more sensitive to the micro structural changes in the spinal cord in MS 
and may imply that pathology in the spinal cord is present even when lesions are 
only seen in the brain. 
Using diffusion weighted imaging, a three dimensional modelling technique can 
be used to visually represent neural tracts. Although tractography is typically 
done in the brain, it may also be performed in the spinal cord. However, there 
have been limitations with tractography algorithms that inhibit their application 
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in clinical practice or trials: the process of generating tract measures may be 
laborious and with high variability, which can limit sensitivity to detect 
longitudinal change and may be further compounded in destructive processes 
(Wheeler-Kingshott et al., 2009). To overcome these difficulties two novel 
techniques have been developed: (i) tract based spatial statistics, allowing 
comparison of different tracts by simplifying the structure (Smith et al., 2006); 
(ii) tract probability maps from DTI data, based on probability of a voxel 
belonging to a known tract (Hua et al., 2008). Reich et al. compared these 
techniques in a recent study (Reich et al., 2010). MRI scans were performed on 
healthy volunteers to generate tract probability maps and patients with MS were 
studied and results from the two methods were compared. It was found that the 
there was a correlation found in the optic radiation and corpus callosum but less 
so in the optic tract. It was also found that the tract probability map method 
correlated well with Paced Auditory Serial-Addition Test (PASAT – a component 
of the MSFC [Cutter et al., 1999]) scores for the corpus callosum. 
DTI has also been used to elucidate the mechanism whereby some people with 
MS do not accrue increasing levels of disability over a prolonged period of time, 
in a variant of the disease known as benign MS (BMS) (Benedetti et al., 2010). In 
this study BMS patients were compared with SPMS, who had a higher EDSS. 
Parameters recorded included: cervical cord MD and FA, with histograms 
produced for each, cross sectional area of the cord and brain T2 lesion volume. It 
was found that both BMS and SPMS patients had significant increases in cord MD 
compared to healthy controls, SPMS patients were also found to have a 
significant decrease in average FA compared with BMS and healthy controls. The 
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authors suggest that the discrepancy between FA and MD in BMS may be due to a 
preservation of white matter bundles in the cervical cord. Thus DTI can 
potentially give a further insight into the mechanism of disability in MS and why 
some individuals are relatively spared. 
In a recent study by Oh et al. (2012) spinal cord FA and MD were found to be 
independently associated with hip flexion, vibration sense and EDSS. 
Associations with a number of similar measures of physical disability, used in the 
study by Oh et al., have also been shown to be associated with spinal cord RD and 
FA (Naismith et al., 2013). Furthermore, spinal cord DTI metrics (FA and MD) 
were shown to be able to discriminate between disability levels in MS, whereas 
T2-weighted lesions were unable to do so (Oh et al., 2013). These important 
associations with disability and discriminatory capacity of DTI may reflect the 
microstructural abnormalities (such as axonal loss and demyelination) being 
detected in the spinal cord, that may not be detected using conventional T2-
weighted images (Bergers et al., 2002). 
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Chapter 4 - Spinal cord atrophy in long disease duration multiple sclerosis 
 
4.1 Introduction 
Understanding the causes of long-term disability in MS is a key goal of current 
research; it is directly relevant to how we monitor and treat the disease. 
Histopathology studies have shown that MS affects brain grey (GM) and white 
matter (WM) (Brownwell and Hughes 1962), and the spinal cord (Fog 1950). 
However, from such work (Bø et al., 2003; Kutzelnigg et al., 2005; Gilmore et al., 
2006) it is difficult to determine which is most clinically relevant, and which is 
most likely to serve as a useful marker of disease progression and treatment 
effectiveness. MRI, while being less pathologically specific, facilitates assessment 
of tissue abnormalities in vivo and approximate histopathological changes. 
Previous work measuring brain lesion load, brain and spinal cord atrophy, has 
demonstrated correlations between changes in all these regions and clinical 
outcomes, albeit of varying strengths in different cohorts and with no single 
measure found to fully explain variability in disability scores. Given this, there 
has been increasing interest in the use of combinations of MRI measures in 
parallel to more fully characterise clinically relevant pathology in life. 
Of the conventional MRI techniques available, WM lesions determined using T2-
weighted imaging have been studied more extensively, and have a clear role in 
the diagnosis of MS (Polman et al., 2011) and in monitoring response in 
treatment trials (Barkhof et al., 2011). Following a clinically isolated syndrome 
(CIS) the load and location of brain and spinal cord lesions seen on T2 weighted 
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scans, and appearance of new lesions on serial scans, has been shown to predict 
the conversion from CIS to MS. The accrual of brain WM lesions also, in part, 
predicts disability and conversion to secondary progressive MS (Brex et al., 
2002; Rudick et al., 2006; Fisniku et al., 2008). Furthermore, a combination of 
lesions and relapses has been proposed as a marker of progression in MS 
(Sormani et al., 2011). However, despite the frequent use of brain T2-lesion 
volume (T2LV) as an endpoint in clinical trials (Polman et al., 2006; Coles et al., 
2012; Radue et al., 2012) its contribution to disability in the long term has yet to 
be fully elucidated (Barkhof et al., 2009), although some evidence suggests T2LV 
early in the course of the disease may be predictive of mortality (Goodin et al., 
2012).  
Neuro-axonal loss has been shown on histopathological examination of brain GM 
and WM (Trapp et al., 1998; Ganter et al., 1999; Wegner et al., 2006) and MRI 
parameters that are affected by this, such as GM volumes, have been found to 
correlate with disability (Fisniku et al., 2008; Roosendaal et al., 2011). In 
particular, GM atrophy has been shown to have a role in predicting conversion 
from CIS to MS (Calabrese et al., 2011), as well as reflecting disease subtype 
(Fisniku et al., 2008; Fisher et al., 2008). Atrophy has also been observed in WM 
but appears to progress less rapidly than in GM (Ge et al., 2001; Chard et al., 
2002) albeit with the caveat that there have been few very long-term studies, 
and correlations with disability have not been consistently found. Measures of 
brain atrophy are being used as outcome measures in clinical trials in both 
relapsing remitting (Miller et al., 2007, Kappos et al., 2010) and progressive MS 
(Leary et al., 2003; Kapoor et al., 2010; Connick et al., 2012). 
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Spinal cord involvement by MS is a major cause of locomotor disability. Axonal 
loss has been demonstrated in the spinal cord, and is a contributory factor for 
spinal cord atrophy in pathological studies (Ganter et al., 1999; Bergers et al., 
2002; Bot et al., 2004). Several MRI studies have found correlations of disability 
with upper cervical spinal cord atrophy (Losseff et al., 1996; Stevenson et al., 
1998; Horsfield et al., 2010; Rocca et al., 2011).  
Two studies have investigated brain and spinal cord atrophy in combination. A 
single site study of 70 people followed up for 20 years after a CIS suggestive of 
MS, 43 of whom had clinically definite MS when scanned (median expanded 
disability status scale [EDSS] in the whole group 2.5, in the clinically definite MS 
group 3.5), found that brain grey matter and spinal cord atrophy both 
independently associated with disability (Bonati et al., 2011); and another 
smaller single site study (21 patients) in patients with a shorter disease duration 
(mean 8 years) and lower levels of disability (mean EDSS 1.6) found that 
measures of spinal cord atrophy correlated with disability, while brain lesion 
load and atrophy did not (Cohen et al., 2012). 
In this multicentre cross-sectional study, the relationship between spinal cord 
and brain atrophy and brain lesion load with long term disability in MS is 
explored. The aim of this study is to investigate whether spinal cord atrophy is 
associated with higher levels of physical disability, independently from brain 
pathology, in people with at least twenty years disease duration. 
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4.2 Methods 
4.2.1 Patients  
Seven centres participated in this study, and patients with relapse-onset 
(relapsing remitting [RR] or secondary progressive [SP]) MS with first symptom 
onset 20 or more years prior to their clinical and MRI examinations were 
included. MS subgroups were classified by Lublin-Reingold criteria (Lublin and 
Reingold 1996). Previous or on-going disease modifying drugs (DMD) were 
noted.  
All patients had EDSS determined (Kurtzke 1983). RRMS patients who had an 
EDSS score of ≤3 were defined as having benign MS (Filippi et al., 1994). 
Data from patients who had been treated with steroids in the month prior to MRI 
acquisition were excluded. The ethics committee from each of the participating 
centres approved this work, and written informed consent was obtained from 
each subject. 
4.2.2 MRI acquisition 
MRI scans were acquired using 1.5T (n=5) or 3T (n=2) scanners and included 3D 
T1-weighted gradient echo sequences of the brain and cervical cord, and dual-
echo 2D spin-echo sequences of the brain. The acquisition parameters are 
summarised in Table 4.1. 
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Table 4.1 MRI parameters in each participating centre 
 
 
 
 
 
 
 
 
 
 
 
 
 Centre London Barcelona Basel Milan 
Don 
Gnocchi 
Milan 
San-
Raffaele 
Rome Amsterdam 
 Scanner 
manufacturer    
Phillips 
(3T) 
Siemens 
(1.5T) 
Siemens 
(1.5T) 
Siemens 
(1.5T) 
Siemens 
(1.5T) 
GE (1.5T) GE (3T) 
T2 brain 
scan 
Slice (mm) 3 3 3 3 5 4 3 
TR (ms) 3500 2500 3980 3310 3800 2620 2300 
TE (ms) 85 91 112 11 112 116 114.1 
Matrix (mm2) 240x240 240x320 250x256 256x256 256x256 512x512 512x512 
Resolution 
(mm2) 
1x1 0.78x0.78 0.98x0.98 0.98x0.98 0.98x0.98 0.63x0.63 0.49x0.49 
3D T1 
brain 
scan 
Slice (mm) 1 1.2 1 1 1.5 1 1 
TR (ms) 6.8 2300 2080 1900 2000 21 7.8 
TE (ms) 3.1 3 2.93 3.4 2.9 6 3 
Matrix (mm2) 256x256 240x256 250x256 192x256 256x256 256x256 256x256 
Resolution 
(mm2) 
1x1 1x1 0.98x0.98 1x1 0.82x0.82 0.98x0.98 0.94x0.94 
3D T1 
cervical 
spine 
scan 
Slice (mm) 1 1.2 1 0.9 1 1 1 
TR (ms) 8.1 2300 2700 1160 1160 21 7.2 
TE (ms) 3.7 3 4.2 4.2 4.2 6 3 
Matrix (mm2) 256x256 240x256 256x256 256x512 256x256 256x256 512x512 
Resolution 
(mm2) 
1x1 1x1 1x1 0.45x0.45 1x1 0.98x0.98 0.5x0.5 
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4.2.3 Image analysis 
T2 lesion volume 
Lesions on T2-weighted scans were outlined using a semi-automated edge 
finding tool (JIM v. 6.0, Xinapse systems, Aldwincle, UK, 
http://www.xinapse.com). Total lesion volume was recorded in mLs for each 
subject. 
Brain tissue volumes 
To avoid segmentation errors due to WM lesions, an automated lesion-filling 
technique was employed (Chard et al., 2010). Lesion masks were created based 
on 3D-T1 weighted sequences only (i.e. without reference to previously created 
masks on T2-weighted images). The lesion-filled images were segmented into 
WM, GM and cerebrospinal fluid (CSF) using the ‘new segment’ option on SPM8 
(statistical parametric mapping; Wellcome Trust centre for NeuroImaging, UCL 
Institute of Neurology, London). All segmentations were reviewed to exclude 
errors. WM and GM fractional (WMF and GMF) volumes relative to total 
intracranial volume (the sum of GM, WM and CSF volumes) were calculated.  
Spinal cord atrophy 
Sagittal spinal cord images were reformatted axially into five 3mm thick slices 
perpendicular to the long axis of the spinal cord centred at C2/C3. Upper cervical 
cord cross-sectional area (UCCA) was then evaluated using an active surface 
model (Horsfield et al., 2010), which has been used in a multi-centre study 
(Rocca et al., 2011). Mean cord area of the five slices was determined for each 
subject (Healy et al., 2012). 
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4.2.4 Statistical analysis 
Univariable associations between EDSS and the four MRI predictors (WMF, GMF, 
T2LV, and UCCA) and between MRI variables were assessed using Spearman 
correlation. 
For the binary EDSS models (dividing into groups by EDSS scores <6/6, as an 
EDSS score of 6 marks the requirement of a walking aid) univariable logistic 
regression followed by multiple logistic regression were performed with the four 
MRI predictors and centre, age at scan, age at onset, disease duration, disease 
modifying drugs and gender initially included as potentially confounding 
covariates: only centre and age at scan, contributed significantly (at p<0.05) or 
materially affected coefficients, and these were subsequently retained in all 
models. Along with centre and age at scan, the four MRI predictors were entered 
together and then individually removed from the final multivariable model if 
they did not significantly contribute (at p<0.05). The C-statistic was calculated to 
assess the predictive performance of the logistic model; this statistic can range 
from 0.5 (no better than chance) to 1 (perfect prediction). 
With four-category EDSS (1.5/>1.5,<3/3,<6/6, categories chosen for even 
frequency distribution) a similar procedure to the above was carried out using 
instead proportional odds multiple ordered logistic regression; again centre and 
age at scan were the only covariates to either be significant (at p<0.05) or 
materially affect MRI coefficients, and were retained in models. The four part 
model enabled more complete analysis across the spectrum of disability, as per 
previously published work (Fisniku et al., 2008). 
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Differences in means between patient groups were assessed by t-test or ANOVA 
(for comparison of RR and SP and subgroups of RR with SP). In the same way 
patients with an EDSS 3 were compared to those with an EDSS 6, irrespective 
of disease subtype. 
Analyses were carried out in Stata 12 (Stata Corporation, College Station, TX, 
USA) and SPSS 20 (IBM, USA). 
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4.3 Results 
Demographics of patients in each participating centre and disability category are 
summarised in Tables 4.2 and 4.3. For the whole group, patients had a mean age 
of 52 years (SD 8.8) with a mean age of disease onset 25.8 years (SD 7.7), 111 
females and 48 males, of whom 92 had RRMS and 67 SPMS, with a mean disease 
duration of 26.2 years (SD 6.7) and a median EDSS of 4 (range 0-8). For the four-
category EDSS model patient numbers were as follows: ≤1.5: 28, >1.5, <3: 33, ≥3, 
<6: 44, ≥6: 54. 
Brain segmentation failed for four people (155 volumetric brain scans were 
used), two patients did not have a T2W scan (157 patients were included in 
T2LV analysis) and in three patients spinal cord scan was distorted so could not 
be analysed. 
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Table 4.2 patient demographics by centre 
 
Table 4.3 patient demographics by EDSS category 
 RRMS (EDSS ≤3) RRMS (EDSS ≥3.5) SPMS 
n 70 22 67 
Age (years) mean 
± SD 
49.5 ± 8.1 49.7 ± 7.5 55.4 ± 8.7 
Gender (female, 
male) 
49, 21 20, 2 42, 25 
Disease duration 
mean ± SD 
25.2 ± 0.5 26.1 ± 4.1 27.3 ± 7.8 
 
Centre Age 
(years) 
Mean ± 
SD 
Gender 
(female, 
male) 
Age at 
disease 
onset 
(years) 
Mean ± 
SD 
Disease 
duration 
(years) 
Mean ± 
SD 
Number 
of 
RRMS, 
patients 
Number 
of SPMS 
patients 
EDSS 
Median, 
range 
1. London, n=20 55.3 ± 
7.9 
13, 7 27.8 ± 
6.7 
27.0 ± 
6.3 
9 11 6, 1-8 
2. Barcelona, n=20 53.6 ± 
8.9 
14, 6 25.2 ± 
6.9 
28.4 ± 
9.1 
7 13 4, 2-8 
3. Basel, n=12 56.0 ± 
9.9 
7, 5 24.0 ± 
8.4 
32.0 ± 
7.8 
8 4 4, 2-6 
4. Milan Don 
Gnocchi, n=23 
53.0 ± 
8.0 
17, 6 28.0 ± 
9.0 
25.0 ± 
6.0 
8 15 6, 2-7.5 
5. Milan San-
Raffaele, n=64 
50.0 ± 
8.9 
43, 21 25.0 ± 
8.0 
25.0 ± 
6.0 
45 19 2.5, 0-6.5 
6. Rome, n=11 47.4 ± 
5.9 
11, 0 25.9 ± 
6.2 
25.0 ± 5 9 2 2, 0-6.5 
7. Amsterdam, n=9 52.2 ± 
9.0 
6, 3 29.1 ± 
7.5 
22.7 ± 
4.0 
6 3 4, 1.5-7 
All centres 
n=159 
52.0 ± 
8.8 
111, 48 25.8 ± 
7.7 
26.2 ± 
6.7 
92 67 4, 0-8 
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4.3.1 Correlations between MRI features  
WMF was significantly correlated with T2LV (r=-0.21, p=0.01) and UCCA (r=0.28, 
p<0.01). GMF did not correlate significantly with either T2LV or UCCA but was 
inversely correlated with WMF (r=-0.26, p<0.01).  
4.3.2 MRI features and clinical subgroups (Table 4.4 and 4.5) 
WMF, T2LV and UCCA were found to differ significantly in ANOVA analysis 
between the RRMS and SPMS groups, but no significant difference was found for 
GMF.  
T2LV was significantly higher in SPMS than in benign RRMS (EDSS≤3) (mean ± 
SD 21.3 ± 14.7 vs. 15.7 ± 11.7, p=0.02), and showed a non-significant trend to be 
higher in SPMS than in the non-benign RRMS group (mean ± SD 21.3 ± 14.7 vs. 
16.1 ± 14.5, p=0.16). On the other hand T2LV were almost identical in the benign 
and non-benign RRMS groups (mean ± SD 15.7 ± 11.7 vs. 16.1 ± 14.5, p=0.94). 
T2LV was also found to differ significantly between all subjects with EDSS ≥ 6 
and those with EDSS ≤ 3 (mean 24.3 ± SD 14.4 vs. 15.7 ± 11.7, p<0.01). 
UCCA was significantly higher in benign RRMS when compared with both non-
benign RRMS (mean ± SD 69.7 ± 8.1 vs. 64.8 ± 8.7, p=0.02) and SPMS (mean ± SD 
69.7 ± 8.1 vs. 64.2 ± 9.7, p<0.01). On the other hand, UCCA values were almost 
identical in non-benign RRMS and SPMS subgroups (mean ± SD 64.8 ± 8.7 vs. 
64.2 ± 9.7, p=0.80). UCCA was also found to differ significantly between all 
subjects with EDSS ≥ 6 and those with EDSS ≤ 3 (mean 63.3 ± SD 10.3 vs. 69.7 ± 
8.1, p<0.01).  
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Table 4.4 MRI parameters in benign and ‘non-benign’ RRMS and SPMS 
  All 
RRMS 
Benign 
RRMS 
Non-
Benign 
RRMS 
SPMS 
T2LV (mLs) Mean 16.0 15.7 16.1 21.3 
SD 12.3 11.7 14.5 14.7 
UCCA (mm2) Mean 68.6 69.7 64.8 64.2 
SD 8.4 8.1 8.7 9.7 
WMF Mean 0.332 0.335 0.324 0.324 
SD 0.019 0.018 0.021 0.017 
GMF Mean 0.460 0.462 0.457 0.460 
SD 0.014 0.014 0.012 0.014 
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Table 4.5 Comparison of MRI parameters between benign and ‘non-benign’ 
RRMS and SPMS using ANOVA 
 MS subtypes being 
compared 
p value 
T2LV (mLs) Benign RRMS/Non-
Benign RRMS 
0.94 
Benign RRMS/SPMS 0.02 
Non-Benign RRMS/SPMS 0.16 
All RRMS/SPMS 0.02 
UCCA (mm2) Benign RRMS/Non-
Benign RRMS 
0.02 
Benign RRMS/SPMS <0.01 
Non-Benign RRMS/SPMS 0.80 
All RRMS/SPMS <0.01 
WMF Benign RRMS/Non-
Benign RRMS 
0.02 
Benign RRMS/SPMS <0.01 
Non-Benign RRMS/SPMS 0.98 
All RRMS/SPMS 0.01 
GMF Benign RRMS/Non-
Benign RRMS 
0.24 
Benign RRMS/SPMS 0.55 
Non-Benign RRMS/SPMS 0.47 
All RRMS/SPMS 0.81 
 
4.3.3 MRI features and physical disability (EDSS) 
EDSS was significantly correlated with T2LV (Spearman’s r=0.19, p=0.02), WMF 
(r=-0.32, p<0.01) and UCCA (r=-0.31, p<0.01), whereas the correlation between 
EDSS and GMF was not significant (r=-0.07, p=0.36). Scatter plots of MRI 
variables against EDSS are shown in Figure 4.1. 
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Figure 4.1 Graphs of spinal cord area (A), T2 lesion volume (B), white matter 
fraction (C) and grey matter fraction (D) against EDSS. 
In a univariable logistic regression analysis for binary EDSS groups, both T2LV 
(odds ratio=1.98 per 1 SD larger T2LV, 95% CI 1.39, 2.82, p<0.01) and UCCA 
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(odds ratio=0.55 per 1 SD higher cord area, 95% CI 0.38, 0.79, p<0.01) were 
found to be associated with EDSS ≥6. In a univariable ordered logistic regression 
for four-category EDSS the following were found to be associated with EDSS: 
T2LV (odds ratio=1.56 per 1 SD larger T2LV, 95% CI 1.16, 2.10, p<0.01), UCCA 
(odds ratio=0.53 per 1 SD higher cord area, 95% CI 0.39, 0.72, p<0.01) and WMF 
(odds ratio=0.62 per 1 SD WMF, 95% CI 0.47, 0.82, p<0.01). 
Subsequently in a multivariable analysis was performed, again using a binary 
and then four-part model of EDSS. Both T2LV (odds ratio=1.67 per 1 SD larger 
T2LV, 95% CI 1.09, 2.56, p=0.02) and UCCA (odds ratio=0.57 per 1 SD higher 
cord area, 95% CI 0.37, 0.86, p=0.01) were found to be associated independently 
with the requirement of a walking aid (i.e. EDSS ≥6). The C-statistic for this 
model was 0.8, with 81% sensitivity and 75% specificity and 77% correctly 
classified. 
In a multivariable ordered logistic regression model with a four-part model of 
EDSS, the following were found to be associated with EDSS: UCCA (odds 
ratio=0.55 per 1 SD higher cord area, 95% CI 0.40, 0.77, p<0.01), T2LV (odds 
ratio=1.56 per 1 SD larger T2LV, 95% CI 1.08, 2.25, p=0.02) and GMF (odds 
ratio=0.67 per 1 SD GMF, 95% CI 0.46, 0.98, p=0.04). 
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4.4 Discussion 
In this chapter a large group of MS patients, two to three decades after first 
symptom onset, were studied. The results demonstrate a strong association 
between spinal cord atrophy and EDSS. In the same model T2LV and to a lesser 
extent GM atrophy were also found to be independently associated with physical 
disability. 
When considering the results, it should be noted that this cohort differs from 
previous studies looking simultaneously at spinal cord and brain measures in MS 
(Bonati et al., 2011; Cohen et al., 2012). Firstly, the present cohort is larger, with 
159 patients, compared with 70 studied by Bonati et al. and 21 by Cohen et al. 
Secondly, it includes patients with longer disease durations (mean of 26 years 
compared to 20 years and 8 respectively). Thirdly, it includes more people with 
higher levels of disability (median EDSS 4, Bonati et al. median EDSS 2.5, Cohen 
et al. mean EDSS 1.6), and more SPMS patients (current study n=67, Bonati et al 
n=11, Cohen et al. n=1). However, (unlike the previous two studies), this is a 
multicentre study and so differences in scanners can introduce inter-site 
variability (Reig et al., 2009). The statistical analyses employed in this study 
adjusted for centre effects, thereby minimising this effect on the results. 
Overall, these findings are in agreement with previous studies (Bonati et al., 
2011; Cohen et al., 2012) demonstrating spinal cord atrophy to be independently 
related to disability. With regard to changes in the brain, Cohen et al. found no 
additional association with disability in a group of mostly RRMS patients with 
low EDSS scores, while in a mixed CIS, RRMS and SPMS cohort with long disease 
duration Bonati et al. observed that GMF independently associated with EDSS in 
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all cases, and T2LV in those with clinically definite MS. In the present cohort, 
T2LV and – in the four-part EDSS model only - GMF were found to contribute to 
variability in EDSS. The consistent independent relationship of spinal cord 
atrophy with disability in all three studies of cohorts with RRMS and SPMS and 
disease durations ranging from a mean of 8-26 years is noteworthy. An 
association of disability with T2LV and GM atrophy independent of spinal cord 
atrophy was only evident in the 20 and 26 year disease duration cohorts, 
suggesting that the effects of brain GM pathology in MS may become more 
relevant with longer disease duration. 
Given that it can be difficult to determine the onset of progressive MS, and a 
natural history study suggested SPMS tends to occur at a similar rate when a 
disability threshold is reached rather than being determined by prior relapses 
(Confavereux et al., 2000), it is of interest to see if there are MRI differences 
between benign and non-benign RRMS, and non-benign RRMS and SPMS. In 
order to do this the RRMS cohort was split into ‘benign’ (i.e. EDSS 3) and those 
with an EDSS of ≥3.5. In doing so it is important to be aware that this division is 
defined by physical disability, and that cognitive deficits may be considerable in 
people with physically ‘benign’ MS (Rovaris et al., 2008). No significant 
differences emerged between T2LV brain or cord atrophy between non-benign 
RRMS and SPMS. This suggests that, the division between these groups on the 
basis of clinical progression may be arbitrary and not strongly supported by 
differences in MRI characteristics. 
Lower cord areas were evident in both SPMS and non-benign RRMS when 
compared with benign MS, thus spinal cord atrophy seems to relate to 
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concurrent physical disability. In this study EDSS was used as a measure of 
disability, although it does not fully reflect the clinical impact of MS. Above 3.5, 
the EDSS is heavily weighted towards mobility, and so corticospinal tract 
integrity. In turn, those MRI measures that are more directly linked with the 
corticospinal tracts are more likely to correlate with EDSS, hence the association 
between spinal cord atrophy and disability emerges consistently in all models. 
This study builds on previous work, demonstrating that spinal cord atrophy is 
relevant to physical disability in MS, and that this relationship remains 
significant in the long-term, in people with higher EDSS. 
A question arising from our observation that the highest T2LV was seen in SPMS 
is whether a high T2LV in earlier years might predict future secondary 
progression? Although our cross-sectional study could not directly investigate 
this, evidence from two other studies supports a long term prognostic role of 
T2LV in relapse-onset MS. First, a 20-year follow up of a CIS cohort found that 
the rate of increase of T2LV was three times higher in those that develop SPMS 
compared to those patients who remained RRMS, and the higher T2LV was 
already evident after 5 years in those who later developed SPMS (Fisniku et al., 
2008). Secondly, in a recent 21-year follow up study that reported mortality 
outcomes of RRMS patients who had participated in a clinical trial of beta 
interferon, Goodin et al. found that the baseline T2LV was an independent 
predictor of death (Goodin et al., 2012); although no information on neurological 
status was provided in that study, it is plausible that the higher mortality reflects 
a greater likelihood of patients with high lesion loads having developed 
secondary progression with severe disability. 
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In the current study, in univariable analyses WMF was associated with EDSS, but 
not in multivariable analysis where GMF was independently associated. This can 
be explained by inter-relationships between MRI measures. For an MRI measure 
to be retained in a regression model, it must correlate with the outcome of 
interest and do so at least partly independently of other measures. WMF was 
significantly correlated with both T2LV and UCCA, whereas GMF was not, and 
when both T2LV and UCCA were included in the statistical multivariable model, 
WMF did not add to the predictive power of the model above that of T2LV and 
UCCA alone. In contrast, while GMF alone did not correlate with clinical 
measures in univariate analysis, once variability due to T2LV and UCCA had been 
accounted for, it did contribute independently to disability in the four-part 
model of EDSS, albeit with modest significance (p=0.04). Although a negative 
correlation was found between GMF and WMF, this is very likely to represent a 
mathematical interaction between the two fractional volumes that have a 
common denominator, rather than an error in segmentation - when the actual 
GM and WM volumes were compared without normalisation, a strong positive 
correlation was seen, as expected (data not shown). 
As a conceptual limitation of this chapter, it cannot be assumed the same 
associations would be observed if different outcome measures were used. 
Cognitive impairment is common in MS, particularly in SPMS (Rao et al., 1991; 
Comi et al., 1995), and if cognitive scores were used instead, the imaging 
associations may differ. A previous longitudinal study in SPMS demonstrated a 
significant correlation of reductions in GM volume, but not UCCA or T2LV, with 
paced auditory serial addition test (PASAT) scores (Furby et al., 2010). However 
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in this current study physical disability is the main outcome measure of interest 
in order to determine the contribution of spinal cord atrophy to disability in long 
disease duration MS. 
Although GMF was associated independently with EDSS in the four-part model, 
no significant differences were established between GMF in RRMS and SPMS 
cohorts, although a weak trend was observed between lower GMF values with 
higher EDSS scores. A stronger correlation between EDSS and GMF was observed 
in a previous study of a MS cohort with 20-year disease duration (Fisniku et al., 
2008). Several factors may have limited the association observed in the present 
study. First, many subjects had large lesion loads, which could have had subtle 
effects on brain segmentation in spite of using lesion filling to correct tissue 
volumes (Chard et al., 2010). Secondly, lesions partly involving the deep GM may 
still sometimes have been classified as WM leading to slight inaccuracies of WMF 
and GMF computation. Thirdly, there was often substantial atrophy. The GM and 
WM segmentation algorithm used (SPM) has been developed from a normal 
(non-atrophic) brain template and its performance may differ in the presence of 
marked brain atrophy. Finally, the cohort studied had a disease duration that 
considerably exceeds that of other cohorts in whom associations were observed 
between GM atrophy and disability (Fisher et al., 2008; Fisniku et al., 2008) and it 
is possible that GM atrophy may reach a nadir at a later point in the natural 
history of the disease, beyond which it has a lesser independent contribution to 
disability. 
Two other study limitations are noted. First this study was cross-sectional, and 
although T2LV, spinal cord atrophy, and to a lesser extent GMF, were found to be 
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independently associated with concurrent disability, the rate of change of these 
measures over time was not examined. Longitudinal observations would be 
required to clarify their temporal dynamics, and relationship to changes in 
disability measures. 
Secondly, this study was multi-centre. This allowed a larger cohort to be studied, 
but will have introduced some variability in MRI measures, and while these were 
accounted for in the statistical models, they may still have influenced the 
apparent strength of associations between MRI measures and clinical scores. 
This chapter demonstrates that spinal cord and brain pathology are both 
relevant, and contribute independently to long-term physical disability in 
relapse-onset MS. 
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Chapter 5 - Evaluation of methodologies for improved quantification of 
spinal cord atrophy 
 
5.1 Introduction 
Spinal cord involvement in MS often results in clinically manifest progressive 
locomotor disability (Mc Donald and Compston 2006) and is relevant in 
determining physical disability in long disease duration as demonstrated in the 
preceding chapter. Although the presence of demyelinating plaques is a 
characteristic feature of MS in the spinal cord (Fog 1950; Oppenheimer 1978), it 
is axonal loss rather than lesions that represent the main pathological substrate 
of irreversible physical disability, as demonstrated by spinal cord 
neuropathological studies (Ganter et al., 1999; Lovas et al., 2000; DeLuca et al., 
2006). 
In vivo measurement of the spinal cord cross-sectional area (CSA) is possible 
using MRI (Kidd et al., 1993). A reduction in CSA of the spinal cord can be 
expected to occur when there is significant axonal loss (Losseff et al., 1996; Bot 
et al., 2004), and a robust correlation has been established between CSA and the 
expanded disability status scale (EDSS), which mainly reflects impairment in 
ambulatory function (Kurtzke 1983). Considering that a decrease in CSA may 
reflect pathological processes that underlie progressive disability, it is a 
biologically plausible surrogate endpoint to clinical trials, to evaluate the effect 
of treatments that aim to prevent neuroaxonal loss and irreversible disability in 
MS. 
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Perhaps because of the challenges in developing a sensitive and reproducible 
method of measuring cord atrophy in MS, only a small number of clinical trials 
(one relapsing remitting MS (Lin et al., 2003) and three in PPMS (Kalkers et al., 
2002; Leary et al., 2003; Montalban et al., 2009) have used CSA as an exploratory 
endpoint. CSA may be a particularly pertinent outcome measure in progressive 
forms of the disease, where there is currently no effective disease modifying 
treatment, and where trials with clinical disability endpoints require large 
numbers of subjects and long term (2-3 years) follow up, in order to achieve 
sufficient power to observe a useful treatment effect on disability. Therefore, a 
sensitive surrogate imaging marker that reflects the pathology causing 
irreversible physical disability could serve as an endpoint in proof-of-concept 
phase one and two clinical trials in patients with progressive disease. 
The average rate of atrophy of the spinal cord in MS subjects is estimated to be 
approximately 1% per year, although with substantial inter-subject variation 
(Rashid et al., 2006). In order to detect these small changes longitudinally, a 
highly reproducible method is required. Such a method has proven difficult to 
establish due to several factors, above and beyond the challenges posed by 
conventional clinical MRI scanning of the spinal cord (Dietrich et al., 2008). 
Early efforts to measure CSA involved manual outlining of axial images (Kidd et 
al., 1993). Subsequently, Losseff et al. reported a semi-automated edge-detection 
(SAED) method. This involves manually drawing two regions of interest (ROIs), 
one around the spinal cord and the other around the outer boundary of the 
surrounding cerebrospinal fluid (CSF) and then calculating the mean signal 
intensity of the cord and surrounding CSF and using a signal intensity threshold 
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halfway between the two to define the edge of the spinal cord, from which CSA 
can be measured (Losseff et al., 1996). Following on from this, a method was 
developed that used an automated edge detection technique (which reduced 
operator input) (Lin et al., 2003; Vaithinanthar et al., 2003). 
A new method known as the active surface model (ASM) has been developed, 
which allows rapid measurement of the spinal cord size (Horsfield et al., 2010). 
This involves the placement of cord markers on some representative axial slices 
and subsequently an outline of the spinal cord is created automatically and 
allows detection of atrophy over a larger portion of the cervical cord. Following 
development of the ASM, it has been used in a large multicentre study (Rocca et 
al., 2011).  
The reproducibility of these methods is variable with published intra-rater 
coefficients of variation (COV) ranging from 0.73% to 2.15% for the SAED 
technique (Losseff et al., 1996; Horsfield et al., 2010); using different techniques 
to the SAED (such as the automated edge finding and ASM), lower intra-rater 
COVs (0.42% and 0.44%) have been reported (Lin et al., 2003; Horsfield et al., 
2010). For inter-rater reproducibility COV, values have been reported ranging 
from 0.83% to 7.95% for SAED method and 1.07% for ASM. Data on scan re-scan 
reproducibility is reported as 0.79% using SAED method. 
In order to determine the most reproducible combination of sequence and 
estimate the number of patients required for clinical trials, in this chapter the 
SAED and ASM methods are tested with two different sequences: 3D 
magnetization prepared rapid acquisition T1-weighted gradient echo (3D-TFE) 
and 3D-phase sensitive inversion recovery imaging (3D-PSIR).  
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T1-weighted 3D-TFE is the most frequently used sequence for the calculation of 
CSA in MS (Losseff et al., 1996; Lin et al., 2003; Leary et al., 2003; Horsfield et al., 
2010). This sequence can be used with isotropic voxel dimensions, thereby 
allowing axial reconstruction (without in-plane resolution being affected). High-
resolution imaging also reduces partial volume averaging, as it has been shown 
that approximately half of voxels in the spinal cord edge form the cord-
cerebrospinal fluid (CSF) interface and are subject to partial volume averaging 
(Tench et al., 2003). In a T1-weighted image there is a strong signal intensity 
gradient between the cord and CSF, which facilitates identification of the edge of 
the cord (Losseff et al., 1996). 
PSIR sequence was chosen for comparison as it is a T1 weighted sequence with 
phase reconstruction. The inversion recovery pulse and phase sensitive 
reconstruction confer a number of advantages. Firstly this sequence applies an 
inversion radio-frequency (RF) pulse; therefore the magnetisation can be 
positive or negative depending on the tissue relaxation times (Hou et al., 2005). 
In this case the mean signal intensity of the cord is positive, while the mean 
signal intensity of the CSF is negative. This feature of PSIR sequence was 
expected to further reduce partial volume averaging between the cord and CSF. 
Secondly, PSIR has been shown to improve signal to noise ratio (Bernstein et al., 
1989), which could further enhance detection of the cord outline. Lastly, this 
sequence can be acquired at higher in-plane resolution within a clinically 
acceptable scan time (Hou et al., 2005). 
The aim of this chapter is to investigate whether a combination of high 
resolution axial PSIR images, with an active surface model, provides a more 
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reproducible measure of upper cervical cord cross-sectional area in MS; 
compared to a semi-automated edge finding method combined with both axially 
acquired or axially reconstructed images of the upper cervical cord. 
 
5.2 Methods 
5.2.1 Subjects 
15 healthy controls (6 female, mean age 37 years, SD 9.5) and 15 patients with a 
diagnosis of MS (Polman et al., 2011) (10 female, 7 with relapsing-remitting MS 
(RRMS) were included in this study, 8 with secondary-progressive MS (SPMS), 
mean age 44.9 years, SD 12.3). Patients’ level of disability was evaluated using 
the EDSS prior to MRI (median EDSS score at baseline 4, range 0-6.5). None of 
the subjects had experienced a relapse or received a course of corticosteroids 
within a month prior to imaging. Six patients were being treated with interferon 
- at the time of recruitment. 
Nine patients (5 female, mean age 42, SD 10.6, 5 SPMS, 4 RRMS) and nine healthy 
controls (3 female, mean age 34, SD 6.4) returned for follow up at six month time 
point, MR imaging and clinical assessment was repeated. In patients, the median 
EDSS score at 6-months was 4. At this time point, the scan was performed twice 
with the subject being removed from the scanner coil then repositioned within it 
between the scans. This enabled an evaluation of scan-rescan reproducibility. 
Informed written consent was obtained from all subjects. 
5.2.2 MRI Protocol 
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Subjects were scanned at 3T using a Philips Achieva MRI system with RF multi-
transmit technology (Philips Healthcare, Best, the Netherlands) and a 16-channel 
neurovascular coil (which permitted coverage of the entire cervical spine), with 
care taken to position the patient comfortably to minimize motion artefact and 
allowed consistent re-positioning of subjects for follow up scans.  
Firstly a 3D-TFE sequence was acquired in the sagittal plane with 
FoV=256x256mm2, matrix=256x256, TR=8ms, TE=3.7ms, TI=860ms, SENSE 
factor 2 in the anterior-posterior direction, TFE factor 205 (using a linear k-
space profile order). The voxel size was 1x1x1mm3 (Figure 5.1). Secondly, a 3D-
PSIR sequence was acquired in the axial plane with a voxel size of 0.5 x 0.5 x 3 
mm3, TR = 8 ms; TE = 3.7 ms; flip angle α = 5°; FOV = 256 x 256 mm; NEX = 1. 
The scanning time was 14:22 min for PSIR sequence and 6:31 min for 3D-TFE 
(Figure 5.2).  
3D-TFE imaging covered the entire cervical spine, while PSIR imaging was 
centred at C2/C3 intervertebral disc. This anatomical location was chosen as 
post-mortem work has demonstrated that with flexion and extension of the head 
the spinal cord can move up to 1.8cm, however this effect is least evident in the 
high cervical cord (Reid 1960). Secondly, in previous work this level yields the 
most reproducible-cross sectional area values (Losseff et al., 1996). Therefore, to 
minimise cord displacement due to movement and optimise reproducibility, 
C2/C3 was chosen for this study. 
5.2.3 Image Analysis 
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From the 3D-TFE images five contiguous 3mm axial slices were reformatted 
using the centre of C2/C3 intervertebral disc as a caudal landmark, with the 
slices perpendicular to the spinal cord (Figure 5.1). Five contiguous 3mm axial 
slices were also extracted from the 3D PSIR images in a similar way (i.e. ensuring 
by visual inspection that the central slice was through the centre of C2/C3 
intervertebral disc). 
 
Figure 5.1 3D-TFE 1x1x1mm3 voxels 6min 30secs 16 channel NV coil. A: sagittal 
view. B: Axial 3D-TFE reconstruction at C2/C3 
The five axial slices for the two sequences were then analyzed in two ways: (i) 
using SAED technique (Losseff et al., 1996), the mean area of the slices were 
calculated using Dispunc display software package (D.L. Plummer, University 
College, London, UK). (ii) ASM using Jim6 software (Xinapse systems, 
www.xinapse.com). 
The SAED method (i) is based on the principle that if the signal intensities (SI) of 
the cord and CSF are uniform then an outline drawn at the point where the SI is 
midway between the two, would represent the position of the cord outline. This 
method involves manually drawing a region of interest (ROI) around the spinal 
cord, and then a ROI is manually drawn around the outer edge of the CSF space. 
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From these two manually drawn ROIs, the mean signal intensities of cord and 
CSF are calculated. The cord/CSF boundary is indicated by calculating the 
halfway SI between the two and an automated border is constructed around the 
spinal cord, from which CSA is measured for each of the five slices and the mean 
CSA is obtained.  
 
Figure 5.2 PSIR 0.5x0.5x3mm3 acquired with 16 channel NV coil. 
The ASM (Figure 5.3) (ii) involves placing a pre-determined size and shape ROI 
in the centre of the cord on each slice. The programme then uses intensity 
gradient information to calculate the radius of each slice and the centre of each 
slice. The centre line is refined from the initial user estimate and segmentation 
then involves a multistage approach allowing greater complexity of the cord 
radius to be calculated (Horsfield et al., 2010). This enhances the cord outline 
where it has been distorted due to atrophic changes. The outline of the cord is 
then automatically generated for each slice. Similarly to the SAED method, the 
CSA is measured for each of the five slices and the mean area is calculated. 
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Figure 5.3 Spinal cord outlined using ASM. A: axially reformatted 3D-TFE B: 
PSIR 
Spinal cord scans are sometimes normalised by brain volume or other measures 
of body size. The purpose of this process is to remove differences between 
patients that are unrelated to pathology. A recent study investigated the effects 
of eight different methods of normalisation including: number of slices, 
intracranial volume, body mass index, body surface area, no normalisation and 
combinations of these parameters (Healy et al., 2012). Of these, only the number 
of slices had a notable effect on reproducibility or discrimination between an 
atrophic and healthy cord. Therefore, the spinal cord area was normalised by the 
number of slices. 
5.2.3.1 Calculation of relative contrast 
The relative contrast was calculated for all scans (Lavdas et al., 2010). The mean 
signal intensity was estimated in the CSF and spinal cord by placing an identical 
ROI in each structure (Figure 5.4). Relative contrast was calculated by using the 
formula: ((S1-S2)/(S1+S2)) x 100, where S1=signal in the spinal cord and S2=signal 
in the CSF. 
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Figure 5.4 Calculation of CNR with ROI placed in CSF and on spinal cord. A: 3D-
TFE B: 3D-PSIR 
5.2.3.2 Reproducibility 
After an interval of one week all the reformatted images were re-analysed using 
both methods by one reader to evaluate intra-rater reproducibility. The same 
reformatted images were analysed by two other readers to evaluate inter-rater 
reproducibility. At six month follow up the images were analysed by the same 
reader to evaluate scan re-scan reproducibility. In addition, the first of the two 
scans at six month time point was used for comparison with baseline to evaluate 
longitudinal change in CSA over time. 
 
5.2.4 Statistics 
SPSS software package (version 20, SPSS Inc.) for Macintosh was used for 
statistical analysis. 
Average CSA was calculated for each combination of sequence and method used. 
Firstly, an independent samples t-test was employed to determine differences 
 124 
between mean, CSA and age in patients and controls; significance was 
established as p≤0.05 with 95% confidence intervals. 
5.2.4.1 Reproducibility  
Reproducibility was evaluated in all subjects together as follows.  
Firstly intra-rater reproducibility was measured by calculating COV expressed as 
a percentage of the mean area (COV=100x(SD of the two measurements/Mean of 
the two measurements)) (Kirkwood and Sterne 2003). Intra-rater 
reproducibility was further examined by calculating the intra-class correlation 
coefficient (ICC) and subsequently 1-ICC (Bland and Altmann 1986). In this 
context 1-ICC represents the proportion of variability, which is due to 
measurement error (within-subject) rather than biological variation (between-
subject). Thus, whereas the COV assesses within-subject variability as a 
proportion of the mean, the ICC assesses within-subject variability as a 
proportion of the total variability (within plus between). 
Inter-rater reproducibility was examined by recording the COV between the 
three raters and both ICC and 1-ICC for each combination of sequence and 
processing technique.  
Similarly, scan-rescan reproducibility was calculated using COV, ICC and 1-ICC. 
5.2.4.2 Change in CSA over six month follow up and correlation with disability at 
baseline 
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To examine differences in mean CSA over time, a paired t-test was used in both 
the patient and healthy control groups. In each group, this test was repeated for 
each combination of sequence and analysis technique.  
Spearman correlation coefficients were calculated to determine the correlation 
between CSA and EDSS scores for all combinations of sequences and analysis 
methods at baseline.  
5.2.4.3 Sample size calculations for clinical trials 
Sample sizes were calculated for each combination of sequence and analysis 
method. These calculations were based on the between-subject SD of the mean 
CSA of 15 patients at baseline. An estimate of the Pearson correlation coefficient 
is given between CSA at baseline and six months.  
Estimate of treatment effects were calculated by measuring the change in cord 
area (in 9 patients and 9 controls) after six months. The difference between 
these mean changes, control-patient, was obtained and considered to be the MS 
disease-specific change in CSA. A decrease of this full amount of CSA change 
while on an experimental treatment was then considered to be a 100% 
treatment effect for a six-month duration trial. From this, the amount of decrease 
in CSA change constituting a 30% and 50% treatment effect, and the 
corresponding sample sizes for a placebo-controlled trial, were calculated. The 
reduction in CSA change for a 100% treatment effect over six months were 
doubled to allow an estimation of sample sizes for a 12-month trial (assuming 
linearity in the changes over time in both groups). 
5.3 Results 
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5.3.1 Comparison of relative contrast between PSIR and 3D-TFE 
Relative contrast was found to be 1811.11% for PSIR, and 74.45% for the 3D-
TFE. The relative contrast for PSIR was found to be higher than the 3D-TFE by a 
factor of 24. 
5.3.2 Differences between groups at baseline  
A significant difference between patients and controls was found for CSA 
(p<0.001) for all combinations of sequence and method of analysis. No 
significant difference was found in the ages of patients and controls. 
5.3.3 Reproducibility  
The combination of ASM with PSIR was more reproducible than the other 
methods (intra-rater COV for PSIR/ASM 0.002%, inter-rater COV for PSIR/ASM 
0.03%); in terms of both lower COV and higher ICC, for all subjects. Again the 
combination of ASM technique with PSIR proved to have greater reproducibility 
for scan-rescan (scan-rescan reproducibility COV for PSIR/ASM 0.1%). Results of 
intra-observer and inter-observer reproducibility are summarised in tables 5.1 
and 5.2. Results of scan-rescan reproducibility are summarised in table 5.3. 
Analysis 
method/MRI 
sequence 
Mean 
CSA 
(mm2) 
COV 
(%) 
ICC 1-ICC 
SAED/3D-
TFE 
70.94 3.86 0.108 0.892 
SAED/PSIR 72.49 0.3 0.946 0.054 
ASM/3D-
TFE 
72.98 0.04 0.990 0.01 
ASM/PSIR 76.52 0.002 0.999 0.001 
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Table 5.1 Intra-observer reproducibility in all subjects (COV: coefficient of 
variation) 
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Analysis 
method/MRI 
sequence 
Observer 
1  
mean 
CSA 
(mm2) 
Observer 
2  
mean 
CSA 
(mm2) 
Observer 
3  
mean 
CSA 
(mm2) 
COV 
(%) 
ICC 1-ICC 
SAED/3D-
TFE 
70.94 69.72 70.49 0.88 0.782 0.218 
SAED/PSIR 72.49 72.82 73.12 0.43 0.919 0.081 
ASM/3D-
TFE 
72.98 72.95 73.23 0.21 0.993 0.007 
ASM/PSIR 76.52 76.48 76.47 0.03 0.999 0.001 
 
Table 5.2 Inter-observer reproducibility in all subjects 
 
Analysis 
method/MRI 
sequence 
Scan 1 
mean 
CSA 
(mm2) 
Scan 2 
mean 
CSA 
(mm2) 
COV 
(%) 
ICC 1-ICC 
SAED/3D-
TFE 
69.76 69.37 0.41 0.755 0.245 
SAED/PSIR 70.43 69.99 0.45 0.911 0.089 
ASM/3D-
TFE 
72.64 73.14 0.48 0.978 0.022 
ASM/PSIR 75.11 75.00 0.10 0.981 0.019 
 
Table 5.3 Scan-rescan reproducibility in all subjects 
5.3.4 Change in cord area over six month follow up and correlation with disability 
at baseline 
At six month follow up none of the patients had a change in EDSS. The control 
scans did not show any significant change. The least change in control CSA was 
seen with ASM/3D-TFE (absolute change of 0.06mm2). In patients all methods 
demonstrated a decrease in CSA, apart from the combination of ASM and 3D-TFE 
which demonstrated a 0.18% increase in CSA. None of the changes detected in 
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patients reached significance with a paired t-test. Results of patients and 
controls longitudinal data are shown in tables 5.4 and 5.5 respectively. 
Analysis 
method/MRI 
sequence 
Mean 
CSA at 
baseline 
± SD 
(mm2) 
Mean 
CSA at 
6 
month 
follow 
up ± 
SD 
(mm2) 
Absolute 
change in 
mean 
CSA 
(mm2) 
Change 
in 
mean 
CSA 
(%) 
p value 
from t-test 
comparing 
baseline 
to follow 
up 
 
SAED/3D-
TFE 
64.93 ± 
11.79 
62.98 
± 
10.10 
-1.96 -3.01 0.410 
SAED/PSIR 64.11 ± 
10.76 
62.07 
± 8.57 
-2.04 -3.19 0.102 
ASM/3D-
TFE 
63.85 ± 
11.01 
63.96 
± 9.82 
+0.11 +0.18 0.512 
ASM/PSIR 67.92 ± 
10.57 
66.48 
± 
10.34 
-1.44 -2.11 0.061 
 
Table 5.4 Longitudinal cord area measures in patients 
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Analysis 
method/MRI 
sequence 
Mean 
CSA at 
baseline 
± SD 
(mm2) 
Mean 
CSA at 
6 
month 
follow 
up ± 
SD 
(mm2) 
Absolute 
change in 
mean CSA 
(mm2) 
% 
change 
in 
mean 
CSA 
p value 
from t-test 
comparing 
baseline 
to follow 
up 
 
SAED/3D-
TFE 
77.76 ± 
6.28 
76.53 
± 8.79 
-1.22 -1.57 0.277 
SAED/PSIR 80.16 ± 
8.27 
78.81 
± 9.88 
-1.35 -1.68 0.186 
ASM/3D-
TFE 
81.17 ± 
7.27 
81.12 
± 7.31 
-0.06 -0.07 0.224 
ASM/PSIR 84.50 ± 
7.99 
83.93 
± 9.12 
-0.57 -0.68 0.119 
 
Table 5.5 Longitudinal cord area measures in controls 
 
Using each combination of sequence and method a significant negative 
correlation was seen between CSA and EDSS. The strongest correlation was seen 
with SAED and PSIR (r=-0.75, p=0.001) (Table 5.6). 
Analysis 
method/MRI 
sequence 
Spearman’s 
R 
p value 
SAED/3D-
TFE 
-0.525 0.045 
SAED/PSIR -0.745 0.001 
ASM/3D-
TFE 
-0.693 0.004 
ASM/PSIR -0.725 0.002 
 
Table 5.6 Correlation with EDSS at baseline (15 patients) 
5.3.5 Sample size calculations 
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The calculations of differences between longitudinal CSA changes in patients and 
controls - that were used to estimate treatment effects and perform sample size 
calculations for a placebo-controlled trial in which an active treatment reduces 
CSA loss over time - are provided in Table 5.7. Estimated sample sizes are given 
per arm for six month and 12 month trials in Table 5.8. For a 12 month 
treatment trial with 50% treatment effect and 80% power the lowest number of 
subjects required was found using PSIR/ASM combination (n=89), which was 
substantially lower than the number required with SAED/3D-TFE (n=1172).  
 ASM/PSIR ASM/3D-
TFE 
SAED/PSIR SAED/3D-
TFE 
SD 11.27 11.13 10.83 11.25 
Correlation 0.98 0.99 0.97 0.83 
Mean 
change in 
controls 
-0.57 0.12 -1.35 -1.22 
Mean 
change in 
patients 
-1.44 -0.34 -2.04 -1.96 
Difference 
in mean 
changes1 
(100% 
treatment 
effect) 
0.87 0.47 0.70 0.73 
1 Discrepancies on subtraction due to rounding 
Table 5.7 Calculation of differences between longitudinal changes in patients 
and controls to estimate treatment effect 
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 ASM/PSIR ASM/3D-TFE SAED/PSIR SAED/3D-TFE 
Treatment 
effect; 
power 
6 m 12 m 6 m 12 m 6 m 12 m 6 m 12 m 
30%  90% 1323 331 1454 364 3279 820 17427 4357 
30% 80% 988 247 1086 272 2449 613 13018 3255 
50% 90% 476 119 524 131 1181 296 6274 1569 
50% 80% 356 89 391 98 882 221 4687 1172 
 
Table 5.8 Estimated sample sizes per arm for six month (m) and 12 month 
placebo-controlled treatment trials 
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5.4 Discussion 
Spinal cord atrophy has already been used as an exploratory endpoint in clinical 
trials in MS (Kalkers et al., 2002; Leary et al., 2003; Lin et al., 2003; Montalban et 
al., 2009). Improving reproducibility of cord area measurement should be 
beneficial for clinical trials by increasing sensitivity to detect neuroprotective 
therapies and reducing the sample sizes needed to show such a treatment effect. 
Spinal cord atrophy could then be especially useful as an outcome measure in 
phase 1 and 2 proof-of-concept trials. 
In this chapter the cross sectional area of the spinal cord is measured, as this has 
been measured in previous MS clinical trials (Kalkers et al., 2002; Leary et al., 
2003; Lin et al., 2003; Montalban et al., 2009) and the image analysis software 
used in this study enabled area to be measured with both SAED and ASM 
techniques. However, other studies have measured spinal cord volume as an 
assessment of atrophy in MS (Hickman et al., 2003; Zivadinov et al., 2008) and a 
future study comparing the COVs of area (using the methodology in this study) 
and volume measurements would be of interest. 
Two methods of analysis were evaluated in this study at baseline and at six 
month follow up. The combination of PSIR and ASM in all subjects yielded the 
highest intra-rater reproducibility for cord area reported so far in MS 
(COV=0.002%). This combination also had the lowest value of COV for inter-
observer (0.03%) and scan-rescan reproducibility (COV 0.1%). The lowest value 
of 1-ICC was seen with PSIR/ASM, demonstrating that there is a low proportion 
of variability due to measurement errors. Intra-rater reproducibility was 
substantially lower with the combination of 3D-TFE and SAED method. This was 
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likely to have been due to the manual input required by the rater combined with 
the lower in-plane scan resolution. 
The relative contrast was higher in both 3D-PSIR than 3D-TFE by a factor of 24. 
This provides a higher contrast between cord and CSF, thereby improving the 
detection of the cord outline. PSIR also had a higher in-plane resolution than 3D-
TFE (0.5x0.5mm vs. 1x1mm) which reduced partial volume effects at the 
boundary between cord tissue and CSF. PSIR scans did not require 
reconstruction in a different plane, unlike 3D-TFE. Owing to the fact that the 
PSIR sequence is a 3D acquisition, three views can be reviewed simultaneously 
allowing accurate choice of the central slice for analysis from the sagittal view. A 
combination of these factors is likely to have contributed to the improved 
reproducibility with PSIR sequence. 
Though not significant the rate of change in patients’ cord area was higher than 
expected for 3 of the 4 analysis methods over the course of six months. The small 
cohort size with different subtypes of MS may have been a contributory factor to 
this finding. A larger decrease in both patients and controls was seen with the 
SAED method. As this method was shown to have inferior reproducibility 
compared to ASM, measurement error may account for the larger changes seen. 
Cord atrophy measurements are of particular interest as they correlate with 
EDSS (Losseff et al., 1996). In the present study, the Spearman correlations were 
in a similar range to previously reported values in larger MS patient cohorts 
(Losseff et al., 1996; Lin et al., 2003; Horsfield et al., 2010). A strong negative 
correlation was seen with PSIR and active surface model (r=-0.725, p=0.002). 
The correlation seen in this study strengthens the case for the use of spinal cord 
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atrophy as an objective marker of physical disability in studies. Although strong 
correlations were seen with EDSS it was not possible to comment on whether 
change in CSA using PSIR/ASM can reflect significant changes in EDSS as none of 
the patients followed up developed a change in disability status. 
Given the need for sensitive biomarkers in treatment trials sample sizes from the 
data in this study were estimated to demonstrate that it would be feasible to use 
the cord area as an endpoint to a clinical trial. These calculations are based on 
the cohort of nine patients followed up at six months and more accurate figures 
could be established from larger cohorts with longer duration of follow up. 
Nevertheless, based on the estimates in this study it would be possible to detect 
a 50% treatment effect (decrease in cord area loss) in a twelve month trial in less 
than 100 patients per arm, suggesting this would be a feasible endpoint for a 
proof-of-concept trial involving relatively few centres. The results of the sample 
size calculations also reveal that there are minimal differences between PSIR and 
3D-TFE, in the number of patients required in each treatment arm, provided the 
ASM is used to analyse the images. If the SAED method is used sample sizes 
required would be significantly larger.  
5.4.1 Limitations and future directions 
Although the reproducibility of the measures in this study was greater than that 
of previously published methods, a few limitations must be taken into account. 
First, it was not possible in our study to blind raters to the differences between 
3D-TFE and PSIR. Secondly, raters were not blinded to the two time points 
(baseline or six months) or whether scan one or two was being analysed at six 
month time point; however, the raters were blinded to subject status (control or 
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MS) and we are confident that the differences in CSA change between controls 
and MS (Table 5.7) - that formed the basis of the sample size calculations - are 
robust. As already noted the sample size at follow up was small which influenced 
the accuracy of sample size calculations. 
Thirdly, the scan time of PSIR was considerably longer than the 3D-TFE scan, this 
may potentially limit this scans usefulness (as part of a multimodal imaging 
protocol) due to motion artefacts.  
Fourthly, the 3D-TFE scan was acquired in this study with a larger voxel size 
than PSIR. Although this allowed direct comparison with previously published 
results, it may have been a contributory factor to the reduction in reproducibility. 
In order to improve reproducibility with 3D-TFE, this sequence could be 
acquired with a smaller voxel size (0.5x0.5mm in plane) equivalent to the PSIR 
sequence. Fifthly, rather than sagittal acquisition (which potentially introduces 
operator error into the measurement) an axial acquisition of the 3D-TFE 
sequence may improve its reproducibility. Finally, although the PSIR-ASM 
method was the most reproducible, the PSIR sequence may not be routinely 
available with all scanners manufacturers, potentially limiting its use in some 
multicentre trials; in such circumstances, the 3D-TFE-ASM approach may be 
more suitable and in our study it yielded only slightly higher sample sizes. 
This chapter has demonstrated a new methodology for measuring spinal cord 
atrophy in MS that has greater reproducibility than previously reported methods. 
Furthermore it has also demonstrated that it would be feasible to use this 
method as an endpoint in a clinical trial of neuroprotection in MS. 
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Chapter 6 - (i) A Pilot study to evaluate two high resolution axial sequences 
for spinal cord lesion detection in multiple sclerosis 
 
6.1 Introduction 
Spinal cord pathology is a major cause of disability in multiple sclerosis (MS). 
Pathological studies of the spinal cord in MS have detailed the morphology and 
distribution of lesions demonstrating wedge-shaped lesions predominantly in 
the posterior and lateral white matter (WM) columns (Fog, 1950). More recent 
post mortem magnetic resonance imaging (MRI) and histopathologic studies 
have identified additional involvement of central grey matter (GM) by spinal 
cord lesions, with both GM-only and mixed WM-GM lesions being detected 
(Gilmore et al., 2006, Lycklama à Nijeholt et al., 2001, Gilmore et al., 2009, 
Mottershead et al., 2003, Bot et al., 2004). 
Conventional in vivo T2-weighted MRI sequences detect focal spinal cord lesions 
and sometimes more diffuse abnormalities in the spinal cord in MS (Kidd et al., 
1993). The presence of focal cord lesions is valuable in the diagnosis of MS, as 
reflected by their inclusion in new diagnostic criteria (Polman et al., 2011). 
However, the number or load of T2-weighted lesions seen on sagittal scans of the 
spinal cord has little correlation with measures of disability in MS (Bergers et al., 
2002).  
The clinical effects of spinal cord WM lesions will depend on their locations, e.g., 
motor deficits from lateral column lesions and sensory symptoms from posterior 
or anterior column lesions. The effect of GM lesions is uncertain. Better in vivo 
MRI localisation of focal cord lesions should help understand their functional 
effects. Conventional axial T2-weighted MRI sequences have provided limited 
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information on the WM column or GM involvement by MS lesions, because of 
relatively low spatial resolution (typically 1x1mm in plane voxel size), 
insufficient contrast between WM and GM, motion and other types of artefacts 
(Dietrich et al., 2008).  
The hypothesis being investigated in this pilot study is that a combination of two 
high resolution axial images will be able to consistently visualise the spinal cord 
grey matter; the purpose of which is to identify the individual spinal cord white 
matter columns and thereby identify the anatomical location of focal spinal cord 
lesions in MS. 
 
6.2 Methods 
6.2.1 Subjects 
15 patients with a diagnosis of MS were recruited (Polman et al., 2011) (10 
female, 8 with relapsing-remitting MS (RRMS), 7 with secondary-progressive MS 
(SPMS), mean age 44.8, SD 10.53, range 28-64) (Lublin and Reingold, 1996) and 
one patient with a clinically isolated syndrome (CIS). The patient with CIS 
presented with optic neuritis and fulfilled the MS criteria for dissemination in 
space (DIS) but not dissemination in time (DIT) on brain MRI (Polman et al., 
2011). Subject inclusion was based solely on clinical diagnosis supported by 
brain MRI findings. Previous spinal cord MRI findings were not considered in 
order to avoid the potential to bias the study cohort based on prior descriptions 
of spinal cord lesions. 
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None of the subjects had experienced a relapse or received a course of 
corticosteroids within a month prior to imaging. All patients on disease 
modifying treatment were on the treatment for at least six months at the time of 
the study MRI. Informed written consent was obtained from all subjects. 
6.2.2 MRI Protocol 
Scanning was performed using a 3T Philips Achieva MRI system with RF multi-
transmit technology (Philips Healthcare, Best, the Netherlands) and a 16-channel 
neurovascular (NV) coil. Coverage of the two sequences acquired is outlined in 
Figure 6.1. 
 
Figure 6.1 Survey image demonstrating coverage of axial images acquired in this 
study 
Two 3D gradient-echo sequences – one with predominantly proton density 
weighting, the other with T1 weighting – were selected for this study of MS 
patients by an experienced neuroradiologist (KM), as they provided good 
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depiction of central grey matter (GM) and white matter (WM) columns of the 
cord (Figure 6.2), and because it was anticipated that they would detect MS 
lesions that are typically associated with an increase in proton density and T1-
relaxation time. Both of these scans were optimised in healthy controls and 
provided a clear outline of the cord anatomy without distortion by artefacts, 
through 3D averaging. 
 
Figure 6.2 Axial cervical cord MRI (A) FFE and (B) PSIR in a healthy control 
showing central grey matter and white matter columns. (C) Sagittal T2 weighted 
image used for orientation of slices 
The proton density-weighted sequence was a 3D gradient echo (fast field echo 
[FFE]) sequence that showed central GM with higher signal than cord WM. The 
T1-weighted sequence was a phase sensitive inversion recovery (PSIR) sequence, 
i.e. an inversion prepared 3D gradient echo (turbo field echo [TFE]) sequence 
with phase sensitive reconstruction, as has been previously described (Hou et al., 
2005) that provides a greater range of signal intensity because it additively 
combines the effects of negative and positive longitudinal magnetization in the 
image. PSIR also provides better GM-WM tissue contrast than other T1-weighted 
sequences and was previously shown to improve detection of cortical GM lesions 
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and spinal cord lesions when combined with other MR sequences (Nelson et al., 
2007, Poonawalla et al., 2008; Sethi et al., 2012). 
The two scans were acquired in the same position through the upper cervical 
cord, by geometrically linking the two volumes during prescription, with the 
middle of the volume through the C2/C intervertebral disc. The copied geometry 
of the two volumes allowed corresponding slices to be reviewed simultaneously. 
High in plane resolution (0.5 x 0.5mm voxel size) and relatively small voxel sizes 
(1.25mm3) were chosen to achieve good anatomical definition. Care was given to 
immobilizing the patient using polystyrene filled bags to reduce motion artefact.  
 The sequence details were: 
1. 3D PSIR was acquired in the axial plane without parallel imaging 
containing 10 contiguous slices, FOV=256x128mm2, matrix=512x256, 
TR=12ms, TE=6.1ms, dual RF transmit, TI=843.6ms and number of 
averaged signals=3. The voxel dimensions were 0.5x0.5x5mm3 and the 
acquisition time was 14:22 minutes.  
2. 3D FFE image was acquired in the axial plane containing 10 contiguous 
slices, FOV 240x180mm2, TR 23ms, TE 5ms, flip angle α=7°, and number 
of averaged signals=8. The voxel dimensions were 0.5x0.5x5mm3 and the 
acquisition time was 13:34 minutes.  
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6.2.3 Image Analysis 
6.2.3.1 Lesion identification and location 
Two readers (HK and KM) reviewed both axial images simultaneously (i.e. on a 
slice-by-slice basis). Lesions were identified first on 3D-FFE images then 
confirmed on the 3D-PSIR images. Lesions were identified as sharply delineated 
areas of increased signal intensity on 3D-FFE imaging and hypo-intensity on 3D-
PSIR images (Figure 6.3 and 6.4). 
 
 
Figure 6.3 Axial cervical cord MRI (A) FFE and (B) PSIR in a MS patient showing 
(i) a WM-GM lesion involving the anterior column lesion and ventral horn of GM 
and (ii) a GM-WM lesion in the left lateral column and extending to adjacent 
dorsal horn and posterior column. (C) Sagittal T2 weighted image used for slice 
orientation showing a hyper-intense lesion at C2/C3 level 
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Figure 6.4 Axial cervical cord MRI (A) FFE and (B) PSIR in a MS patient showing 
a WM-GM lesion involving the left lateral column and adjacent dorsal horn GM. 
(C) Sagittal T2 weighted image with no visible lesions 
Following lesion identification on 3D-FFE, GM involvement was defined using 
PSIR. As lesions were hyper-intense on 3D-FFE, they have similar signal intensity 
to GM; this problem was not encountered on PSIR. Thus PSIR helped to clarify 
GM involvement by a lesion. Areas of diffuse abnormality were sometimes visible, 
mainly on the FFE sequence (Figure 6.5), in both subtypes of MS; however, only 
focal lesions were recorded in this study. Both images were used to define lesion 
location as fully as possible. Lesions were differentiated from motion artefact as 
any lesion included had to be identifiable on both sequences in the same location, 
as the two sequences were acquired separately this reduced the possibility of 
motion artefacts being misclassified as lesions. 
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Figure 6.5 Axial cervical cord MRI (A) FFE and (B) PSIR demonstrating diffuse 
changes seen in both lateral columns and posterior column on the FFE sequence. 
These were seen on 3 consecutive FFE slices at the C2/C3 level in the absence of 
focal lesions at the same level. (C) Sagittal T2 weighted image shows a focal 
lesion at C3-4 only 
Lesions were classified as WM-only (Figures 6.6 and 6.8), mixed WM-GM 
(Figures 6.4 and 6.7) or GM-only. Location within WM columns was also 
recorded: posterior column (PC), lateral column (LC), anterior column (AC). If a 
lesion involved more than one column, it was recorded as involving the column 
where it was predominantly located. When lesions extended over more than one 
slice, involvement of both WM and GM on any slice was sufficient to classify it as 
a mixed WM-GM lesion (Figure 6.4). Lesions were classified as WM-only when no 
GM involvement was seen on any slice over the entire lesion length (Figure 6.6 
and 6.8). GM-only lesions were categorised as not involving WM on any slices. 
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Figure 6.6 Axial cervical cord MRI (A) FFE and (B) PSIR in a MS patient showing 
a WM-only lesion in the right lateral column. (C) Sagittal T2 weighted image with 
multiple focal lesions 
 
 
Figure 6.7 Axial cervical cord MRI (A) FFE and (B) PSIR in a MS patient showing 
a WM-GM lesion involving posterior column and adjacent left dorsal horn GM; 
the GM involvement is more clearly evident on PSIR. (C) Sagittal T2 weighted 
image with large focal lesion at the level of the foramen magnum 
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Figure 6.8 Axial cervical cord MRI (A) FFE and (B) PSIR in a MS patient showing 
a WM-only lesion in the posterior column. (C) Sagittal T2 weighted image with a 
focal lesion visible above the C3/4 intervertebral disc 
6.2.3.2 Lesion area and length 
Cross-sectional cervical cord area of each subject was calculated on 3D-PSIR 
images using an active surface model on JIM software (Horsfield et al., 2010) 
(version 6, Xinapse Systems, Northants, UK), and mean cord area for each slice 
was calculated. The 3D-PSIR sequence was chosen for this purpose as it has a 
high contrast to noise ratio between cord and CSF (Hou et al., 2005). Lesions 
within each WM tract were outlined on the same 3D-PSIR image using a semi-
automated tool on JIM software package. The area of each lesion was recorded 
on each slice. The proportion of the whole cross-sectional cord area affected by 
lesions was calculated as: (lesion area/whole cord area) x 100%. The number of 
axial slices that each lesion involved was also recorded to document lesion 
length. 
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6.3 Results (Tables 6.1 and 6.2) 
51 lesions were identified in total, 24 in RRMS cohort, 22 in SPMS cohort, and 5 
in the case of CIS. Three lesions were seen in the AC (one in CIS, one in RRMS 
group and one in SPMS), 30 in LC (three in CIS, 16 in RRMS and 11 in SPMS) and 
18 in PC (one in CIS, seven in RRMS, ten in SPMS). The highest number of lesions 
was seen in the LC (n=30, 59%) and PC (n=18, 35%) with the lowest number 
seen in AC (n=3, 6%).  
In total 19 (37%) WM-only lesions were seen and 32 (63%) mixed GM/WM 
lesions were seen. Lesions typically involved only a part of a WM column and it 
was possible to detect lesions with a wide range of areas (range 1.9-20.6mm2). 
An occasional WM lesion was seen to extend from one column across central GM 
and in to another WM column (Figure 6.2). No GM-only lesions were identified.  
In the CIS case two of the five lesions were mixed GM/WM lesions and three 
were WM only. In RRMS cohort, 8 (33%) WM-only and 16 (67%) mixed GM/WM 
lesions were seen. In the SPMS cohort, 8 WM-only (36%) and14 mixed GM/WM 
(64%) lesions were seen. 
Mean lesion area was 4.3mm2 in AC (SD 0.97), 8.5mm2 in the LC (SD 3.72) and 
11.3mm2 in the PC (SD 4.61), which corresponded with 6.1%, 12% and 16.1% of 
mean cord area respectively. Mean lesion length in AC was 18.3mm, in the LC 
was 17.6mm and in the PC was 24.8mm.
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Table 6.1 Spinal cord lesion number and location in all MS patients and clinical subgroups (WM: white mater, GM: Grey matter) 
 All Subjects CIS RRMS SPMS 
 WM only Mixed WM 
/GM 
All WM 
only 
Mixed 
WM/GM 
All WM 
only 
Mixed 
WM/GM 
All WM only Mixed 
WM/GM 
All 
Anterior Column 1 2 3 0 1 1 0 1 1 1 0 1 
Posterior Column 7 11 18 1 0 1 3 5 8 3 6 9 
Lateral Column 11 19 30 2 1 3 5 10 15 4 8 12 
All regions 19 32 51 3 2 5 8 16 24 8 14 22 
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  Total CIS RRMS SPMS 
Mean 
Lesion 
Area 
(mm2) 
Anterior 
Column 
4.3 ± 0.9 4.8 ± 1.1 4.5 ± 0.5 3.6 ± 0.4 
Lateral 
Column 
8.5 ± 3.7 4.8 ± 1.9 9.5 ± 3.7 7.8 ± 3.3 
Posterior 
Column 
11.3 ± 4.6 6.3 ± 3.2 11.9 ± 4.7 10.5 ± 4.3 
Mean 
lesion 
length 
(mm) 
Anterior 
Column 
18.3 ± 7.6 20  10  25  
Lateral 
Column 
17.6 ± 12.8 11.7 ± 7.1 20.6 ± 12.5 20.5 ± 14.8 
Posterior 
Column 
24.8 ± 12.8 15  30.6 ± 10.2 28.9 ± 14.5 
% of cord 
area 
covered 
by lesion 
Anterior 
Column 
6.1 6.8 6.4 5.1 
Lateral 
Column 
12 6.8 13.4 11.1 
Posterior 
Column 
16.1 8.9 16.9 14.9 
 
Table 6.2 Mean (±SD) Lesion area and length in white matter columns 
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6.4 Discussion 
In this pilot study a 3T MR system and 3D-FFE and 3D-PSIR sequences were used, 
as an alternative to 2D conventional acquisitions. It was possible to visualise 
lesions affecting the central GM and WM columns in the spinal cord of patients 
with MS. Many WM-only and mixed WM-GM MS lesions were detected, whilst no 
GM-only lesions were detected. 
The imaging appearances of the WM column lesions correspond well with 
several pathological studies (Fog, 1950, Gilmore et al., 2006, Lycklama à Nijeholt 
et al., 2001) as does their predominant location in the posterior and lateral 
columns.  
The relative proportion of lesions classified as WM-only or as mixed WM-GM 
lesions (37% versus 63% respectively) is similar to the proportions that were 
reported in a previous detailed histopathological study (33% versus 45% 
respectively) (Gilmore et al., 2006), suggesting that the sensitivity of these two 
sequences for detecting such lesions is good. However, although it was possible 
to comment on the involvement of GM it was not possible to accurately 
determine the border between the lesion and the normal appearing GM, 
especially on the 3D-FFE sequence where central GM had a signal intensity that 
was often similar to the WM lesions. The 3D-PSIR sequence improves detection 
of MS lesions in the cerebral cortex (Nelson et al., 2007), and it was helpful in 
depicting GM involvement in the spinal cord. 
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The absence of GM-only lesions seen in our study differs from a previous 
histopathological study that reported 22% of cord lesions being confined to 
central GM (Gilmore et al., 2006). The pathology study noted that GM-only 
lesions seen on a single slice were sometimes seen to expand into the WM in 
subsequent slices, suggesting that they were in fact mixed WM-GM lesions. 
However, it is likely that the MR parameters used with each sequence in this 
study may have been suboptimal for detecting GM-only lesions. 
Difficulties with conventional T2-weighted fast spin echo (FSE) imaging in the 
spinal cord have been well documented and other sequences have proved 
superior in lesion detection in the cervical spinal cord (Rocca et al., 1999). 
Recently, conventional FSE imaging has been compared to multi-echo 
recombined gradient echo (MERGE) sequence (similar to FFE sequence in this 
study) (White et al., 2011, Martin et al., 2012). In both studies MERGE appears 
superior in detection of spinal cord lesions with the rational given that improved 
contrast between GM and WM aids lesion detection. In a similar manner PSIR has 
been compared to short time inversion recovery (STIR) and FSE and also was 
found to improve lesion detection with GM visible on axial images (Poonawalla 
et al., 2008). However none of these studies comment on the frequency of 
involvement of GM by spinal cord lesions.  
Better detection of central GM involvement in vivo might be possible with higher 
resolution images, providing that adequate SNR can be achieved within a feasible 
imaging time. This should be facilitated by acquiring the present sequences with 
thinner slices, e.g., 3mm thickness. Alternative ways to improve resolution and 
SNR would involve the use of improved multi-channel coil designs, or higher 
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magnetic field 7 Tesla scanners (where improved cerebral cortical MS lesion 
detection has already been shown [Mainero et al., 2009, Schmierer et al., 2010]) 
and higher resolution spinal cord images may be acquired in clinically acceptable 
time frames in the spinal cord (Zhao et al., 2013). There may also be other 
sequences (e.g. double inversion recovery) and contrast mechanisms with 
potential to improve GM lesion detection in the spinal cord. 
The imaging sequences used in this pilot study are not likely to be useful in 
routine diagnosis, mainly because of their long acquisition time and limited 
coverage of spinal cord. However, they may be helpful in research directed at 
understanding the structure-function relationship of MS spinal cord pathology. 
Therefore, in the latter half of this chapter these two sequences are employed in 
a significantly larger cohort of people with CIS and MS to accurately characterise 
spinal cord lesion morphology on axial imaging. 
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(ii) Classification of spinal cord lesions in different phenotypes of multiple 
sclerosis using high resolution axial MRI 
 
6.5 Introduction 
Spinal cord abnormalities may be detected in up to 90% of cases of MS on MRI 
(Bot et al., 2002; Bot et al., 2004) and are typically seen as abnormal regions of 
hyper-intense signal, less than two vertebral segments in length, on T2-weighted 
images (Kidd et al., 1993). 
Although spinal cord lesions may be visualised on sagittal imaging, it has been 
suggested that this approach underestimates their number (Bergers et al., 2002) 
and axial acquisitions may improve detection (Weier et al., 2012). A further 
advantage of axial imaging is that the spinal cord grey matter (GM) and columns 
may be visualised (Poonawalla et al., 2008; White et al., 2011; Martin et al., 2012). 
However, to our knowledge, there are no reports to date investigating the 
association between spinal cord lesions’ GM involvement in vivo and MS. 
In the pilot study, in the former part of this chapter, the utility of a combination 
of axial (0.5 x 0.5 mm2 in plane) 3D-fast field echo (FFE) and 3D-phase sensitive 
inversion recovery (PSIR) scans was evaluated, using a 3T MRI system, to record 
the anatomical location and grey matter involvement of cervical cord lesions. 
In this latter part of the chapter, spinal cord lesion morphology is studied in a 
larger cohort of people with MS, in order to investigate whether diffuse 
abnormalities and more extensive focal lesions, that traverse two or more spinal 
cord columns and involve the grey matter, are associated with progressive MS. 
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6.6 Methods 
6.6.1 Subjects 
People with clinically isolated syndrome (CIS) or MS (Polman et al., 2011) were 
recruited. Subtypes of MS were classified using published criteria (Lublin and 
Reingold 1996). Recruitment was performed without reference to earlier spinal 
cord imaging findings. None of the subjects had a relapse or received 
corticosteroids within a month prior to participation. Disability was recorded 
using the expanded disability status scale (EDSS [Kurtzke 1983]). Informed 
written consent was obtained from all participants. 
6.6.2 MRI protocol 
MRI scans were performed using a 3T Philips Achieva MRI system with 
radiofrequency (RF) multi-transmit technology (Philips Healthcare, Best, the 
Netherlands). To minimise motion artefacts during scanning a polystyrene filled 
vacuum bag was placed behind the neck of each participant and subsequently 
the air was removed to immobilise the neck. The axial spinal cord images 
acquired in the upper cervical cord contained ten slices of 5mm thickness and 
were centred at C2/C3: 
6.6.2.1 Spinal cord acquisitions 
(i) Sagittal PD/T2 cervical spine: TR=4000ms, TE=15/80ms (dual echo), 
NEX=2, FOV=256 X 160 mm2, 12 slices, voxel size=1 x 1 x 3mm3, 
TSE=12. 
(ii) Axial 3D-PSIR: was acquired in the axial plane in the cervical cord centred 
at C2/C3 intervertebral disc, with a voxel size of 0.5 x 0.5 x 5 mm3, TR 
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= 8 ms; TE = 3.7 ms; α = 5°; FOV = 256 x 256 mm2; NEX = 1. 
(iii) Axial 3D-FFE sequence using identical slice prescription geometry as in 
(ii) with TR = 23ms; TE = 5ms; α = 7°; FOV 240 x 180mm2; voxel size 
0.5 x 0.5 x 5mm3 
 
6.6.2.2 Brain acquisition 
 
(i) Axial PD/T2 images using a 2D turbo spin echo sequence (TSE) with 3mm 
slice thickness; the following parameters were employed: TR=3500 ms; 
TE=19/85 ms; matrix 240 x 240 mm2; in plane voxel size = 1 x 1 mm. 
 
6.6.3 Image analysis 
Using the sagittal image for orientation of axial slices, lesions were recorded on 
the slice-matched 3D-FFE and 3D-PSIR images by one reader (HK) under the 
supervision of an experienced neuroradiologist (KM). Lesions were analysed on 
all ten 5mm thick slices of the axial images. Both readers were blinded to the 
clinical status of the cases being reviewed. 
6.6.3.1 Focal lesions 
Focal lesions were defined as abnormal areas of clearly increased signal intensity 
on the 3D-FFE image and decreased signal intensity on 3D-PSIR and a clearly 
demarcated border from the surrounding tissue. Focal lesions were only 
recorded when they were clearly visible simultaneously as a hyper-intense 
abnormality on the 3D-FFE scan and hypo-intense abnormality on 3D-PSIR scan. 
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Focal lesions were then categorised based on the number of spinal cord columns 
involved. For this, either unilateral or bilateral involvement of the anterior and 
posterior columns was counted as a single column and involvement of the right 
and left lateral columns was counted separately. Thus anywhere between one 
and four columns could be involved (Table 6.3). The spinal cord column 
predominantly involved by the lesion was recorded and if extension into one or 
more additional columns was seen (e.g. a lateral column lesion extending into 
the posterior column) this was also noted. 
 
Type I Spinal cord lesion involving a single 
column and confined to the white 
matter 
Type II Spinal cord lesion involving a single 
column and grey matter 
Type III Spinal cord lesion involving two 
columns and grey matter 
Type IV Spinal cord lesion involving three or 
four spinal cord columns and grey 
matter 
 
Table 6.3 Classification system used for focal spinal cord lesions identified on 
axial scans 
 
Lesions involving a single column were either confined to white matter only 
(Type I – demonstrated in Figure 6.9), or extended to involve GM (Type II – 
Figure 6.10). When focal lesions involved two (Type III –Figure 6.11) or more 
(Type IV – Figure 6.12) columns, the GM adjacent to the affected columns was 
also invariably involved, i.e., no lesions involved two or more columns without 
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including GM. For lesions that covered multiple slices of the image, their extent 
was classified from the slice with maximal involvement. 
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Figure 6.9 Three cases of lesions involving a single spinal cord column restricted 
to the white matter (Type I lesions). 1A-C: 3D-FFE 0.5 x 0.5 mm2 in plane voxel 
size, 1D-F: 3D-PSIR 0.5 x 0.5 mm2 in plane voxel size. Focal lesions are marked by 
a yellow single chevron and are located in the left lateral column (Figures A/D 
and C/F) and in the right lateral column (Figures B/E and C/F) 
 
 
Figure 6.10 Three cases of lesions involving a single spinal cord column also 
involving the grey matter (Type II lesions). 2A-C: 3D-FFE 0.5 x 0.5 mm2 in plane 
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voxel size, 2D-F: 3D-PSIR 0.5 x 0.5 mm2 in plane voxel size. Diffuse abnormalities 
are demonstrated on the 3D-FFE images 2B and 2C in the right lateral column 
indicated by a double chevron. Focal lesions involving the grey matter are 
demonstrated in the left lateral column by a single chevron in all images and a 
separate focal lesion is demonstrated in the posterior column (Figure B and E). 
 
 
Figure 6.11 Three cases of focal lesions (indicated by single chevrons) involving 
two spinal cord columns and the grey matter (Type III lesions). 3A-C: 3D-FFE 0.5 
x 0.5 mm2 in plane voxel size, 3D-F: 3D-PSIR 0.5 x 0.5 mm2 in plane voxel size. A 
focal lesion crossing from the anterior to posterior column is demonstrated in 
Figures A and D. Figure B and E demonstrate lesions crossing from the lateral to 
the posterior column and a separate focal lesion in the left lateral column. Figure 
A also shows diffuse abnormalities in the right lateral column (indicated by 
double chevron). A focal lesion crossing from the lateral to the anterior column is 
demonstrated in Figure C and F. 
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Figure 6.12 Three cases of lesions involving three spinal cord columns and the 
grey matter (Type IV lesions). 4A-C: 3D-FFE 0.5 x 0.5 mm2 in plane voxel size, 
4D-F: 3D-PSIR 0.5 x 0.5 mm2 in plane voxel size. Focal lesions are shown in all 
images by a single chevron. 
 
6.6.3.2 Diffuse abnormalities 
These were defined as abnormal areas of intermediate signal intensity, between 
that of focal plaques and normal appearing spinal cord tissue (Figure 6.13). 
Diffuse abnormalities also lacked a well demarcated border from adjacent 
normal appearing spinal cord tissue. These were recorded on the 3D-FFE scan, 
where they were visible as an intermediate hyper-intense abnormality relative 
to the normal appearing spinal cord. Diffuse abnormalities were often not seen 
on the PSIR scan, or if they were, they were less well defined areas of subtle 
hypo-intensity relative to normal appearing cord. 
Diffuse abnormalities were recorded, when seen, as present or absent. An 
anatomical classification system based on spinal cord columnar involvement – as 
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undertaken for focal lesions - could not be implemented for diffuse abnormalities, 
due to the absence of a clearly defined border demarcating their termination. 
Images degraded by artefacts on visual inspection were excluded from analysis. 
 
 
Figure 6.13 Images demonstrating diffuse abnormalities on 3D-FFE images (A 
and B) shown by double chevrons. Corresponding slices of 3D-PSIR image shown 
in images C and D. 
 
6.6.4 Statistical analysis 
Stata 13 (Stata Corporation, College Station, Texas, USA) was used for statistical 
analysis. 
6.6.4.1 Comparison of focal lesion characteristics, GM involvement and diffuse 
abnormalities between CIS and MS subtypes 
 
Firstly, to investigate significant differences in the number of focal spinal cord 
lesions between CIS and MS and between each MS subtype, a single test for 
‘linear trend’ (Altman et al., 1991) by regressing the lesion variable (i.e. number 
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of focal lesions) on a group variable coded numerically in the order: 0=CIS, 
1=RRMS, 2=PPMS, 3=SPMS. 
Secondly, to test the hypotheses that more extensive focal lesions, GM 
involvement and diffuse abnormalities would be seen more frequently in 
progressive MS, these lesion characteristics were compared between CIS and MS 
subtypes using logistic regression.  
In each regression model constructed, the lesional element being compared 
(lesion extent, GM involvement and diffuse abnormalities) was entered in a 
binary fashion as the dependent variable. Disease subtype (CIS or MS) was 
entered as a predictor in each model and adjustment was made for age, gender 
and disease duration (where appropriate). Separate adjustment was performed 
so that age and duration were not in the model simultaneously, since across 
subject groups duration will necessarily vary substantially in patients of the 
same age. Where patients did not have a particular lesion characteristic (e.g. 
diffuse abnormalities) an exact chi-square test was used and this is indicated in 
the Results. Comparisons performed were as follows: CIS vs. RRMS, SPMS vs. 
RRMS and PPMS vs. RRMS/SPMS. 
Due to the exploratory nature of the study, no adjustment for multiple 
comparisons was performed (Bender and Lange 2001). However, to limit the 
number of statistical tests being performed, comparisons were restricted solely 
to the hypotheses being investigated. 
6.6.4.2 Investigation of independent associations between spinal cord lesion 
characteristics and physical disability 
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In order to investigate independent associations between lesion variables and 
physical disability, a multiple linear regression model was constructed with 
EDSS as response variable on the lesion predictors listed in the Table 6.4. A 
standard manual forward stepwise procedure was used as follows: (i) age, 
gender and disease duration were retained in the model throughout; the first 
MRI variable entered was the subject classification according to their most 
extensive lesion (ii) each MRI variable entered was retained if P<0.05, while any 
MRI variables with P>0.05 were removed; with each new variable combination 
thus constructed, the procedure was repeated, until all MRI variables in the 
model were P<0.05 and no other variable improved the model at P<0.05. There 
was no marked deviation from normality or homoscedascity of regression 
residuals, but the regression estimates for the final model were confirmed using 
the non-parametric bias-corrected and accelerated bootstrap (Carpenter and 
Bithall 2000). 
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Lesion number The total number of lesions per patient 
Lesion characteristics The most extensive lesion seen in each 
patient (Type I – IV) 
Diffuse abnormalities The presence of diffuse abnormalities 
Spinal cord columnar involvement by 
focal lesions 
The mean number of columns involved 
per lesion 
The largest number of columns 
involved in any one lesion 
The number of lesions involving the 
anterior, lateral or posterior columns 
Spinal cord grey matter involvement 
by focal lesions 
The number of lesions involving the 
grey matter 
The number of lesions involving the 
anterior, lateral or posterior columns 
and the grey matter 
Diffuse abnormalities and spinal cord 
grey matter involvement by a focal 
lesion 
 
Table 6.4 A list of all MRI variables that were tested prior to construction of the 
final regression model investigating independent associations between spinal 
cord lesion variables with EDSS 
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6.7 Results 
6.7.1 Demographics of CIS and MS groups 
In this study 120 people were recruited: 25 CIS, 35 RRMS, 30 SPMS and 30 PPMS. 
Demographic details of the subjects recruited are summarised in Table 6.5. 
Three scans were excluded due to motion artefacts: CIS (1), RRMS (1) and SPMS 
(1). 
 CIS 
n = 25 
RRMS 
n = 35 
PPMS 
n = 30 
SPMS 
n = 30 
Age (years) 36.5 ± 9.0 38.7 ± 9.7 50.6 ± 
9.9 
51.1 ± 9.2 
Gender 
Female: Male 
14:11 23:12 13:17 18:12 
Disease 
duration 
(years) 
0.4 ± 0.4 6.5 ± 5.2 10.4 ± 
7.5 
19.9 ± 11.5 
Median EDSS 
(range) 
1 (0 – 3.5) 2.5 (0 – 6) 6 (2 – 
7.5) 
6.5 (4 - 8) 
Disease 
modifying 
drugs (%) 
0 (0) 19 (54) 0 (0) 5 (17) 
 
Table 6.5 Demographics of all CIS and MS patients recruited for this study. Data 
represents mean ± standard deviation (SD). 
 
The CIS cohort had the following presentations: optic neuritis (21), partial 
myelitis (2), multifocal CIS (1, optic neuritis with a brainstem syndrome) and 
hemispheric presentation (1, unilateral hand weakness due to a motor cortex 
lesion). Criteria for dissemination in space was fulfilled in 15 cases, however, 
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dissemination in time could not be determined as gadolinium was not used 
(Polman et al., 2011). 
In the MS cohort 19 of the 35 RRMS patients were taking disease modifying 
drugs: -interferon (13), natalizumab (5), and glatiramer acetate (1). In the 
SPMS cohort, five of the 30 patients were taking -interferon. 
6.7.2 Number of spinal cord lesions recorded (Tables 6.6a and 6.6b) 
Lesion numbers in each category (Type I-IV) are summarised in Table 6.6a in 
total 354 focal spinal cord lesions were identified. A higher number of Type IV 
lesions were identified in progressive MS: SPMS (8), PPMS (5) than RRMS (1) 
and CIS (0). 
Total number 
of lesions 
Type I Type II Type III Type IV 
CIS  
n = 18 
8 (44.5%) 8 (44.5%) 2 (11%) 0 (0%) 
RRMS  
n = 94 
36 (38%) 41 (44%) 16 (17%) 1 (1%) 
PPMS  
n = 106 
36 (34%) 55 (52%) 10 (9%) 5 (5%) 
SPMS  
n = 136 
37 (27%) 69 (51%) 22 (16%) 8 (6%) 
All subjects 
n = 354 
117 (33%) 173 (49%) 50 (14%) 14 (4%) 
 
Table 6.6a Number (percentage) of lesion types I-IV recorded in each clinical 
subgroup. 
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In line with pathological reports of the MS spinal cord, lesions involved the 
lateral and posterior columns more frequently (75% and 38% of lesions 
respectively) than the anterior column (6%). The GM was involved by 67% of the 
lesions seen. Lesion numbers recorded in each anatomical location are 
summarised in Table 6.6b. 
Total number 
of lesions 
Grey matter 
involvement 
Anterior 
column 
Posterior 
column 
Lateral 
column 
CIS  
n = 18 
10 (56%) 2 (11%) 5 (28%) 13 (72%) 
RRMS  
n = 94 
58 (62%) 5 (5%) 38 (40%) 67 (71%) 
PPMS  
n = 106 
70 (66%) 7 (7%) 37 (35%) 79 (75%) 
SPMS  
n = 136 
99 (73%) 6 (4%) 54 (40%) 107 (79%) 
All subjects 
n = 354 
237 (67%) 20 (6%) 134 (38%) 266 (75%) 
 
Table 6.6b The number (percentage) of lesions involving the spinal cord grey 
matter and each column of the spinal cord in each clinical subgroup. Note: the 
numbers in this table do not add to the total number of lesions, since some 
lesions seen involved more than one column e.g. extension into the lateral and 
posterior column by the same lesion. 
6.7.3 Lesion characteristics by MS subtype (Tables 6.7a, 6.7b) 
The proportion of people with focal spinal cord lesions increased in the order: 
CIS (42%), RRMS (85%), PPMS (97%) and SPMS (100%) - Table 6.7a. 
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Total number 
of people 
Number of 
people with 
focal spinal 
cord lesions 
Number of 
people with 
Type I lesions 
Number of 
people with 
Type II 
lesions 
Number of 
people with 
Type III 
lesions 
Number of 
people with 
Type IV 
lesions 
Number of 
people with 
lesions 
involving the 
grey matter 
Number of 
people with 
diffuse 
abnormalities 
CIS 
n = 24 
10 (42%) 8 (33%) 5 (21%) 2 (8%) 0 (0%) 6 (25%) 0 (0%) 
RRMS 
n = 34 
29 (85%) 20 (59%) 21 (62%) 12 (35%) 1 (3%) 25 (74%) 6 (18%) 
PPMS 
n = 30 
29 (97%) 22 (73%) 25 (83%) 9 (30%) 5 (17%) 27 (90%) 17 (57%) 
SPMS 
n = 29 
29 (100%) 20 (69%) 27 (93%) 17 (59%) 7 (24%) 28 (97%) 16 (55%) 
 
Table 6.7a Number (percentage) of people with CIS or MS with spinal cord lesions, each lesion type, spinal cord grey matter 
involvement and diffuse abnormalities. Note: Three peoples’ scans were excluded from analysis due to motion artifacts on images: CIS 
(1), RRMS (1) and SPMS (1). 
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Table 6.7b shows mean number and type of lesions per person. The mean of the 
total number of lesions per patient increases also in the order CIS (mean 0.8), 
RRMS (2.8), PPMS (3.5), and SPMS (4.7). This increase is approximately linear 
with a significant increase of 1.2 (95% CI 0.9, 1.6; P<0.001) lesions per MS 
subtype. Adjustment for age and gender did not affect the results. 
 
Number of 
people 
Type I Type II Type III Type IV Grey matter 
involvement 
CIS 
n = 24 
0.33, 0 (0-
1) 
0.33, 0 (0-
2) 
0.08, 0 (0-
1) 
0, 0 (0) 0.42, 0 (0-3) 
RRMS 
n = 34 
1.06, 1 (0-
5) 
1.21, 1 (0-
4) 
0.47, 0 (0-
3) 
0.03, 0 (0-
1) 
1.71, 1 (0-5) 
PPMS 
n = 30 
1.20, 1 (0-
4) 
1.83, 1.5 
(0-6) 
0.33, 0 (0-
2) 
0.17, 0 (0-
1) 
2.33, 2 (0-6) 
SPMS 
n = 29 
1.27, 1 (0-
5) 
2.37, 2 (0-
6) 
0.75, 1 (0-
3) 
0.28, 0 (0-
2) 
3.41, 3 (0-8) 
 
Table 6.7b Mean, median (range) of the number of spinal cord lesions in each 
category and involving the grey matter seen in each person with CIS and MS. 
 
In line with the hypothesis being explored, the proportion of subjects with more 
extensive lesions (defined as Type III or IV), was significantly higher in RRMS vs. 
CIS (OR 6.8, 95% CI 1.4, 33.9; P=0.019), SPMS vs. RRMS (3.1, 95% CI 1.1, 8.7; 
P=0.033) and in SPMS vs. PPMS (OR 3.8, 95% CI 1.3, 11.2; P=0.015). These 
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comparisons were not materially affected by adjustment for age, gender or 
disease duration. 
The proportion of subjects with lesions involving the GM (Type II, III and IV 
lesions) was also greater in RRMS vs. CIS (OR 8.3, 95% CI 2.5,27.6; P=0.001) and 
SPMS vs. RRMS (10.1, 95% CI 1.2, 85.3; P=0.034) but not significantly greater in 
SPMS vs. PPMS (OR 3.1, 95% CI 0.3, 31.8; P=0.338). 
As anticipated, diffuse abnormalities were present in over half of PPMS (57%) 
and SPMS (55%) patients but only in 18% of RRMS and none of CIS (P=0.037 for 
RRMS vs. CIS, exact chi-square test). The odds ratio for having diffuse 
abnormalities in PPMS vs. RRMS was 6.1 (CI 2.0, 19.1; P=0.002) and for SPMS vs. 
RRMS, 5.7 (95% CI 1.8, 18.1; P=0.003). Adjustment for age, gender or disease 
duration did not materially alter these results. 
 
6.7.4 Independent associations between EDSS and spinal cord lesion 
characteristics 
The best independent predictor of EDSS was found to be the number of a 
subject’s lesions which involved both a lateral column and GM. Compared to 
subjects with no such lesions, having 1, 2 and 3+ lateral column lesions with GM 
involvement, predicted respectively 0.8 (95% CI -0.26,1.77; P=0.143), 0.7 (-0.46, 
1.81; P=0.239) and 2.1 (0.94, 3.32; P=0.001) higher mean EDSS (with P=0.0007 
for the overall contribution of the categorical variable). 
None of the other MRI variables entered additionally into this model (see Table 
6.4) was significant, but in particular neither (i) the total number of lesions, nor 
(ii) the number of lesions involving a lateral column, nor (iii) the number of 
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lesions with GM involvement, contributed significantly to the above model, 
confirming the importance of the more specific predictor.  
EDSS was also predicted with borderline significance to be higher by 0.4 (95% CI 
0.01, 0.78; P=0.046) per category (Type I-IV) of the subject’s most extensive 
lesion. 
Age at scan (predicted 0.06 increase in mean EDSS per year of age, P<0.001), 
gender (predicted 0.60 higher mean EDSS in men compared to women, P=0.032) 
and disease duration (predicted 0.07 increase in mean EDSS per year duration, 
P=0.001) were also associated with EDSS. 
The proportion of explained variance (R2) in this regression model was 66%, 
compared to 46% for a model with only age, gender and duration, and with 44% 
for a model with just the two lesion variables (though this rose to 50% when 
subject’s most extensive lesion was entered as categorical). 
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6.8 Discussion 
 
In this study two novel associations between spinal cord lesion characteristics 
and progressive MS have been demonstrated. Firstly, lesions involving two or 
more spinal cord columns and the grey matter, as well as diffuse abnormalities, 
are more frequent in progressive MS. Secondly, lateral column lesions with grey 
matter involvement, are independently associated with physical disability. 
 
6.8.1 Association of more extensive focal lesions and diffuse abnormalities with 
progressive MS 
 
Post mortem spinal cord studies have demonstrated extensive ‘fan shaped’ focal 
lesions traversing several white matter columns and grey matter (Fog 1950; 
Oppenheimer 1978), as well as diffuse abnormalities in progressive MS (Bergers 
et al., 2002). However, due to the inherent limitations of axial spinal cord 
imaging (Stroman et al., 2014), there are limited data on the morphology of focal 
lesions seen in progressive MS in vivo; compared directly to earlier stages of the 
disease. 
This present study is in agreement with previous studies demonstrating a 
greater number of focal lesions in progressive MS (Lycklama et al., 1997; Nijeholt 
et al., 1998; White et al., 2011; Weier et al., 2012; Lukas et al., 2013). However, 
this study extends these findings in two ways. Firstly, a greater number of spinal 
cord columns covered by individual focal lesions in progressive MS was noted 
(as seen in pathology studies [Fog 1950; Oppenheimer 1979]). This observation 
was in comparison to RRMS and CIS, where focal lesions seen were more 
 173 
frequently restricted to a single column. Through the inclusion of people with 
earlier phases of the disease, an association has been demonstrated between 
these larger lesions, covering two or three columns, and progressive MS. 
Secondly the grey matter involvement of the extensive focal lesions seen was 
recorded. These results suggest that spinal cord grey matter involvement is 
extensive in progressive MS, in line with pathology reports (Gilmore et al., 2006; 
Gilmore et al., 2009). 
A question arising from this observation is how lesions restricted to a single 
column of the cord, evolve to encompass multiple columns. Pathology reports of 
the spinal cord in progressive MS have demonstrated extensive inflammation 
and demyelination (Lovas et al., 2000; DeLuca et al., 2004). This may provide a 
milieu in the spinal cord conducive to the formation of new extensive lesions, or 
facilitate the extension and/or coalescence of existing lesions. However, 
longitudinal studies are required to elucidate the exact mechanisms involved. 
Consistent with previous spinal cord studies we have also observed frequent 
diffuse abnormalities in progressive MS (Lycklama et al., 1997; Nijeholt et al., 
1998; Weier et al., 2012; Lukas et al., 2013). An ex vivo study has suggested the 
histopathological correlate of this imaging abnormality is demyelination 
(Bergers et al., 2002). Therefore, the more frequent identification of diffuse 
abnormalities in progressive MS in this study is in agreement with the extensive 
demyelination seen in post mortem spinal cord studies (Fog 1950; Oppenheimer 
1979; Lovas et al., 2000; DeLuca et al., 2004; Gilmore et al., 2009). 
In this present study patients with progressive MS were almost six times more 
likely to have diffuse abnormalities, compared to RRMS. The significance of 
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diffuse abnormalities in progressive MS is discussed in the 2005 revisions to the 
McDonald diagnostic criteria (Polman et al., 2005). However, diffuse 
abnormalities were not included due to a lack of reliability. The spinal cord 
imaging studies referenced in the 2005 revisions contained sagittal views only, 
unlike the present axial study. The detection of diffuse abnormalities in 
progressive MS may be improved upon (as seen with focal lesions [Weier et al., 
2012]), through the use of high resolution axial views in future studies. 
 
6.8.2 Lesions involving lateral columns and grey matter are independently 
associated with disability 
 
In the subsequent chapter (seven) of this thesis, spinal cord lesion load 
measured quantitatively is shown to be independently associated with disability. 
In line with this, the current chapter also demonstrates an independent 
association between spinal cord lesions and disability. However, this present 
study characterised the anatomical location of lesions, in order to identify their 
functional effects in individual spinal cord columns. 
The independent association between lateral column lesions with grey matter 
involvement and EDSS, may be due to corticospinal tract abnormalities and/or 
de-afferentation between sensory and motor tracts, as a consequence of grey 
matter inter-neuronal loss (Gilmore et al., 2009). The EDSS is heavily weighted 
towards ambulatory function (Hobart et al., 2000), which may explain the 
association between lateral column abnormalities and physical disability. 
The most extensive lesion seen in patients (defined by the number of columns 
involved), not recorded in previous studies, was also associated with EDSS, albeit 
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with borderline significance. Such extensive lesions may contribute to axonal 
pathology by acute transaction (Trapp et al., 1998) or Wallerian degeneration 
(DeLuca et al., 2004). However, the strength of the association seen may have 
been weakened by the effect of lesions outside of the field of view of the scans 
acquired. 
 
6.8.3 Limitations and future directions 
A number of limitations should be considered in the interpretation of the results 
of this study. Firstly, the images acquired were restricted to the upper cervical 
cord. Although limited, this approach minimised physiological motion and likely 
provided the greatest yield of lesions for analysis (Fog 1950; Oppenheimer 
1979). 
 
Secondly, with multiple statistical tests there may be an increased chance of 
obtaining false positive results: caution is especially needed interpreting results 
when the P-values obtained were significant at the 0.05 but not 0.01 level; such 
results should be regarded as hypothesis-generating only and need to be 
confirmed in future studies. 
 
Finally, small focal lesions and subpial or peripheral lesions of the spinal cord, 
extending over two columns without GM involvement, may not have been 
visualised with the in-plane resolution used in the present study. Furthermore, 
lesions’ extent within the spinal cord GM could not be quantified. Spinal cord 
lesion detection and classification may be improved upon in future studies 
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performed at 7T, with higher resolution acquisitions within clinically acceptable 
timeframes (Zhao et al., 2013). 
 
6.8.4 Conclusions 
Through the use of high resolution, axial cervical spinal cord MR imaging on a 3T 
scanner, significant associations have been demonstrated in this chapter 
between the extent of focal spinal cord lesions, grey matter involvement and 
diffuse abnormalities with progressive MS and disability. The techniques used 
improve the detection and quantification of cord lesions in MS, and warrant 
further investigation for their potential to assist diagnosis and provide new 
outcome measures in clinical trials. 
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Chapter 7 - Investigation of associations between spinal cord lesion load, 
magnetisation transfer ratio and physical disability 
 
7.1 Introduction 
The progressive phase of MS often includes a prominent spinal cord syndrome 
(Kremenchutzky et al., 2006) and post mortem studies have demonstrated 
multiple and sometimes extensive ‘wedge-like’ or ‘fan-shaped’ lesions (Fog 1950; 
Oppenheimer 1978). However, the relationship of spinal cord lesion-load with 
clinical course is uncertain and direct pathological comparison of lesion-load in 
progressive forms of MS versus the relapsing-remitting (RR) phase of the disease 
is impeded by the rarity with which MS tissue becomes available in early disease.  
MRI provides a technique to detect spinal cord lesions in vivo and can compare 
their frequency and extent at all stages of the disease. Perhaps surprisingly, MRI 
studies have generally shown no or only limited correlations between measures 
of spinal cord lesion-load and physical disability (Kidd et al., 1993; Nijeholt et al., 
1998). However, almost all MRI studies of spinal cord lesions have been based on 
images acquired only in a sagittal plane, and therefore provide no indication of 
the extent to which the spinal cord is involved in its transverse dimensions. 
These studies have also used qualitative or only semi-quantitative methods to 
measure lesion-load, such as counts of lesion number (Kidd et al., 1993; Nijeholt 
et al., 1998) or the number of segments involved by lesions (Lukas et al., 2013). 
Only one study has reported on lesions detected with axial (transverse) MRI 
scans, and in this study lesions were counted but their size was not reported 
(Weier et al., 2012).  
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No study has previously attempted to quantify the extent of lesions involvement 
of the spinal cord by measuring the total lesion area in images acquired in the 
axial (transverse plane). Newer T2- and T1-weighted sequences have been 
developed that acquire high in-plane axial images through the upper cervical 
cord (Chapter 6), a level at which lesions are often seen pathologically and on 
conventional T2-weighted MRI. Lesions are clearly depicted on these sequences 
and demonstrate morphological appearances similar to those described on 
transverse histopathological slices (Fog 1950; Oppenheimer 1978). 
In the present study, high in-plane resolution axial upper cervical cord images 
were acquired in a large cohort of patients with both RR and progressive forms 
of MS and with widely varying disease duration and disability. The hypotheses 
being explored were that firstly; carefully quantified cross-sectional spinal cord 
lesion area – measured on high-resolution axial slices - would be higher in 
progressive forms of MS than in RR disease and secondly, that lesion load would 
be significantly correlated with disability. Thirdly, magnetisation transfer ratio 
(MTR) values were measured in both intrinsic lesional and non-lesional spinal 
cord tissue, to investigate whether greater MTR abnormalities, reflecting more 
extensive demyelination, would be identified in progressive MS, compared to 
earlier stages of the disease (Dousset et al., 1992; Bot et al., 2004; Schmierer et 
al., 2004; Chen et al., 2013). 
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7.2 Methods 
7.2.1 Subjects 
In this study people with MS (Polman et al., 2011) were recruited. MS subtype 
was classified using published criteria (Lublin and Reingold) and physical 
disability was recorded prior to the MRI scan using the expanded disability 
status scale (EDSS) (Kurtzke 1983) and multiple sclerosis functional composite 
(MSFC) (Fischer et al., 1999). The nine hole peg test (9-HPT) and paced auditory 
serial addition tests (PASAT) were analysed in standard z-score form. The timed 
walk test (TWT) was analysed as a z-score formed from the inverse of walk times 
(i.e. walk speed), as walk times are highly positively skewed. None of the subjects 
had experienced a relapse within a month prior to participation. This study was 
approved by our local ethics committee and informed written consent was 
obtained from all participants. 
7.2.2 MRI protocol 
MRI scans were acquired using a 3T Philips Achieva MRI system with 
radiofrequency (RF) multi-transmit technology. To minimise motion during 
scans a polystyrene filled bag surrounding the neck was used. The spinal cord 
sequences were performed in the upper cervical cord centred at the C2/C3 level 
and covering C2-C4. 
SC Imaging: 
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(i) 3D phase sensitive inversion recovery (PSIR): voxel size of 0.5 x 0.5 x 3 
mm3, TR = 8 ms; TE = 3.7 ms; flip angle α = 5°; FOV = 256 x 256 mm; 
NEX = 1 
(ii) MTR data were obtained by acquiring a 3D slab selective spoiled gradient 
echo sequence with two echoes using TR = 36ms, TE1/TE2 = 
3.5/5.9ms, flip angle (α)=9°, with and without Sinc-Gaussian shaped 
MT saturating pulses of nominal α=360°, offset frequency 1kHz, 
duration 16ms applied prior to the excitation pulse. Twenty-two 5mm 
slices were acquired in an axial orientation, with FOV = 180 x 240 
mm2 and acquisition matrix = 240 x 320 (voxel size 0.75 x 0.75mm2, 
reconstructed to 0.5 x 0.5mm2), with SENSE factor 2 in the foot/head 
direction, and 2 signal averages (NEX). 
(iii) 3D fat-suppressed fast field echo (3D-FFE) was acquired in the axial 
plane containing 10 contiguous slices, FOV 240x180mm
2
, TR 23ms, TE 
5ms, flip angle α=7°, and number of averaged signals=8 
Brain imaging: 
(i) 3D magnetisation-prepared turbo field echo (3D-TFE) sequence was used 
with slice thickness= 1mm; TR=6.8 ms; TE=3.1 ms; matrix = 256 x 256 
mm2; in plane voxel size 1 x 1mm2  
(ii) Axial PD/T2 images using a 2D turbo spin echo sequence (TSE) with 3mm 
slice thickness, and the following acquisition parameters: TR=3500 
ms; TE1/TE2=19/85 ms; matrix 240 x 240 mm2; in plane voxel size = 
1 x 1 mm2 
7.2.3 Image analysis 
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7.2.3.1 Upper cervical cord lesion-load and cross-sectional area 
An inclusion criterion for each scan was the absence of motion artefacts. Focal 
spinal cord lesions were defined as abnormal areas of decreased signal change, 
with a clearly visible hypo-intense abnormality suggestive of a demyelinating 
plaque that had clearly defined margins and could be demarcated from the 
surrounding tissue on 3D-PSIR images. Lesions were outlined using a semi-
automated edge-finding tool in JIM 6.0 (Xinapse systems, 
http://www.xinapse.com) on the 3D-PSIR image (Figure 7.1). Poorly demarcated 
areas of equivocal decrease in signal intensity were not outlined. The area of 
individual SC lesions and calculated the upper cervical cord lesion load for each 
subject (as described in Chapter six). Reproducibility of cord lesion-load 
measurement was evaluated by re-analyzing ten MS subjects’ scans after a 
period of one week. The mean upper cervical cord cross-sectional area was also 
recorded (Chapter five) and then the cord lesion load was expressed as a 
percentage of cord area. 
 
Figure 7.1 3D-Phase sensitive inversion recovery image (PSIR); 0.5 x 0.5 mm2 in 
plane voxel size, centred at C2/C3 intervertebral disc acquired using 16-channel 
neurovascular coil. Image (A) demonstrating lesions seen as hypo-intense areas 
in both lateral columns and posterior column in the spinal cord of a patient with 
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SPMS (EDSS 6.5). The central canal can also be seen as a hypo-intensity above 
the central grey matter. Image (B) shows lesions circumscribed to calculate 
cervical cord lesion-load. The cord lesion load in this case was 12.59 mm2 the 
ratio between cord lesion load/area was 18.62%. 
 
7.2.3.2 MTR analysis 
The central ten slices of the MT volume were extracted and then the MT-on and 
MT-off images were registered using the linear registration tool in FSL 
(http://www.fmrib.ox.ac.uk/fsl/). An MTR map was created in the MT-off space 
regions of interest (ROIs) were marked on the MT-off image to avoid bias. All 
focal lesions seen were marked using a semi-automated edge-finding tool. As the 
MT-off image was geometrically linked to the 3D-FFE during prescription, this 
enabled its use as a reference for marking lesions (Figure 7.2). The perimeter of 
the spinal cord on the MT-off image was outlined using the active surface model 
(Horsfield et al., 2010) (Figure 7.3) to create a whole-cord mask. In the cases 
where focal lesions were identified, a lesion masks was created by applying the 
respective ROIs independently to the MTR mask. Both masks were converted to 
binary format using FSL and the lesion mask was then subtracted from the 
whole-cord mask, resulting in a mask of normal appearing spinal cord (NASC) 
tissue. Mean MTR values were obtained for: whole-cord, lesions and NASC. In 
healthy controls (i.e. without lesions) whole-cord measurements only were 
obtained. 
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Figure 7.2 Images (A) and (C) demonstrate representative images of the 3D-FFE 
sequence; 0.5 x 0.5 mm2 in plane voxel size, centred at C2/C3 intervertebral disc 
acquired using 16-channel neurovascular coil. Images (B) and (D) demonstrate 
the corresponding MT-off images; 0.5 x 0.5 mm2 in plane voxel size, centred at 
C2/C3 intervertebral disc acquired using 16-channel neurovascular coil. Images 
(A) and (B) demonstrate a focal lateral column lesion (indicated by yellow 
chevron) with extension into the dorsal horn of the grey matter. Images (C) and 
(D) show a posterior column lesion restricted to the white matter (indicated by 
yellow chevron). 
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Figure 7.3 MT-off images; 0.5 x 0.5 mm2 in plane voxel size, centred at C2/C3 
intervertebral disc acquired using 16-channel neurovascular coil demonstrating 
the cord outline region of interest acquired using the active surface model. 
 
7.2.3.3 Brain image analysis 
Brain T2 lesion volume (T2LV) and brain parenchymal fraction (BPF) (the sum 
of white and grey matter relative to total intracranial volume) were measured as 
described in Chapter four. 
 
7.2.4 Statistical analysis 
Reproducibility of cord lesion-load measurement was analyzed using the 
coefficient of variation (expressed as a percentage [COV]) and intra-class 
correlation coefficient (ICC) between the two measures. 
To compare MRI variables, multiple linear regression was used on the whole 
sample (including controls except for lesion-MTR) with MRI as response variable 
and subject group indicators as predictors with the following potential 
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confounders as covariates: age, gender, BPF and cord area (except when cord 
area was the response variable being compared across groups). 
P-values and confidence intervals for the multiple comparisons between groups 
were inflated, to account for the six between-group differences, using Šidák’s 
method (Šidák 1967), though this is quite conservative since the comparisons 
are not all independent. The control versus MS group comparisons were 
adjusted for the covariates above and adjustment for two other covariates – 
disease duration and EDSS - is also reported for comparisons between MS 
subtypes. 
There was no indication that regression residuals deviated materially from 
normality; some comparisons showed signs of heteroskedasticity, and in these 
cases the regression was repeated using robust Huber-White standard errors 
(Huber 1967), and this result is reported if materially different. 
To identify independent predictors of disability, multiple regression models 
were constructed for the disability scores: all MRI and socio-demographic 
predictors (Tables 7.1 and 7.2) were entered, and manual stepwise backwards 
elimination removed singly predictors with highest P-value, until all model 
predictors were significant at P<0.05 (or borderline). Regression residuals did 
not materially deviate from normality but, as a precaution, for EDSS inference 
was confirmed using the bias-corrected and accelerated non-parametric 
bootstrap. 
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Analyses were implemented in Stata 13.1 (Stata Corporation, College Station, 
Texas, USA). All p-values are two-tailed and statistical significance is reported at 
P<0.05 (including any Šidák inflation). 
7.3 Results 
7.3.1 Subjects and MRI measures 
120 people were recruited: 28 controls, 34 RRMS, 29 SPMS and 29 PPMS 
patients. Lesions in the SC were visible in 80% (27/34) of cases with RRMS, 96% 
(28/29) with SPMS and 90% (26/29) in PPMS. Group demographics are 
summarised in Table 7.1. 
 Gender Age 
(years) 
Median 
EDSS 
(range) 
Disease 
duration 
(years) 
Controls 
n=28 
 
19 F, 9 
M 
41.43 ± 
10.33 
  
RRMS 
n=34 
 
22 F, 12 
M 
38.59 ± 
9.82 
2.5  
(0 – 6) 
6.53 ± 
5.23 
SPMS 
n=29 
 
17 F, 12 
M 
51.34 ± 
9.25 
6.5 
(4 – 
8.5) 
19.86 ± 
11.74 
PPMS 
n=29 
 
12 F, 
17M 
50.66 ± 
10.05 
6.0  
(2 – 
7.5) 
10.50 ± 
7.66 
 
Table 7.1 Demographics of cohort studied presented as mean ± standard 
deviation. 
7.3.2 Reproducibility analysis 
Cord lesion load measurement was found to be reproducible with a COV of 
1.95% and ICC 0.995. 
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7.3.3 Comparison of MRI measures between MS and controls 
 Controls 
n=28 
RRMS n=34 SPMS n=29 PPMS n=29 
Upper 
cervical cord 
lesion-load 
(mm2) 
 8.10 (9.26) 16.68 (7.41) 13.2 (10.85) 
Upper 
cervical cord 
cross-
sectional area 
(mm2) 
79.59 (8.24) 76.79 (7.50) 63.64 (9.66) 69.33 (9.54) 
% Spinal cord 
area covered 
by lesions 
 11.1 (12.1) 28.4 (14.5) 19.3 (15.9) 
Whole cord 
MTR 
49.70 (1.04) 47.75 (2.29) 45.49 (2.53) 46.48 (2.89) 
Normal 
appearing 
spinal cord 
MTR 
49.70 (1.04) 48.31 (2.06) 46.56 (2.49) 47.51 (2.51) 
Spinal cord 
lesion MTR 
 43.37 (3.49) 40.54 (2.04) 41.26 (2.28) 
Brain 
parenchymal 
fraction (BPF 
0.823 (0.015) 0.811 (0.018) 0.788 (0.022) 0.799 (0.014) 
Brain T2 
lesion volume 
(mLs) 
 13.00 (13.51) 23.34 (16.71) 16.57 (19.72) 
 
Table 7.2 Mean (standard deviation) of MRI parameters analyzed in controls 
and each subtype of MS 
 
In keeping with the first hypothesis being tested, spinal cord lesion-load was 
significantly higher in progressive MS compared to RRMS. Mean differences: 
SPMS vs. RRMS 8.06mm2, P=0.008 (95% CI 1.69, 14.44) and PPMS vs. RRMS: 
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6.38mm2, P=0.021 (95% CI 0.74, 12.02). However, the difference between PPMS 
and SPMS was not significant: 1.69mm2, P=0.817 (95% CI -3.53, 6.80). 
When the regression was repeated accounting for some heteroscedasticity of 
residuals, the SPMS vs. RRMS comparison remained significant (P=0.005) but the 
PPMS vs. RRMS comparison lost significance (P=0.09). When Including EDSS as a 
covariate, these differences were greatly reduced and non-significant: SPMS vs. 
RRMS: 11.56mm2, P=0.980 and PPMS vs. RRMS: 4.73 mm2, P=0.997. 
As anticipated, both SPMS and PPMS groups had significantly lower cord areas 
compared to controls: mean adjusted differences were SPMS vs. controls: -
15.08mm2, P<0.001 (95% CI -22.83, -7.33), PPMS vs. controls: -10.45mm2, 
P=0.001 (95% CI -17.40, -3.50). No differences in cord area were seen between 
RRMS and controls -2.40mm2, P=0.893 (95% CI –8.71, 3.91). 
Significantly smaller cord areas were recorded in SPMS vs. RRMS (-12.68mm2, 
P<0.001, 95% CI -19.65, -5.71) and PPMS vs. RRMS (-8.05mm2, P=0.009, -14.65, -
1.46). However, no significant difference in cord area was seen between the two 
progressive cohorts: (-4.63mm2, P=0.302, 95% CI -11.10, 1.85). 
Both progressive MS subtypes had significantly lower whole-cord-MTR than 
controls. Mean adjusted differences were SPMS vs. controls: -2.46, P=0.011(95% 
CI -4.52, -0.40), PPMS vs. controls: -2.32, P=0.004 (95% CI -4.10, -0.55), RRMS vs. 
controls -1.09, P=0.288 (95% CI -2.61, 0.42). However, there were no significant 
adjusted differences in whole-cord-MTR between the MS groups. There were no 
significant adjusted differences in NASC-MTR between MS subgroups and 
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controls and between MS subgroups. There were no significant differences in 
lesion MTR between MS subgroups. 
 
7.3.4 Associations between MRI measures and disability 
In line with the second hypothesis EDSS was independently associated with cord 
lesion-load (P<0.001), along with cord area (P=0.003), age (P<0.001) and gender 
(P=0.001, R2=0.58 for this model). 
Cord lesion-load increase by 1mm2 predicts an increase in EDSS by 0.008 (95% 
CI 0.004, 0.012), which translates to a predicted EDSS increase of 0.37 SDs per 1 
SD increase in lesion-load. A decrease of 1mm2 in cord area predicts an increase 
in EDSS by 0.05 (95% CI 0.02, 0.09), translating to a 0.27 SD EDSS increase per 
SD decrease in cord area. 
Further support for our hypothesis that cord lesion-load would be associated 
with disability, was seen in the independent association with the 9-HPT 
(P=0.003) in addition to cord area (P=0.034), BPF (P=0.007) and, with 
borderline significance, gender (P=0.085) (R2=0.42). 
A 1mm2 increase in lesion-load predicts a 9-HPT z-score decrease by 0.003 SD 
(95% CI 0.001, 0.005). A 1mm2 smaller cord area predicts a z-score decrease by 
0.02 SD (95% CI 0.002, 0.04) and a 0.1 increase in BPF predicts a higher z-score 
by 1.33 SD (95% CI 0.37, 2.29). 
Independent associations with the TWT were seen with: cord area (P<0.001), 
disease duration (P<0.001) and gender (P=0.007), (R2=0.38). A 1mm2 higher 
cord area predicts 0.035 SD (95% CI 0.02, 0.05) higher walk speed. 
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As expected none of the spinal cord MRI measures were associated with PASAT. 
However, brain T2LV (P=0.035) and, with borderline significance, BPF (P=0.05) 
were associated with PASAT (R2=0.14). 
7.3.5 Associations with disability in MS patients with EDSS ≤ 6 
To determine if the independent associations seen in this study maintained 
significance in populations with lower levels of physical disability - such as those 
commonly seen in clinical trials in RRMS - the analysis was repeated in this 
subset of the study population. 
The independent associations between spinal cord lesion-load and age 
coefficients with EDSS were not materially altered and retained significance 
(P=0.001 and P<0.001 respectively), while gender also remained significant at 
P=0.02. However, the association with cord area lost significance, (P=0.868, cord 
area coefficient over 90% smaller). 
The association between cord lesion load and 9-HPT also remained significant at 
P=0.01. In contrast, the cord area coefficient lost significance (P=0.876) and BPF 
maintains borderline significance (P=0.048). 
The associations between cord area (P=0.632), gender (P=0.116) and TWT also 
lost significance and the coefficients are reduced, though disease duration 
remains significant at P=0.014. 
No significant associations with the PASAT test were seen in patients with an 
EDSS ≤ 6. 
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7.4 Discussion 
The main study finding is that a quantitative measure of upper cervical cord 
lesion-load – measured from axial, high-resolution images - is significantly 
greater in progressive forms of MS than in RRMS and is associated with physical 
disability in MS, independent of an effect of cord atrophy. 
7.4.1 Association of cord lesion-load with progressive MS and disability 
In this present study cord lesion-load was calculated, for the first time, by 
circumscribing individual lesions on axial scans and measuring their mean area 
across all axial slices in mm2, in an effort to replicate the methodology in post 
mortem studies (Evangelou et al., 2005; DeLuca et al., 2006). The cord lesion-
load was significantly higher in progressive than RRMS in spite of the smaller 
cord area in the progressive groups. Indeed, the proportion of the transverse 
section of the upper cervical cord involved by lesions was about 30% in SPMS 
and 20% in PPMS whereas it was around only 10% in RRMS. 
The associations of physical disability with cord lesion-load (EDSS and 9-HPT) 
were independent of the associations observed with cord atrophy. Only one 
previous study of MS, with axial cord imaging has investigated lesion counts and 
atrophy qualitatively (Weier et al., 2012). However, in this present study, lesion 
area was quantified electronically (in mm2) with higher in-plane resolution (0.5 
x 0.5 mm2 vs. 1.1 x 0.5 mm2 voxel size) and acquired at higher field strength (3T 
vs. 1.5T) than in the previous study. The PSIR sequence was chosen for lesion-
load measurement, as it has previously been shown to improve both lesion 
localization, and boundary definition with normal appearing spinal cord tissue 
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(Poonawalla et al., 2008). A combination of these factors should have led to more 
sensitive and accurate quantitation of lesion-load, and thereby facilitated 
detection of a robust independent association with disability. 
Although the cord lesion-load and area differences between progressive and 
RRMS lost significance when including EDSS as a covariate, this is likely to reflect 
the strong association between these MRI measures and EDSS. Therefore, people 
with the same EDSS score will tend to have very similar lesion-load irrespective 
of the MS subtype. However, in the analysis of MS patients with an EDSS ≤ 6, the 
association between cord lesion-load and disability is maintained. In contrast, 
the association between cord atrophy and disability loses significance. These 
results, combined with its reproducibility, support the use of cord lesion-load as 
a potential endpoint for clinical trials involving MS subjects with an EDSS ≤ 6, 
which is the case in virtually all trials in RRMS. 
Previous regression analyses have investigated the contributions of brain MRI 
measures of lesion-load and/or atrophy along with cord atrophy to EDSS, and 
have identified independent associations with both (Chapter four, Bonati et al., 
2011). Our present regression analyses have identified independent 
contributions to EDSS variability by cord measures alone, and this probably 
reflects the sensitive measures of cord pathology used, especially cord lesion-
load. Our study emphasizes the predominant role of cord pathology in causing 
locomotor disability and thereby contributing to higher EDSS scores seen in 
progressive MS. 
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7.4.2 Associations between other MRI measures and disability 
In confirmation of previous studies, this present study has also shown that both 
progressive cohorts had more marked cord atrophy than RRMS and that cord 
atrophy was also associated with physical disability (Losseff et al., 1996; 
Horsfield et al., 2010; Rocca et al., 2011; Furby et al., 2010). The greater extent of 
atrophy is consistent with more severe axonal loss in the cord in both 
progressive MS groups compared with RRMS (Ganter et al., 1999; Lovas et al., 
2000), thereby resulting in locomotor-disability. Given the limited region of cord 
investigated, it is also possible that atrophy is contributed to by Wallerian 
degeneration from distant lesions. 
Although abnormalities in the whole-cord MTR were evident in progressive MS 
groups, the measure was not independently associated with disability. The MT 
ratio may reflect demyelination and/or inflammation in the spinal cord (Dousset 
et al., 1992). However, it is thought that axonal loss, rather than demyelination, 
represents the pathological substrate for disability in the spinal cord (Ganter et 
al., 1999; Lovas et al., 2000; Tallantyre et al., 2010). The lack of evidence of 
abnormal whole cord MTR in RRMS may reflect limited sensitivity to detect 
effects of Wallerian degeneration.  
Brain atrophy (BPF) had a significant and independent association with the 9-
HPT. The association between brain atrophy and 9-HPT might reflect cerebellar 
pathology resulting in impaired co-ordination. The lack of an association 
between the spinal cord MRI parameters used and PASAT test emphasizes their 
specificity, as cord measures were exclusively associated with physical disability. 
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7.4.3 Association of demographic features with disability 
Not surprisingly older age and longer disease duration were more likely 
associated with higher disability and progressive MS (Confavreux and Vukusic 
2006; Leray et al., 2010; Scalfari et al., 2014). Male gender also associated with 
higher disability and there was a higher male-female ratio in PPMS versus other 
MS subtypes, consistent with previous studies (Thompson et al., 1997; 
McDonnell et al., 1998; Kremenchutzky et al., 2006).  
7.4.4 Spinal cord MRI findings in primary and secondary progressive MS 
Both spinal cord atrophy and lesion-load measurements did not significantly 
differ between SPMS and PPMS. These results are coherent with the similar 
levels of disability recorded in both subtypes. As cord atrophy and lesion-load 
are independently associated with disability, it is plausible that they each 
contribute to disability in both progressive MS groups. 
No difference was found in lesion-MTR when comparing the progressive and 
RRMS groups. However, MTR is sensitive to demyelination per se (Dousset et al., 
1992; Bot et al., 2004; Schmierer et al., 2004; Chen et al., 2013) and it is 
conceivable that a reduction in lesion-MTR reflects an effect of demyelination 
alone, while not excluding a difference in axonal density. More specific in vivo 
assessment of axonal density within lesions may be possible using measures 
based on diffusion tensor (Xu et al., 2013) and/or diffusion-weighted (Zhang et 
al., 2012) imaging sequences, and analysis of lesions in PPMS and SPMS using 
such techniques would be of interest in a future study. 
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7.4.5 Study limitations 
The study has several limitations. First, the imaging acquisitions were confined 
to the upper cervical cord, in order to minimize physiological motion and enable 
high resolution multi-sequence imaging within an acceptable time frame. 
Although lesions in the upper cervical cord are common in MS (Fog 1950; 
Oppenheimer 1978) further studies should investigate cord lesions at other 
levels and their relationship to clinical function.  
Secondly, although cord lesion load and atrophy were independently associated 
with disability, the variability in these imaging measures (and additional clinical 
parameters) only explained about a half of the variability in disability measures. 
Probably multiple factors impact on the strength of such associations, including 
limitations in coverage of the spinal cord, and the pathophysiological specificity 
of the imaging metrics themselves. 
Thirdly, although the sample size was sufficient to investigate our a priori 
hypotheses that cord lesion load is greater in progressive MS groups than in 
RRMS and is associated with disability, it may not have been sufficient to detect a 
smaller difference in lesion load between the PPMS and SPMS groups. A study 
comparing quantitative spinal cord MRI measures in larger cohorts with PPMS 
and SPMS would be of interest. 
7.4.6 Conclusion 
The results presented in this chapter show that both cord lesion-load and 
atrophy are independently associated with physical disability in MS. 
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Longitudinal studies are required to understand the evolution of cord lesion-load 
in MS, and to consider its potential as an outcome measure in clinical trials. 
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Chapter 8 - Investigation of magnetisation transfer ratio-derived pial and 
subpial abnormalities in the multiple sclerosis spinal cord 
 
8.1 Introduction 
Although the exact causative mechanisms of multiple sclerosis are unclear, it has 
been suggested from the findings in neuropathological studies that meningeal 
inflammation may play a role in the development of earlier disability in 
progressive forms of the disease (Magliozzi et al., 2007; Howell et al., 2011; Choi 
et al., 2012). It has also been reported that B cell follicles (as well as T cells) are 
present in the meninges of post-mortem brain specimens (Serafini et al., 2004; 
Lovato et al., 2011). However, Frischer et al. (2009) reported that B cells may 
only be found in the progressive forms of the disease. Neuropathology studies 
have also suggested that cortical demyelination may be a characteristic finding in 
multiple sclerosis (Dawson 1916; Brownwell and Hughes 1962). Another post-
mortem study has suggested that cortical demyelination is more commonly 
found in progressive multiple sclerosis and inflammation is more diffuse, when 
compared directly to the relapsing-remitting form of the disease (Kutzelnigg et 
al., 2005). 
 
Taking in to account the above observations, an hypothesis has arisen that the 
pathological processes of meningeal inflammation and cortical demyelination 
may be interconnected and in turn play a role in the development of a 
progressive disease course. A paper by Magliozzi et al. (2010) has demonstrated 
the co-localisation of areas of meningeal inflammation (composed of B cells and 
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dendritic cells) and cortical demyelination. Furthermore, extensive subpial 
demyelination has been recorded in the cortex in multiple sclerosis (Bø et al., 
2003; Bö et al., 2007). It has been proposed that cortical demyelination 
(especially subpial) may occur in the presence of meningeal inflammation due to 
the release of inflammatory cytokines in the subarachnoid space (Brown et al., 
2007; Ransohoff 2009). In progressive forms of multiple sclerosis, where there 
appears to be long standing inflammation, this may create a milieu, which 
favours further retention of inflammatory cells (Krumbholz et al., 2005; Meinl et 
al., 2008). This retention of inflammatory cells in multiple sclerosis may result in 
the activation of microglia and subsequently demyelination (Magliozzi et al., 
2010). 
 
It has been reported that in relapsing-remitting multiple sclerosis meningeal 
inflammation may be present, with inflammation involving T cells rather than B 
cells (Frischer et al., 2009). As neuropathology studies are predominantly 
composed of cases of progressive multiple sclerosis, an important insight was 
gained into the process of meningeal inflammation in a study examining biopsies 
of patients with early relapsing-remitting multiple sclerosis or a clinically 
isolated syndrome (Lucchinetti et al., 2011). In this paper it was found that 
subpial cortical demyelination may be associated with meningeal inflammation.  
 
Imaging studies have also provided a means of studying patients when they 
present with a clinically isolated syndrome suggestive of multiple sclerosis, 
which is the earliest clinical manifestation of the condition in most cases. The use 
of a double inversion recovery sequence has demonstrated the presence of 
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cortical lesions in clinically isolated syndrome patients (Calabrese et al., 2007). 
Furthermore, a decrease in magnetisation transfer ratio (MTR) of the cortex, 
which might reflect demyelination (Chen et al., 2013), - has also been observed 
in clinically isolated syndrome subjects (Audoin et al., 2005; Fernando et al., 
2005). These imaging observations also suggest that cortical demyelination 
occurs early in the disease course. 
 
The meninges of the spinal cord have also been reported to be inflamed in 
multiple sclerosis (Androdias et al., 2010; DeLuca et al., 2013), with the 
inflammatory cells predominantly composed of T cells in one study (Androdias 
et al., 2010). Meningeal inflammation in the spinal cord has been related to 
axonal loss (Androdias et al., 2010; DeLuca et al., 2013). As axonal loss has been 
hypothesised to be the pathological substrate for disability (Ganter et al., 1999; 
Evangelou et al., 2000; Lovas et al., 2000; Schirmer et al., 2011), and because 
much of the physical disability from multiple sclerosis arises from spinal cord 
involvement, a greater understanding of meningeal abnormalities in the spinal 
cord, and their relationship to disease course, would seem to be relevant. 
 
However, to date the effect of multiple sclerosis on the spinal cord meninges has 
not been investigated in vivo, due to image resolution constraints and other 
technical challenges associated with magnetic resonance imaging (MRI) protocol 
optimisation in the spinal cord (Dietrich et al., 2008; Stroman et al., 2013). 
Magnetisation transfer ratio (MTR) imaging in the spinal cord has been 
employed for some time (Mezzapesa et al., 2004; Charil et al., 2006). The MTR of 
a tissue is related to its macromolecular structure and an important contribution 
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in central nervous system tissue comes from myelin (Dousset et al., 1992). 
Recent MTR imaging studies in the spinal cord have provided insights into the 
mechanisms of disability in multiple sclerosis (Zackowski et al., 2009; Oh et al., 
2013). With the implementation of higher resolution structural and MTR 
acquisitions in the spinal cord than those previously acquired (Yiannakas et al., 
2012), the potential to investigate the effects of multiple sclerosis on the outer 
region of the spinal cord, that would be expected to include the pia mater of the 
meninges, could provide further insights into the pathophysiology of multiple 
sclerosis. 
 
The aims of this chapter are threefold: 
1. To characterise the outermost region of the spinal cord which is expected 
to include contributions from the pia mater and subpial region of the 
spinal cord, using high in-plane resolution, magnetisation transfer-
weighted images to measure MT ratio (MTR) in healthy controls and in 
people with multiple sclerosis or a clinically isolated syndrome.  
2. To compare the outer spinal cord MTR measures of people with a 
clinically isolated syndrome or multiple sclerosis with those of healthy 
controls 
3. To compare outer spinal cord MTR findings seen in different clinical 
subgroups – clinically isolated syndrome, relapsing remitting, primary 
and secondary progressive multiple sclerosis – and explore the 
relationship of outer cord MTR with measures of both spinal cord atrophy 
and physical disability. 
 201 
 
8.2 Methods 
8.2.1 Subjects 
People with no prior neurological diseases (n = 26) and those with either 
clinically isolated syndrome (n = 22) or multiple sclerosis: relapsing 
remitting (n = 29), secondary progressive (n = 28) and primary progressive 
(n = 28), were recruited. Multiple sclerosis (MS) was diagnosed using the 
2010 McDonald criteria (Polman et al., 2011). The clinically isolated 
syndrome (CIS) cohort was recruited following a single clinical episode 
consistent with demyelination and at least one lesion on a T2-weighted axial 
brain scan. The MS subgroups were classified using the Lublin-Reingold 
criteria (Lublin and Reingold 1996). Informed written consent was obtained 
from each participant prior to inclusion in the study. 
 
All people with CIS or MS had expanded disability status scale (EDSS [Kurtzke 
1983]) determined as well as multiple sclerosis functional composite (MSFC) 
(Fischer et al., 1999). Subsequently Z-scores were calculated from normative 
values displayed in the National Multiple Sclerosis Society Task Force 
Database (Fischer et al., 1999) for the 25-foot timed walk test (TWT), 9-hole 
peg test (HPT) and 3 s paced auditory serial addition test B (PASAT). 
American Spinal Injury Association (ASIA) motor (m) and sensory (s) scores 
(Maynard et al., 1997) were also recorded for all people with MS and CIS. 
Assessment of physical function was performed immediately before the 
magnetic resonance imaging (MRI). 
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None of the subjects had experienced a relapse or received a course of 
corticosteroids within a month prior to imaging. 
 
8.2.2 MRI protocol 
Subjects were scanned at 3T using a Philips Achieva MRI system with 
radiofrequency (rf) multi-transmit technology (Philips Healthcare, Best, the 
Netherlands). A 16-channel receive-only neurovascular coil was used for 
spinal cord scanning and brain scanning was performed using the product 
32-channel receive-only coil. A polystyrene filled vacuum fixation bag was 
placed behind the neck of all participants to provide a head rest and neck 
restraint and to minimise motion artefacts. The following sequences were 
acquired:  
(iv) 3D fat-suppressed fast field echo (3D-FFE) was acquired in the axial 
plane containing 10 contiguous slices, FOV 240x180mm2, TR 23ms, TE 
5ms, flip angle α=7°, and number of averaged signals=8 
 
(v) MTR data were obtained by acquiring a 3D slab selective spoiled gradient 
echo sequence with two echoes using TR = 36ms, TE1/TE2 = 
3.5/5.9ms, flip angle (α)=9°, with and without Sinc-Gaussian shaped 
MT saturating pulses of nominal α=360°, offset frequency 1kHz, 
duration 16ms applied prior to the excitation pulse. Twenty-two 5mm 
slices were acquired in an axial orientation, with FOV = 180 x 240 
mm2 and acquisition matrix = 240 x 320 (voxel size 0.75 x 0.75mm2, 
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reconstructed to 0.5 x 0.5mm2), with SENSE factor 2 in the foot/head 
direction, and 2 signal averages (NEX). 
 
(vi) 3D-phase sensitive inversion recovery (PSIR): voxel size of 0.5 x 0.5 x 
3 mm3, TR = 8 ms; TE = 3.7 ms; flip angle α = 5°; FOV = 256 x 256 mm; 
NEX = 1 
 
(vii) Axial PD/T2 images using a 2D turbo spin echo sequence (TSE) with 
3mm slice thickness, and the following acquisition parameters: 
TR=3500 ms; TE1/TE2=19/85 ms; matrix 240 x 240 mm2; in plane 
voxel size= 1 x 1 mm2 
 
(viii) 3D magnetisation-prepared turbo field echo (3D-TFE) sequence was 
used with slice thickness= 1mm; TR=6.8 ms; TE=3.1 ms; matrix = 256 
x 256 mm2; in plane voxel size 1 x 1mm2 
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8.2.3 Image Analysis 
 
8.2.3.1 MTR values 
 
An inclusion criterion for all MRI images was the absence of motion artefacts. 
Using JIM 6.0 (Xinapse systems, http://www.xinapse.com) the central 10 
slices of the MTR volume were extracted and the MT-off and MT-on images 
were registered independently to the volumetric 3D-FFE using linear 
registration in FSL (http://www.fmrib.ox.ac.uk/fsl/). Subsequently an MTR-
map was created in the 3D-FFE space (Figure 8.1) (Yiannakas et al., 2012). All 
MTR-maps were reviewed to confirm that no artefacts were introduced 
during the registration step. 
 
 
Figure 8.1 (A) Axial 3D-FFE image (voxel size 0.5 x 0.5 x 5mm3) through the 
C2/C3 intervertebral disc (B) Following independent linear registration of the 
MT-on and MT-off to the FFE the MTR-map is created in this space (voxel size 0.5 
x 0.5 x 5mm3) 
Three slices centred at the C2/C3 intervertebral disc were extracted from the 
volumetric 3D-FFE image and then created two regions of interest (ROIs): (i) 
spinal cord outline using an active surface model (Horsfield et al. 2010) (ii) 
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spinal cord GM using a semi-automated fuzzy connector method (Udupa and 
Samarasekera 1996) (Figure 8.2). Using these two ROIs a mask of the cord 
outline and GM were created from the MTR-map and then converted to 
binary format using FSL tools (http://www.fmrib.ox.ac.uk/fsl/). This process 
enabled the subtraction of the binary GM mask from the binary cord outline 
resulting in two masks: (i) spinal cord WM MTR-mask and (ii) spinal cord GM 
MTR-mask. The mean value of the spinal cord GM MTR-mask was recorded 
for each participant. 
 
 
Figure 8.2 (A) Axial 3D-FFE image (voxel size 0.5 x 0.5 x 5mm3) demonstrating 
the spinal cord outline created using the active surface model (B) Axial 3D-FFE 
(voxel size 0.5 x 0.5 x 5mm3) demonstrating grey matter region of interest 
outlined using the fuzzy connector. 
 
The WM MTR-mask was then further analysed by eroding the image using 
iterations based on 4-connected neighbours written in Matlab 2012a (the 
Mathworks, Natick USA). The outermost row of pixel of the image was 
discarded to avoid contamination by cerebrospinal fluid (CSF). As the image 
was acquired at 0.75 x 0.75 mm2 voxel size and subsequently reconstructed 
to 0.5 x 0.5 mm2, the next voxel layer was also considered to be also 
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contaminated by CSF due to the voxels’ interpolation and consequently this 
voxel was also discarded. Therefore, the next voxel layer was designated as 
being the outermost voxel layer of the spinal cord and the mean MTR values 
of the voxels in this layer were recorded across the three selected slices for 
each subject. The classification of peripheral voxels in the image is illustrated 
in Figure 8.3 and on MRI in Figure 8.4; this layer was considered likely to 
include both pia mater and subpial spinal cord tissue. Following removal of 
the three outermost voxels the mean value from the spinal cord WM-MTR 
mask was recorded for each subject and this was designated as the WM-MTR 
value. Finally, the mean GM MTR value was recorded across the three slices. 
 
 
Figure 8.3 Graphical representation of voxel layers analysed in the outermost 
region of the spinal cord.  
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Figure 8.4 (A) MTR-map (voxel size 0.5 x 0.5 x 5mm3) demonstrating a square 
shaped region of interest from which (B) was obtained in the periphery of the 
spinal cord (B) Zoomed image of the periphery of the spinal cord demonstrating 
from right to left: Cerebrospinal fluid (CSF), (P) Outer exclusion voxel layer - 
partial volume with CSF (1) inner exclusion layer - interpolation of voxels (2) 
Outermost spinal cord voxel layer, (WM) spinal cord white matter 
 
8.2.3.2 Spinal cord area 
Spinal cord mean cross-sectional area was measured from the 3D-PSIR image 
using the active surface model (Horsfield et al. 2010). In order to do this five 
3mm thick slices centred at C2/C3 were extracted and then the area of each 
of the five slices was recorded (c.f. Chapter Five). Spinal cord area was 
normalised by the number of slices used i.e. the mean area of the five slices 
for each participant was calculated. This method of normalisation was chosen 
as a previously published report has demonstrated that normalisation of 
spinal cord volume by slice number is superior to the use of brain volume or 
other measures of body habitus (Healy et al., 2012). The spinal cord 
measurements are presented as area normalised by slice number rather than 
as volume, as cord area is more commonly reported in clinical trials of 
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multiple sclerosis (Kalkers et al., 2002; Leary et al., 2003; Lin et al., 2003; 
Montalban et al., 2009). 
 
8.2.3.3 Brain scan analysis 
 
The brain parenchymal fraction (BPF) was then recorded for each subject 
using the methodology described in chapter four. The volume of T2-weighted 
lesions (T2LV) was also recorded for each subject in mLs (chapter four). 
 
8.2.4 Statistical Analysis 
 
SPSS 21 (IBM) was used for statistical analysis. 
 
Comparisons of MRI measures in controls and patient subgroups 
In healthy controls the differences in mean MTR values were evaluated between 
(i) Outer spinal cord and spinal cord white matter (ii) Outer spinal cord and 
spinal cord grey matter (iii) spinal cord white matter with grey matter, using a 
paired samples t-test. Subsequently the same tests were employed in clinically 
isolated syndrome patients and each subgroup of multiple sclerosis separately. 
Differences in cord area and brain parenchymal fraction were also tested 
between MS and CIS patients and controls using an independent samples t-test. 
 
To explore the hypothesis that MTR abnormalities in each tissue component of 
the spinal cord (outer spinal cord, white matter and grey matter) may differ 
between clinically isolated syndrome or each subtype of MS patients and 
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controls, a linear regression model was constructed, with the case (i.e. multiple 
sclerosis subgroup, clinically isolated syndrome and control) set as the 
dependent variable and MTR added as an independent variable. To compare 
each patient group (clinically isolated syndrome or multiple sclerosis subgroups) 
with controls, or with each other, a separate regression model was constructed 
for each comparison of MTR values (outer spinal cord, white matter and grey 
matter) being performed. To investigate whether differences seen in MTR values 
between subject groups (dependent variable) were affected by cord atrophy in 
the multiple sclerosis subgroups, spinal cord area was included as an 
independent variable in every model and the comparison was corrected for age 
and gender by adding these as independent variables. Adjustments for multiple 
comparisons were not performed due to the exploratory nature of this study 
(Bender and Lange 2001). 
 
Relationship between cord MTR measures and cord area 
To investigate the relationship between spinal cord MTR and cord area 
univariate Pearson’s correlation coefficients were calculated with the MTR of the 
grey matter, white matter and outer spinal cord versus cord area in all multiple 
sclerosis patients combined. In order to identify the components of the spinal 
cord MTR (i.e. outer spinal cord, grey and white matter) which were associated 
with atrophy, independently from the others and from age and gender, a 
multivariate linear regression model was constructed. In this model cord area 
was set as the dependent variable, and MTR values from each region of the spinal 
cord that had a significant univariate correlation with cord area were added as 
independent variables, in a forward stepwise manner, to determine those with 
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independent associations with cord area. Independent variables retained in the 
final model with a p-value of < 0.05 were considered to be independently 
associated with cord area (dependent variable). 
 
Relationship between MRI and disability measures 
To explore the relationship of each MRI measure analysed (spinal cord area, 
spinal cord MTR [outer cord, white matter and grey matter], brain parenchymal 
fraction and brain lesion load) with disability, univariate correlations were 
calculated firstly between these variables, in all multiple sclerosis patients 
combined. We used Spearman’s rank correlation coefficient for the EDSS, as this 
scale is logarithmic. For all other disability scales (multiple sclerosis functional 
composite Z-scores, ASIAs and ASIAm) univariate correlations were calculated 
with the MRI parameters using Pearson’s correlation coefficient. For univariate 
associations, p < 0.01 was considered significant. 
 
In order to further investigate the relationship between the MRI parameters 
analysed and physical disability, independent associations between these two 
variables were sought. To achieve this, a multivariate linear regression model 
was constructed with the disability measure of interest set as the dependent 
variable. A separate model was constructed for each disability measure used i.e. 
multiple comparisons were not performed. To refine the choice of independent 
variables added to the model, only MRI parameters which had a significant 
univariate correlation with the dependent variable (i.e. the disability measure of 
interest), were included in the regression analysis. In each model constructed, 
age and gender were also added as independent variables, to correct for any 
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influence these may have on the association being tested. The MRI parameters 
were added to the model, as independent variables, in a forward stepwise 
manner and those variables retained in the final model, with a p-value of < 0.05, 
were deemed to be independently associated with the disability scale 
(dependent variable). 
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8.3 Results 
8.3.1 Subjects and their clinical and conventional MRI characteristics 
 
In total 133 subjects were studied; 26 healthy controls, 22 people with CIS, 29 
relapsing remitting (RR) MS, 28 secondary progressive (SP) MS and 28 primary 
progressive (PP) MS. Characteristics of the group are shown in Table 8.1. In the 
CIS cohort there were 18 cases of unilateral optic neuritis, one multifocal CIS 
(consisting of optic neuritis, facial numbness and diplopia), one hemispheric 
presentation (unilateral hand weakness due to a lesion in the right motor cortex) 
and two cases of partial myelitis (one cervical and one thoracic). 
 
With regard to the conventional MRI scans, in the CIS cohort 15 cases fulfilled 
criteria for dissemination in space (DIS) (Polman et al., 2011); the criteria for 
dissemination in time could not be evaluated on this single scan as a gadolinium-
contrast agent was not administered. Asymptomatic T2-weighted brain lesions 
were seen in 18/22 cases and in one case the symptomatic lesion was seen (in 
the motor cortex). There were eight spinal cord lesions seen on cord PSIR and 
FFE scans, seven asymptomatic and one due to cervical cord partial myelitis. 
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 Controls 
n=26 
CIS n=22 RRMS 
n=29 
SPMS 
n=28 
PPMS 
n=28 
Gender F:M 18:8 12:10 20:9 17:11 12:16 
Age in years 40.6 ± 
10.2 
36.2 ± 
9.3 
38.1 ± 9.5 51.3 ± 9.4 50.5 ± 9.9 
Mean disease 
duration 
(years for MS 
groups; 
(months for 
CIS group) 
 5.8 ± 4.3 6.1 ± 4.0 20.11 ± 
11.89 
10.9 ± 7.6 
Median EDSS 
(range) 
 1 (0-3) 2.5 (0-7) 6.5 (4-
8.5) 
6.0 (2-8) 
Brain 
parenchymal 
fraction 
0.824 ± 
0.015 
0.822 ± 
0.013 
0.811 ± 
0.017 § 
0.788 ± 
0.022 § 
0.798 ± 
0.014 § 
T2 lesion 
volume 
(mLs) 
 2.9 ± 3.8 13.1 ± 
14.3 
23.4 ± 
17.0 
16.4 ± 
20.2 
Spinal cord 
cross-
sectional 
area (mm2) 
80.3 ± 7.7 82.6 ± 
7.3 
78.1 ± 9.0 63.6 ± 9.8 
§ 
68.1 ± 9.7 
§ 
 
Table 8.1 Demographics and conventional magnetic resonance imaging 
parameters in healthy controls, CIS and MS. Significant differences 
between MRI parameters from controls (i.e. p < 0.01) are denoted by § 
symbol.  
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8.3.2 Comparison of cord area and brain volume between groups 
 
There was no significant difference in the cord area of healthy controls with 
either the CIS (p = 0.06) or RRMS (p = 0.18) groups. The SPMS (63.5 mm2 ± 10.0 
vs. 80.2 mm2 ± 6.8, p < 0.01) and PPMS (68.1 mm2 ± 9.7, p < 0.01) groups both 
had lower cord areas than healthy controls. Results for all groups are presented 
in Table 8.1. 
 
No significant difference was seen in BPF in the CIS group compared to controls 
but significant differences in BPF were seen between controls and all subgroups 
of MS (p < 0.01), with smaller BPFs in the MS subgroups. 
 
8.3.3 Comparison of outer spinal cord and spinal cord WM MTR values within each 
subject group (Table 8.2) 
 
In each subject group, MTR of the outer spinal cord was higher than MTR of 
spinal cord WM: controls (51.35 ± 1.29 vs. 49.87 ± 1.45, p < 0.01), CIS (50.46 ± 
1.39 vs. 49.13 ± 1.19, p < 0.01), RRMS (48.86 ± 2.89 vs. 47.44 ± 2.70, p < 0.01), 
SPMS (46.33 ± 2.84 vs. 44.75 ± 3.10, p < 0.01), PPMS (46.99 ± 3.78 vs. 45.62 ± 
3.40, p < 0.01).  
 215 
 
 Controls CIS CIS 
(excluding 
two cases 
of 
myelitis) 
RRMS SPMS PPMS 
Outer spinal 
cord MTR  
51.35 ± 
1.29 
50.46 
± 1.39 
49.9 ± 
1.40 
48.86 ± 
2.89 
46.33 
± 2.84 
46.99 
± 3.78 
Comparison 
between 
outer spinal 
cord and 
white 
matter MTR 
values 
p < 0.01 p < 
0.01 
p < 0.01 p < 
0.01 
p < 
0.01 
p < 
0.01 
MTR spinal 
cord white 
matter 
49.87 ± 
1.45 
49.13 
± 1.19 
49.21 ± 
1.31 
47.44 ± 
2.70 
44.75 
± 3.10 
45.62 
± 3.4 
Comparison 
between 
spinal cord 
white and 
grey matter 
MTR values 
p < 0.01 p < 
0.01 
p < 0.01 p < 
0.01 
p = 
0.02 
p < 
0.01 
MTR spinal 
cord grey 
matter  
48.23 ± 
1.76 
47.72 
± 1.23 
47.8 ± 
1.30 
46.6 ± 
2.43 
43.88 
± 2.62 
44.88 
± 3.09 
 
Table 8.2 Mean MTR values (± standard deviation) of spinal cord region 
subtypes (outer cord, white matter, grey matter) in the control group and 
in each patient group. The CIS cohort is presented with and without the 
two cases of myelitis included. 
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8.3.4 Comparison of spinal cord WM and GM MTR values within each subject group 
(Table 8.2) 
 In each subject groups, the spinal cord WM had higher MTR values than spinal 
cord GM. 
 
8.3.5 Outer spinal cord MTR in controls versus patient subgroups (Table 8.3) 
The outer spinal cord MTR values were higher in controls than all patient 
groups: controls vs. CIS (coefficient = -0.32, p = 0.03, 95% CI -0.22, -0.01), 
controls vs. RRMS (coefficient = -0.48, p < 0.01, 95% CI -0.28, 0.09), controls vs. 
SPMS (coefficient = -0.51, p < 0.01, 95% CI -0.31, -0.15), controls vs. PPMS 
(coefficient = -0.38, p < 0.01, 95% CI -0.36, -0.06). Cord area was not a significant 
covariate in any of the models used. 
 
8.3.6 Spinal cord WM and GM MTR in controls versus patient subgroups (Table 
8.3) 
MTR of spinal cord WM was higher in controls than in all patient groups. MTR of 
spinal cord GM was not different between controls and the CIS group but was 
significantly higher in controls than in all three MS subgroups.  
 
8.3.7 Outer spinal cord MTR: comparison between patient subgroups (Table 8.3) 
Outer spinal cord MTR was lower in RRMS than CIS (coefficient = -0.28, p = 0.02, 
95% CI -0.10, -0.01). Both SPMS (coefficient -0.24, p = 0.02, 95% CI -0.07, -0.01) 
and PPMS (coefficient = -0.29, p = 0.02, 95% CI -0.16, -0.01) had lower outer 
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spinal cord MTR values compared to RRMS. No significant difference was found 
between SPMS and PPMS. 
MTR 
value 
Groups being 
compared 
SE Coefficient Significance 
(p value) 
95% CI 
(lower, 
upper) 
Outer 
spinal 
cord MTR 
CIS/control 0.05 -0.32 0.03 -0.22, -
0.01 
 RRMS/control 0.05 -0.48 < 0.01 -0.28, -
0.09 
 SPMS/control 0.04 -0.51 < 0.01 -0.31, -
0.15 
 PPMS/control 0.07 -0.38 < 0.01 -0.36, -
0.06 
 CIS/RRMS 0.02 -0.28 0.02 -0.10, -
0.01 
 RRMS/SPMS 0.02 -0.24 0.02 -0.07, -
0.01 
 RRMS/PPMS 0.04 -0.29 0.02 -0.16, -
0.01 
 SPMS/PPMS 0.02 -0.02 0.89 -0.05, 0.04 
MTR WM CIS/control 0.39 -0.34 0.03 -1.69, -
1.05 
 RRMS/control 0.30 -0.56 <0.01 -1.95, -
0.76 
 SPMS/control 0.23 -0.98 <0.01 -2.74, -
1.80 
 PPMS/control 0.22 -0.80 <0.01 -1.79, -
0.92 
MTR GM CIS/control 0.42 -0.17 0.26 -1.3, 0.37 
 RRMS/control 0.29 -0.36 <0.01 -1.38, -
0.21 
 SPMS/control 0.20 -0.74 <0.01 -1.84, -
1.05 
 PPMS/control 0.19 -0.75 <0.01 -1.50, -
0.73 
 
Table 8.3 Comparison of MTR values between patient and control groups using 
a linear regression model adjusted for age, gender and cord area (SE=standard 
error, CI=confidence interval) 
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8.3.8 Univariate correlations and associations between MTR measures and cord 
area in all MS patients combined 
 
The following MRI parameters were correlated with cord area: Outer spinal cord 
MTR (r = 0.39, p < 0.01), MTR WM (r = 0.36, p < 0.01), MTR GM (r = 0.36, p < 
0.01) and BPF (r = 0.27 p = 0.01). However, only outer spinal cord MTR 
(coefficient = 0.40, p < 0.01, 95% CI 0.63, 1.88) was found to be independently 
associated with cord area. 
 
8.3.9 Univariate correlations between MRI parameters and disability in all MS 
patients combined (Table 8. 4) 
 
Significant univariate correlations between MRI parameters and disability are 
presented in Table 8.4. Although significant correlations were seen between 
outer spinal cord MTR and each disability measure used (apart from PASAT z-
score), stronger correlations were seen between cord area and disability 
measures reflecting motor function. Brain T2LV was not found to be correlated 
with any disability measures except for PASAT z-score  
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MRI 
parameter 
Disability measure 
 EDSS* ASIAm ASIAs Z-score 
PASAT 
Z-score 
9-HPT 
Z-score 
25ft 
TWT 
Z-score 
MSFC 
Outer 
MTR 
r = -
0.41  
r = 
0.38 
 
r = 
0.30 
r = 0.03 r = 
0.41 
r = 
0.36 
r = 
0.42 
MTR WM r = -
0.32  
r = 0.23 r = 
0.30 
r = 0.01 r = 
0.42 
r = 
0.40 
r = 
0.43 
MTR GM r = -
0.34  
r = 0.27 r = 
0.29 
r = 0.05 r = 
0.38  
r = 
0.37  
r = 
0.40 
Cord area r = -
0.60  
r = 
0.49 
r = 
0.39 
r = 0.14 r = 
0.48 
r = 
0.38 
r = 
0.44 
BPF r = -
0.40  
r = 0.22 r = 0.06 r = 
0.35 
r = 
0.48 
r = 
0.29 
r = 
0.40 
T2LV r = 0.19 r = -
0.04 
r = 0.17 r = -
0.36 
r = -
0.29 
r = -
0.08 
r = -
0.29 
 
Table 8.4 Significant (p<0.01) univariate correlations between MRI parameters 
and disability measure in all MS patients combined are indicated in bold font 
(*Spearman’s coefficient used for EDSS and Pearson’s coefficient for all other 
disability measures). 
 
 
8.3.10 Independent associations between MRI parameters and disability in all MS 
patients combined (Table 8.5) 
 
Significant independent associations between MRI variables and disability 
measures are summarised in Table 8.5. The 9-HPT z-score was associated with 
MTR in the outer spinal cord. Tests of motor function (EDSS and ASIAm) were 
associated with cord area. The TWT z-score was associated with spinal cord WM 
MTR in MS. The PASAT z-score was associated with both brain T2 lesion volume 
and BPF.  
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Disability 
Measure 
MRI 
parameter 
associated 
with 
disability 
SE Coefficient Significance 
(p value) 
95% CI 
(lower, 
upper) 
EDSS Cord area 0.02 -0.48 < 0.01 -0.13, -0.06 
BPF 9.45 -0.29 < 0.01 -48.78, -
11.17 
ASIAm Cord area 0.13 0.42 <0.01 0.32, 0.85 
ASIAs Cord area 0.08 0.26 0.03 0.02, 0.34 
Z-score 
PASAT 
BPF 8.42 0.25 0.02 2.82, 36.32 
T2LV 0.01 -0.26 0.02 -0.04, -
0.004 
Z-score 9-
HPT 
Outer 
spinal cord 
MTR 
0.04 0.27 < 0.01 0.04, 0.19 
BPF 0.41 0.41 <0.01 16.44, 
14.99 
Z-score 25 
ft. TWT 
MTR WM 0.15 0.36 <0.01 0.30, 0.89 
Z-score 
MSFC 
MTR WM 0.07 0.30 <0.01 0.07, 0.36 
Cord area 0.023 0.22 0.04 0.001, 0.09 
 
Table 8.5 Summary of MRI parameters significantly associated with disability 
measures from linear regression models using disability as dependent variable 
(SE=standard error, CI=confidence interval) 
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8.4 Discussion 
There are a number of novel findings in this chapter. First, a quantitative imaging 
metric (MTR) was measured in vivo in the outer spinal cord – a region likely to 
include the pia mater and subpial spinal cord. Secondly, in healthy controls, 
outer cord MTR was higher than cord white matter MTR. Thirdly, there was a 
reduction in outer cord MTR at an early stage of MS, and in the absence of 
significant cord atrophy, as reflected by the findings in CIS and RRMS subgroups. 
Fourthly, outer cord MTR abnormality was significantly and independently 
correlated with cord atrophy and was also greater in progressive MS subgroups 
when compared with RRMS. Finally, there were several independent 
associations between spinal cord MRI metrics and disability measures. These 
findings are discussed in turn. 
 
The outer spinal cord MTR measure and what it reflects anatomically 
 
MTR was quantified in a voxel layer in the expected location of the pia mater and 
subpial region of the spinal cord. As the spinal cord is surrounded by 
cerebrospinal fluid the outer voxels of the cord are susceptible to partial volume 
effects (Tench et al., 2005). However, by excluding the most peripheral voxel 
layers this influence was likely to be negligible as the outer cord MTR values 
were actually higher than the remaining (deeper) spinal cord tissues, which will 
not be affected by cerebrospinal fluid. 
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The pia mater is composed of two layers in the spinal cord; the intima pia and 
epipial layer, of which the epipial layer (not present over the cerebral 
hemispheres) is the thicker of the two due to its composition of connective tissue 
(Millen and Woollam 1961). The combined thickness of these layers was 0.2mm 
in a post-mortem study of the thoracic spinal cord with an increase in higher 
segments of the cord (Reina et al., 2004). The cord samples in this study were 
fixed with formaldehyde, and a reduction in tissue size of up to 19% can occur 
using a 10% formalin solution (Mouritzen Dam 1979). It therefore seems likely 
that a significant proportion of the outer cord voxel layer of the upper cervical 
cord region studied (which has an in-plane voxel size of 0.5mm) will contain pial 
meningeal tissue, although it is also likely to include subpial spinal cord white 
matter.  
 
Higher outer than white matter spinal cord MTR in healthy controls 
A question arising is why the MTR in the outer cord region should be higher than 
that of normally myelinated cord white matter. One possible explanation is that 
there is a tissue component other than myelin in the outer cord that has a 
relatively high MTR. In this regard, both the pial and subpial tissues in the spinal 
cord contain collagenous fibres (Reina et al., 2004) and in vitro data obtained in 
phantoms has shown that higher MTR is correlated with higher collagen 
concentration (Laurent et al., 2001). It seems therefore possible that collagen 
contributes to the higher outer cord MTR. 
 
Outer spinal cord MTR abnormalities in clinically isolated syndrome and relapsing 
remitting multiple sclerosis in the absence of cord atrophy 
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The finding of reduced outer cord MTR without atrophy in the CIS and RRMS 
groups supports the robustness of the outer cord measure: had partial volume 
effects of cerebrospinal fluid the cause of decreasing outer cord MTR, an 
abnormality would not be seen when there was no difference in cord area 
between patient and control groups.  
 
In the CIS cohort 15 fulfilled the criteria for dissemination in space and 18 of the 
22 participants had at least one asymptomatic T2-weighted brain lesion evident 
on their brain MRI scan and are therefore at higher risk of conversion to MS 
(Fisniku et al., 2008). Seven of this group had asymptomatic spinal cord lesions, 
the presence of which also increases the risk for conversion to MS (Sombekke et 
al., 2013). The abnormalities detected in the outermost spinal cord in CIS 
compared to controls indicate that changes occur at a very early stage in relapse-
onset MS. 
 
The RRMS cohort was also at a relatively early stage of disease had little 
disability and no cord atrophy. Since cord atrophy is related to axonal loss in 
neuropathology studies (McGavern et al., 2000; DeLuca et al., 2004; Evangelou et 
al., 2005), the decrease in MTR in the outer spinal cord seen at this stage of MS 
may be occurring in the absence of – and by implication preceding - significant 
axonal loss.  
 
The pathological basis of the reduced outer cord MTR warrants further 
consideration. In an inflammatory animal model of MS (experimental allergic 
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encephalomyelitis) areas of oedema, signifying inflammation, exhibited a mildly 
decreased MTR in the absence of demyelination (Dousset et al., 1992). A 
decrease in MTR also occurs with inflammation in spinal cord experimental 
allergic encephalomyelitis (Cook et al., 2004). A post-mortem study in MS has 
demonstrated reduced MTR corresponding with an increased number of 
inflammatory T cells (Moll et al., 2009). Other post mortem studies in MS also 
report a reduction in MTR in regions of demyelination in the cerebral cortex 
(Schmierer et al., 2010; Chen et al., 2013), brain white matter (Schmierer et al 
2004) and spinal cord (Bot et al., 2004). As the outer spinal cord voxel layer in 
this study is likely to contain both the pia mater and subpial white matter tissue, 
a combination of inflammation in the former and demyelination in the latter may 
be responsible for the decrease seen in MS.  
 
Although the limits of image resolution prevent a more specific interpretation of 
the MTR decrease that we saw in outer spinal cord region, it may nevertheless 
reflect a distinct pathogenic process in so far as co-localised subpial 
demyelination may occur secondary to meningeal inflammation. These 
pathological changes have been previously associated in brain biopsies of 
patients with early MS, where meningeal inflammation was found to have a 90% 
probability to be topographically associated with subpial demyelination 
(Lucchinetti et al., 2011). Further pathological studies will be needed to 
determine whether such changes are topographically related in the spinal cord. 
 
Association of outer spinal cord MTR with cord atrophy and progressive multiple 
sclerosis 
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In this study, outer spinal cord MTR was independently associated with cord 
atrophy. In a previous study of inflammation in the spinal cord meninges there 
was an association seen between meningeal inflammation and diffuse axonal loss 
in the spinal cord parenchyma (Androdias et al., 2010). In a similar study by 
DeLuca et al. (2013) it was found that small peripheral axons are preferentially 
lost. In these studies inflammatory cells and mediators were demonstrated to be 
present in the cord meninges. Thus, in both of these pathology studies, 
meningeal inflammation and axonal loss were evident. It is likely that axonal loss, 
which can be profound in the MS spinal cord (Ganter et al., 1999; Lovas et al., 
2000), is the major substrate of spinal cord atrophy. Thus, the link observed 
between outer cord MTR and cord atrophy would appear concordant with 
pathological association of meningeal inflammation and axonal loss in the cord. 
In contrast, the lack of independent association between the inner spinal cord 
(grey and white matter) MTR (implying demyelination) and atrophy (consistent 
with neuroaxonal loss) is consistent with a dissociation between these 
pathological processes, in line with previous pathological reports in the spinal 
cord (DeLuca et al., 2006) and brain (Wegner et al., 2006). 
Although at present it is not known how meningeal inflammation might be 
associated with cord pathology, including axonal loss, a possible anatomical 
connection may be via the epi-pial layer of the spinal cord, which contains 
branches of blood vessels that penetrate the spinal cord (Millen and Woollam 
1961). Furthermore, spinal cord lesions tend to occur around small veins 
(Oppenheimer et al., 1978), and therefore the small epi-pial vessels could 
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potentially provide a route of entry for inflammatory cells from the meninges 
into the cord parenchyma. 
 
The comparison of clinical subgroups showed that greater outer cord MTR 
abnormality in both primary and secondary MS groups compared with RRMS 
(Tables 8.2 & 8.3). In the comparison of the two progressive subtypes of MS no 
significant differences were found. These results suggest that the outer spinal 
cord (and by implication pial and/or subpial) abnormalities are greater in the 
progressive stage of MS.  
 
The findings are consistent with previous neuropathology studies in the brain 
that have linked both meningeal inflammation and subpial demyelination with 
the progressive stage of multiple sclerosis (Magliozzi et al., 2007). There can be 
extensive cortical subpial demyelination in progressive multiple sclerosis 
(Peterson et al., 2001; Bö et al., 2003; Kutzelnigg et al., 2005; Vercellino et al., 
2005; Wenger et al 2006). Although cortical subpial lesions are rarely visible on 
MRI (Geurts et al., 2005), post mortem study has identified that regions of 
cortical demyelination have a reduced MTR (Chen et al 2013), and a recent in 
vivo study reported a reduced MTR of the outer cortex in multiple sclerosis that 
was most marked in those with a secondary progressive course (Samson et al., 
2014). These observations support use of MTR to reflect subpial demyelination 
in the cortex and suggest that subpial demyelination could contribute to the 
lower MTR we observed in the outermost region of the spinal cord. 
 
Associations between spinal cord MRI metrics and disability measures 
 227 
 
Although outer spinal cord MTR had a univariate correlation with each disability 
measure used in this study, in a regression analysis it was found only to be 
associated with nine hole peg test z-score. This limited independent association 
with function may reflect the small region of spinal cord included in the outer 
voxel layer; the purpose in studying outer cord MTR was to investigate for 
abnormalities that reflect a process of pathogenic importance (i.e., meningeal 
and subpial pathology) and not for an association with disability. 
 
Spinal cord white matter-MTR was independently associated with 25 foot timed 
walk test and multiple sclerosis functional composite z-scores; this relationship 
plausibly reflects pathology in functionally important motor and sensory 
pathways of the spinal cord. These results also confirm an earlier finding of a 
univariate correlation between spinal cord grey matter MTR and EDSS (Agosta et 
al., 2007), although grey matter MTR was not independently associated with 
EDSS in the subsequent regression analysis. Amongst the several MRI metrics 
studied, the measure of spinal cord cross-sectional area (atrophy) had a 
generally stronger univariate correlation with each of the disability measures 
used. Furthermore, cord area was found to be independently associated with a 
number of measures of disability. The strong relationship between cord atrophy 
and disability may be due to this measure reflecting axonal loss, thought to be 
the pathological substrate for disability (Evangelou et al., 2000; Lovas et al., 
2000; Schirmer et al., 2011). A biologically coherent finding was that the PASAT 
z-score (a measure of cognition) was associated only with the two brain MRI 
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metrics (brain parenchymal fraction and T2 lesion volume) and with none of the 
spinal cord measures. 
 
Limitations and future directions 
 
Limitations should be noted when considering the findings in this chapter. 
Firstly, only the upper cervical spinal cord was studied. However, at this level, a 
robust registration technique could be employed and segmentation of the cord 
into grey matter and white matter regions was possible. Furthermore, spinal 
cord involvement by multiple sclerosis is most common in the cervical cord 
(Oppenheimer et al., 1978), and this approach is likely to have yielded the most 
reliable results within the technical constraints of spinal cord MRI. 
 
Secondly, this study was cross-sectional in nature and future longitudinal studies 
will be needed to elucidate outer cortical MTR changes over time and its 
relationship with evolution of disability and cord atrophy. 
 
Thirdly, the in plane resolution of the axial images was constrained by time 
limitations necessitated in a clinical study. Future studies of the spinal cord at 7 
Tesla field strength (Zhao et al., 2013) may provide higher resolution images 
within an acceptable time frame. 
 
Finally, this in vivo imaging study does not include MTR findings for 
histopathologically confirmed pia mater and subpial cord. To date, no such 
findings have been published, either in ex vivo multiple sclerosis spinal cord or in 
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animal models of the disease. A post mortem MRI-histopathology correlation 
study is needed to consolidate the findings of this in vivo study. 
 
In conclusion MTR abnormalities have been recorded in an area corresponding 
to the expected location of the pia mater and subpial region in the outer cervical 
spinal cord. These outer spinal cord abnormalities occur early in the course of 
multiple sclerosis prior to significant cord atrophy and that a greater reduction 
in MTR values is seen in progressive multiple sclerosis. 
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Chapter 9 - Spinal cord grey matter abnormalities are associated with 
secondary progression and physical disability in multiple sclerosis 
 
9.1 Introduction 
 
Relapse-onset multiple sclerosis (MS) presents as a clinically isolated syndrome 
(CIS), later evolving to relapsing-remitting (RR) MS and, in many cases, 
secondary progressive (SP) MS (Weinshenker et al., 1989). Physical disability in 
SPMS is often due to a progressive spinal cord syndrome (Kremenchutzky et al., 
2006). It is important therefore to understand and monitor spinal cord 
pathology leading to irreversible disability, as it may facilitate treatment 
development. 
While pathology of spinal cord white matter (WM) should contribute to the 
motor and sensory impairments in MS, the functional effects of cord grey matter 
(GM) pathology are uncertain. Noting that spinal GM may be extensively involved 
(Gilmore et al., 2006; Gilmore et al., 2009), and that brain GM abnormalities are 
associated with SPMS (Fisher et al., 2008; Fisniku et al., 2008), further 
investigation of cord GM abnormalities would seem worthwhile. 
Magnetic resonance imaging (MRI) offers a tool for investigating spinal cord 
abnormalities during life and their relationship with functional status. In 
particular, diffusion tensor imaging (DTI) (Le Bihan et al., 1995) may provide 
quantitative measures, sensitive to microstructural abnormalities and can be 
employed in the spinal cord (Wilm et al., 2007).  
 231 
Two recent publications reported associations between cervical cord DTI 
abnormalities and physical disability in an MS cohort containing both RR and 
progressive patients (Oh et al., 2013). However, these studies did not investigate 
whether functional effects observed were related to WM or GM involvement. 
Several studies have investigated DTI in the main WM columns affected by MS 
(posterior and lateral columns); they were largely confined to subjects with 
RRMS and low disability (Hesseltine et al., 2006; Freund et al., 2010; Raz et al., 
2013). Two studies investigated cord GM but only in RRMS (Hesseltine et al., 
2006; Raz et al., 2013). No previous study has reported DTI findings in cord GM 
or WM columns in SPMS. 
In this study a DTI protocol was implemented to investigate microstructural 
integrity of spinal cord grey matter and the two main white matter columns 
affected by MS in cohorts of patients with SPMS and RRMS. A cohort of CIS 
patients was also included along with healthy controls to investigate whether 
microstructural abnormalities are already present at what is often the first 
presentation of relapse-onset MS. The imaging findings were correlated with 
clinical functional measures in order to test the hypotheses - based on known 
pathology findings – that: firstly, abnormalities in cord grey matter would be 
significantly associated with secondary progressive MS and secondly, that grey 
matter microstructural abnormalities would be associated with physical 
disability. 
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9.2 Methods 
 
9.2.1 Subjects 
 
Healthy controls and people with CIS and relapse-onset MS (Polman et al., 2011) 
were recruited. The subtype of MS was classified as RR or SP (Lublin and 
Reingold 1996). Disability was assessed with the expanded disability status scale 
(EDSS) (Kurtzke 1983) and the two motor components of multiple sclerosis 
functional composite (9-hole peg test [9HPT] and timed walk test [TWT]) 
(Fischer et al., 1999) with z-scores calculated using published normative values. 
With a focus on spinal cord function, American spinal injury association (ASIA) 
motor and sensory scores and the Kurtzke functional scores for the motor, 
sensory and sphincter systems were also investigated (Maynard et al., 1997). 
Testing of physical function was performed immediately prior to the MRI scan. 
No one had experienced a relapse or received a course of corticosteroids within a 
month prior to imaging. Informed written consent was obtained from all 
participants. 
9.2.2 MRI protocol 
 
The upper cervical spine and brain of all participants was imaged using a 3T 
Philips Achieva MRI system with radiofrequency (RF) multi-transmit technology 
(Philips Healthcare, Best, the Netherlands). For the spinal cord and brain 
imaging the product 16 and 32 channel coils were used. Subjects were 
immobilised by placing a polystyrene filled vacuum fixation bag behind the 
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cervical spine, to decrease motion artefacts. The spinal cord imaging was centred 
at C2/C3 and imaging volume for all sequences covered from C2-C4. 
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Spinal cord imaging: 
 
(i) Diffusion weighted scan: TE = 52 ms, TR = 12 RRs (cardiac gated), 
reduced FOV of 64 x 48 mm2, SENSE factor = 1.5, acquisition matrix = 64 x 48 
for a voxel size of 1 x 1 x 5 mm3. The DW imaging protocol consisted of 30 b = 
1000 s mm–2 DWI volumes with gradient directions evenly distributed over 
the sphere16 and 3 non–DWI (b = 0, b0) volumes 
 
(ii) 3D phase sensitive inversion recovery (PSIR): voxel size of 0.5 x 
0.5 x 3 mm3, TR = 8 ms; TE = 3.7 ms; flip angle α = 5°; FOV = 256 x 256 mm; 
NEX = 1 
Brain imaging: 
(i) Axial PD/T2 images using a 2D turbo spin echo sequence (TSE) 
with 3mm slice thickness; the following parameters were 
employed: TR=3500 ms; TE=19/85 ms; matrix 240 x 240 mm2; in 
plane resolution= 1 x 1 mm. 
(ii) 3D magnetisation-prepared turbo field echo (3D-TFE) sequence 
was used with slice thickness= 1mm; TR=6.8 ms; TE=3.1 ms; 
matrix = 256 x 256; in plane voxel size 1 x 1mm2 
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9.2.3 Image analysis 
 
9.2.3.1 DTI Analysis 
 
WM regions of interest (ROI): Three circular regions of interest (ROI) were 
marked on all ten slices of the b0 image: one within each lateral column and one 
in the posterior columns, as previously described (Hesseltine et al., 2006; Freund 
et al., 2010); care was taken to place the ROI entirely within the WM column and 
thereby avoid partial volume effects (Figure 9.1A). A single average value for 
each DTI parameter was calculated from the two lateral column ROIs (Freund et 
al., 2010). 
 
GM segmentation: Average diffusion-weighted images (DWIs) were created 
based on the angular threshold of the diffusion gradient direction with respect to 
the longitudinal axis of the spinal cord. All DWIs with diffusion gradient direction 
between 00 (i.e. parallel to the cord axis) and a given cut-off angle were averaged 
and visually assessed for their GM/WM contrast. The cut-off angles were set at 50 
intervals from 400 through to 800. Each threshold involved a variable number of 
DWIs, i.e. 10 images for a cut off value of 400 and one image for 800. After review, 
by visual inspection, a threshold of 500 was chosen as the GM was then clearly 
visible as a hyper-intense ‘H’ shaped structure on a hypo-intense background 
(Figure 9.1B). This allowed the use of a semi-automated tool in JIM 6.0 software 
(Xinapse systems, http://www.xinapse.com) to delineate the GM and construct a 
mask that was then applied to the DTI maps to obtain quantitative values from 
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each parameter (FA, MD, AD, RD). The GM ROI was marked carefully in each case 
around hyper-intense voxels only, to minimise potential partial volume effects 
from the surrounding WM. 
 
 
 
Figure 9.1 A) b0 image with regions of interest displayed in lateral and posterior 
column B) Average transverse diffusion weighted image optimised displaying 
grey matter region of interest (see methods for details). Voxel size of images 1 x 
1 x 5mm3 
To determine the reproducibility of GM segmentation and WM ROI placement, 
ten control scans were analysed and then re-analysed by the same reader after a 
period of one month. 
 
The DTI data were processed using the open-source Camino toolkit (Cook et al., 
2006) to create fractional anisotropy (FA), mean diffusivity (MD), radial 
diffusivity (RD) and axial diffusivity (AD) maps in the spinal cord.  
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9.2.3.2 Conventional MRI analysis 
 
Upper cervical spinal cord cross-sectional area was measured from the PSIR 
image (previously described in chapter five). Spinal cord lesions were identified 
on the PSIR image (described in chapter six). Brain parenchymal fraction (BPF) 
and T2 lesion volume were measured as described in chapter four. 
 
9.2.4 Statistical analysis 
 
SPSS 21 (IBM) and Stata 13 (Stata Corporation, College Station, Texas, USA) were 
used for statistical analysis. 
Reproducibility of GM segmentation and WM ROI placement was assessed using 
the coefficient of variation (COV [expressed as a percentage]) and the intra-class 
correlation coefficient (ICC). 
Means of DTI metrics were compared between subject groups (each patient 
subgroup versus controls and comparisons between the 3 patient subgroups) 
using ANOVA with post hoc Bonferonni correction. 
To further investigate for differences in DTI metrics between the 4 subject 
groups, a “linear trend test” analysis was performed (Altman 1991) across the 
groups by regressing the standardised DTI parameter on a group variables coded 
numerically in the following order: 0=control, 1=CIS, 2=RRMS, 3=SPMS (N.B.: the 
word “trend” in this context refers to a statistical analysis that investigates for 
significant linear differences from one disease subtype to the next; it does not 
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infer a result of borderline significance). Each DTI parameter was standardised 
(to units of 1 standard deviation [SD]) so that the “trend” coefficients are directly 
comparable, reflecting the increase in mean DTI parameter in SD units. 
 
Univariable correlations with disability were calculated: Spearman’s rank 
correlation coefficient for EDSS and Pearson’s correlation coefficient for the 
MSFC. Significant univariable correlations were further investigated to identify 
independent DTI predictors with a multiple regression of the disability measure 
on the DTI parameters, adjusting for age, gender and UCCA. 
 
Statistical significance was defined as p < 0.05. 
9.3 Results 
 
9.3.1 Demographics and conventional MRI scans (Table 9.1) 
A total of 114 people were included; 30 controls, 21 CIS, 33 RRMS, 29 SPMS. 
Spinal cord lesions were identified and counted on 3D-PSIR sequence in 38% 
(8/21) of cases with CIS, 81% (27/33) with RRMS and 96% (28/29) in SPMS. 
In the CIS cohort there were 18 cases of unilateral optic neuritis, one multifocal 
CIS (consisting of optic neuritis, facial numbness and diplopia), and two cases of 
partial myelitis (one cervical and one thoracic). Asymptomatic T2-weighted 
brain lesions were seen in all CIS cases and 15 fulfilled the criteria for 
dissemination in space, dissemination in time could not be assessed as 
gadolinium was not administered (Polman et al., 2011). 
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None of the CIS patients were being treated with disease modifying drugs. In the 
RRMS cohort 19 were on treatment: interferon  (n = 13), glatiramer acetate (n = 
1) and natalizumab (n = 5). Four of the 29 SPMS patients were being treated with 
interferon . 
 
9.3.2 Reproducibility of spinal cord GM segmentation 
Segmentation of the spinal cord GM on the diffusion weighted images was found 
to reproducible: COV = 1.46%, ICC = 0.907. Placement of the ROIs in the lateral 
columns also reproducible, lateral column: COV = 1.05% ICC = 0.925 and 
posterior column: COV = 0.27% ICC = 0.949. 
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 Age (years) Gender (F:M) Disease 
duration 
(years) 
Median EDSS 
(range) 
T2 lesion 
volume (mLs) 
Brain 
parenchymal 
fraction 
Spinal cord 
area (mm2) 
Controls 
(n = 30) 
41.50 ± 10.34 19:11    0.823 ± 0.015 80.28 ± 7.29 
CIS 
(n = 21) 
35.14 ± 8.53 11:10 0.48 ± 0.36 1 (0 – 3) 2.98 ± 3.82 0.822 ± 0.013 83.55 ± 7.42 
RRMS 
(n = 33) 
39.58 ± 9.24 21:12 6.58 ± 5.21 2.5 (0 – 6) 12.90 ± 13.73 0.810 ± 0.018 76.31 ± 7.72 
SPMS 
(n = 29) 
51.14 ± 9.35 17:12 20.21 ± 11.62 6.5 (4 – 8.5) 23.41 ± 16.67 0.789 ± 0.017 62.50 ± 8.63 
 
Table 9.1 Demographic and conventional MRI features of all participants. Presented as mean ± standard deviation.
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9.3.3 DTI measures in controls versus patient subgroups (Table 9.2) 
In the CIS group, compared to healthy controls, significant abnormalities were 
seen in the lateral column FA (p = 0.02) and RD (p = 0.04). 
No significant differences were seen between the CIS and RRMS cohorts. 
In SPMS compared to RRMS, we observed higher MD (p < 0.01) and RD (p < 0.01) 
in the spinal cord GM, in line with the first hypothesis that the most significant 
GM abnormalities would be seen in SPMS. More extensive abnormalities were 
also seen in the posterior column MD (p < 0.01) and RD (p < 0.01) in SPMS, 
compared to RRMS. No differences were seen in AD between any of the groups 
compared. 
Comparisons of CIS and MS subtypes with controls are shown in Table 9.2.  
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Spinal 
cord 
region 
analysed 
DTI metric Control CIS RRMS SPMS 
Lateral 
column 
FA 0.76 ± 0.04 0.72 ± 0.05 
* 
0.71 ± 0.05 
*** 
0.69 ± 0.05 
*** 
MD (x 10-3 
mm2/s) 
0.91 ± 0.06 0.95 ± 0.05  0.96 ± 0.07 
* 
0.98 ± 0.07 
** 
RD (x 10-3 
mm2/s) 
0.39 ± 0.07 0.45 ± 0.06 
* 
0.49 ± 0.08 
*** 
0.50 ± 0.07 
*** 
AD (x 10-3 
mm2/s) 
1.96 ± 0.11 1.95 ± 0.10 1.94 ± 0.10 1.93 ± 0.10  
Posterior 
column 
FA 0.79 ± 0.05 0.77 ± 0.05 0.73 ± 0.05 
*** 
0.71 ± 0.05 
*** 
MD (x 10-3 
mm2/s) 
0.95 ± 0.06 0.93 ± 0.05 0.96 ± 0.06 1.03 ± 0.09 
*** 
RD (x 10-3 
mm2/s) 
0.37 ± 0.07 0.39 ± 0.06 0.45 ± 0.08 
** 
0.51 ± 0.09 
*** 
AD (x 10-3 
mm2/s) 
2.09 ± 0.17 2.01 ± 0.13 1.98 ± 0.10 2.05 ± 0.14 
Grey 
matter 
FA 0.56 ± 0.16 0.53 ± 0.04 
* 
0.51 ± 0.05 
** 
0.48 ± 0.05 
*** 
MD (x 10-3 
mm2/s) 
0.82 ± 0.04 0.84 ± 0.04 0.86 ± 0.05 
** 
0.91 ± 0.06 
*** 
RD (x 10-3 
mm2/s) 
0.53 ± 0.04 0.56 ± 0.04 
** 
0.59 ± 0.04 
*** 
0.64 ± 0.05 
*** 
AD (x 10-3 
mm2/s) 
1.41 ± 0.11 1.41 ± 0.09 1.42 ± 0.10 1.45 ± 0.13 
 
Table 9.2 Mean ± standard deviation of DTI measures in patients and controls. 
Significantly different from controls, ANOVA with post hoc Bonferroni 
correction: * p < 0.05; ** p < 0.01; *** p < 0.001 
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9.3.4 “Linear trend test” analysis of standardised DTI measures across CIS, RRMS 
and SPMS subgroups (Figure 9.2) 
 
As trends in the data displayed in Table 9.2 seemed apparent, these were further 
investigated using a linear trend test analysis and significant changes were 
observed across the three subgroups (from least abnormal in CIS to most 
abnormal SPMS) in FA, RD and MD.  
 
Mean FA decreased significantly by an estimated:  
(i) 0.43 SDs in the lateral column (p < 0.01, 95% CI -0.57, -0.28) 
(ii) 0.48 SDs in the posterior column (p < 0.01, 95% CI -0.62, -0.34) 
(iii) 0.46 SDs in the GM (p < 0.01, 95% CI -0.60, -0.32). 
 
Mean RD increased significantly by an estimated:  
(i) 0.43 SDs in the lateral column (p < 0.01, 95% CI 0.29, 0.57) 
(ii) 0.50 SDs in the posterior column (p < 0.01, 95% CI 0.37, 0.64) 
(iii) 0.59 SDs in the GM (p < 0.01, 95% CI 0.47, 0.71). 
 
Mean MD increased significantly by an estimated: 
(i) 0.32 SDs in the lateral column (p < 0.01, 95% CI 0.17, 0.48) 
(ii) 0.50 SDs in the posterior column (p < 0.01, 95% CI 0.18, 0.49) 
(iii) 0.49 SDs in the GM (p < 0.01, 95% CI 0.35, 0.63). 
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There were no significant changes across the subgroups in AD. Graphs with lines 
fitted across the mean of standardised DTI measures to demonstrate trends seen 
are shown in Figure 9.2. 
 245 
 
 
246 
Figure 9.2 Graphs of standardised DTI measures (FA, RD and MD): the trend 
lines demonstrated are fitted to the means in each group. Bars on either side of 
the mean represent the standard error of group means. CIS – clinically isolated 
syndrome, RR – Relapsing remitting MS, SP – Secondary progressive MS. 
 
9.3.5 Univariable correlations with disability (Table 9.3 and 9.4) 
EDSS was significantly correlated with GM MD and RD; and posterior column FA, 
MD and RD.  
The TWT z-score was significantly correlated with GM FA, MD and RD; and 
posterior column FA, MD and RD. 
The 9-HPT z-score was significantly correlated with GM FA, MD, RD and AD; 
lateral column FA, MD and RD; and posterior column FA, MD and RD. 
Univariable correlations with Kurtzke motor, sensory and sphincter functional 
systems and with ASIA motor and sensory scores are provided in a Table 9.4. 
The pattern of significant DTI correlations with motor and sphincter scores was 
similar to that seen for the EDSS, TWT and 9HPT, i.e., predominantly in GM and 
posterior columns, and including FA, RD, MD but not AD. Significant DTI 
correlations with sensory scales were mainly seen in the posterior column. 
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  EDSS 25ft TWT 9-HPT 
Lateral 
column 
FA -0.22 0.15 0.26 * 
MD 0.14 -0.11 -0.34 ** 
RD 0.22 -0.13 -0.33 ** 
AD -0.01 -0.02 -0.11 
Posterior 
column 
FA -0.47 *** 0.25 * 0.35 ** 
MD 0.36 ** -0.24 * -0.44 *** 
RD 0.51 *** -0.27 * -0.44 *** 
AD 0.06 -0.03 -0.12 
Grey matter FA -0.27 0.25 * 0.25 * 
MD 0.37 ** -0.40 *** -0.52 *** 
RD 0.46 *** -0.42 *** -0.52 *** 
AD 0.16 -0.19 -0.19 
 
Table 9.3 Univariable correlations (r values presented) between DTI metrics 
and physical disability, significant correlations are highlighted in bold font: * p < 
0.05; ** p < 0.01; *** p < 0.001. (EDSS: expanded disability status scale, 25ft TWT: 
25 foot timed walk test, 9-HPT: 9 hole peg test) 
 
 
248 
 
  Pyramidal 
functional 
system 
Sensory 
functional 
system 
Bowel 
and 
bladder 
functional 
system 
ASIA 
motor 
ASIA 
sensory 
Lateral 
column 
FA -0.16 -0.21 -0.34 ** 0.20 0.15 
MD 0.18 0.06 0.21 -0.19 0.01 
RD 0.20 0.17 0.36 ** -0.23 * -0.10 
AD 0.05 0.01 0.04 -0.03 0.05 
Posterior 
column 
FA -0.39 *** -0.34 ** -0.45 *** 0.31 ** 0.22 * 
MD 0.34 ** 0.26 * 0.39 *** -0.28 * -0.16 
RD 0.41 *** 0.34 ** 0.48 *** -0.34 ** -0.21 
AD 0.02 -0.05 0.02 -0.02 0.02 
Grey 
matter 
FA -0.30 ** -0.26 * -0.29 ** 0.24 * 0.21 
MD 0.40 *** 0.18 0.34 ** -0.32 ** -0.06 
RD 0.45 *** 0.26 * 0.42 *** -0.36 ** -0.16 
AD 0.17 -0.01 0.14 -0.12 0.09 
 
Table 9.4 Significant univariable correlations between DTI metrics and physical 
disability. Significant correlations are highlighted in the table in bold font: * p < 
0.05; ** p < 0.01; *** p < 0.001. (ASIA: American spinal injury association) 
 
9.3.6 Independent associations with physical disability 
In confirmation of the second hypothesis being investigated, significant 
independent associations were seen with GM RD (coefficient = 0.33, p < 0.01, 
95% CI 0.89, 1.92) and EDSS. Cord area (coefficient = -0.45, p < 0.01, 95% CI -
0.13, -0.07) was also independently associated with EDSS (R2 = 0.77). No 
independent associations were seen with the brain MRI measures (i.e. T2LV and 
BPF) included in this model. 
Further confirmation of our hypothesis that spinal cord GM would be associated 
with disability, was seen in the independent association with the 9-HPT and GM 
RD (coefficient = -0.33, p < 0.01, 95% CI; -1.14, -.36). UCCA (coefficient = 0.35, p < 
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0.01, 95% CI; 0.02, 0.06) and BPF (coefficient = 0.24, p = 0.02, 95% CI 2.15, 
27.36) were also independently associated with the 9-HPT (R2 = 0.57). 
Spinal cord GM RD (coefficient = -0.20, p = 0.04, 95% CI -0.32, -0.47) and UCCA 
(coefficient = 0.29, p < 0.01, 95% CI 0.04, 0.21) were both independently 
associated with the TWT (R2 = 0.42). 
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9.4 Discussion 
This is the first MRI-DTI study to investigate the spinal cord in a cohort that 
included both CIS and relapse-onset MS patients. It investigated both cord GM 
and WM and found that a DTI measure of GM microstructural integrity (RD) was 
independently associated with disability. 
9.4.1 Spinal cord grey matter findings 
In a post mortem study in progressive MS more than 40% of the upper cervical 
cord GM exhibited demyelination, which was greater than the proportion of WM 
demyelination (Gilmore et al., 2006). Reduced counts of neurons and 
interneurons also have been reported in areas of GM demyelination (Gilmore et 
al., 2006), along with inter-neuronal atrophy in lesions and normal appearing 
GM. 
The cord GM is a more anatomically complex structure than the WM and should 
be less anisotropic. Accordingly it should display a lower FA and AD and a higher 
RD, as was the case in our healthy controls.  
Previous studies in WM tracts have shown associations between DTI and 
pathological abnormalities, the former exhibiting reduced FA and increased RD 
and MD and the latter displaying demyelination and neuroaxonal loss 
(Schmierer et al., 2007; Zhang et al., 2009; Klawiter et al., 2011; Zollinger et al., 
2011). The same DTI abnormalities were observed in this in vivo study of cord 
GM and although such changes are not likely to be specific for any single 
pathological feature, it is plausible that they are a consequence of demyelination 
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and/or neuronal loss. In previous studies, AD abnormalities have been 
associated with acute axonal loss (Budde et al., 2009) and following a spinal cord 
relapse (Freund et al., 2010); the exclusion of subjects having a recent relapse 
may account for the absence of AD abnormalities in our study. 
The clinical spectrum of our cohort is broad (from CIS to SPMS) and the findings 
in this present study indicate that pathological involvement of the cord GM is 
already present in early relapse-onset MS (CIS and RRMS) but is more severe, 
with abnormalities being greatest, in SPMS. 
Pyramidal, sensory and sphincter deficits in MS are generally attributed to 
pathology in the spinal cord WM tracts and little consideration has been given to 
whether GM involvement may contribute. However, the descending motor tracts 
in the spinal cord terminate in the dorsal horn, where they synapse with 
interneurons and in turn with anterior horn cells (Williams and Warwick 1980). 
The spinal cord GM also contains interneurons between sensory and motor 
tracts. It would seem plausible that pathology in the cord GM could affect motor, 
sensory and sphincter function. 
Only two studies have investigated DTI metrics in cord GM and these were 
confined to RRMS patients, most of whom had low disability (Hesseltine et al., 
2006; Raz et al., 2013). These studies either sampled a small region in the 
anterior horn (Raz et al., 2013) or a central cord region that included both GM 
and WM (Hesseltine et al., 2006). This present study is the first to have 
segmented the whole cord, whilst also excluding WM as far as possible within 
the limits of image resolution. This approach, combined with the inclusion of 
both RRMS and SPMS patients, should have facilitated the detection of a 
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significant association of GM microstructural abnormalities with functional 
impairment.  
The functional importance of cord GM pathology is suggested by a GM parameter 
(RD) being the only DTI measure to be independently associated with EDSS. 
Together, cord atrophy (which is already well-known to correlate with disability 
[Losseff et al., 1996]) and abnormal GM RD findings accounted for 77% of the 
variance of EDSS in a regression analysis. GM RD was also independently 
associated with the 9-HPT and TWT. Pathological studies suggest that although 
RD is not specific, it is sensitive to myelin and/or neuroaxonal damage (Klawiter 
et al., 2011; Zollinger et al., 2011); this may explain why RD emerged as the sole 
DTI predictor of disability in the regression model. Interestingly, RD has 
previously been correlated with recovery of clinical function following relapses 
affecting the spinal cord (Freund et al., 2010) and optic nerves (Naismith et al., 
2010). 
Neuropathological studies of the brain in MS have identified extensive GM 
abnormalities (Peterson et al., 2001; Bø et al., 2003; Wegner et al., 2006); 
however, there has been relatively little investigation of spinal cord GM 
involvement. Noting the significance of cortical GM abnormalities, the potential 
functional eloquence of the cord GM, and our new DTI findings that link cord GM 
abnormalities to disability and SPMS, further investigation of the nature of cord 
GM involvement in MS would seem worthwhile. 
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9.4.2 Spinal cord white matter findings 
 
Similar to previous reports (Hesseltine et al., 2006; Freund et al., 2010; Raz et al., 
2013), abnormalities of FA, RD and MD were recorded in the posterior and 
lateral columns in RRMS. However, this study extends previous ones: showing 
abnormalities detectable in the lateral columns at presentation with a CIS, and 
increasing abnormalities across the three clinical subgroups. The increase was 
more evident in posterior columns, with significant differences seen between 
RRMS and SPMS.  
Greater microstructural abnormality in the posterior columns in SPMS may help 
explain the stronger univariable correlations with disability than was seen for 
lateral column DTI measures (Table 9.3). Significant associations – albeit modest 
– were also seen between measures of sensory function and posterior column 
DTI measures only (Table 9.4). Posterior column pathology with deafferentation 
could affect balance and mobility thereby contributing to the associations 
observed. 
The more limited associations of lateral column DTI measures with disability 
may have several explanations. First, although the pyramidal tract travels 
through the lateral columns, it may be affected by pathology at other levels in the 
cord, brain stem or cerebral hemispheres. Secondly, involvement of non-
pyramidal motor tracts, such as cerebellar pathways, could contribute to 
impaired motor function.  
 
 
254 
Thirdly, while DTI investigates the microstructure of residual tissue, it does not 
account for tissue loss and we found that global spinal cord atrophy was 
independently associated with disability. A previous post mortem study reported 
that spinal cord atrophy in MS was due to loss of cord WM, with relative 
preservation of GM volume (Gilmore et al., 2005). It would be of interest to 
investigate cord WM and GM tissue volumes in future work. 
9.4.3 Study limitations 
A number of study limitations are recognised. First, it did not investigate 
longitudinal changes in spinal cord DTI abnormalities and future studies are 
needed to elucidate the evolution of imaging measures and their relationship to 
changes in clinical course and function. 
Secondly, as lesions were not visible on DTI, it was not possible to investigate 
whether abnormalities arose from lesions and/or normal appearing cord. While 
it is nevertheless possible that lesions had a subtle influence on the segmentation 
of the spinal cord GM, in all cases it was possible to readily visualise the GM on 
the optimised average diffusion-weighted image. The image analysis performed 
on the lower resolution diffusion weighted images may be considered a 
somewhat circular approach and has the potential to include partial volume 
effects in the regions analysed. However, in the present study it was not possible 
to establish a satisfactory registration of the 3D-PSIR to the non-diffusion-
weighted EPI-ZOOM images (b = 0), due to a lack of anatomical details. In future, 
it may be possible to co-register high resolution anatomical images sensitive to 
lesions, with the DT images to investigate the effect of spinal cord lesions on DTI 
and further improve cord segmentation. 
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Thirdly, the study was limited to the upper cervical cord. This level is less 
susceptible to distortion or artefact related to physiological motion and has also 
been investigated in previous DTI studies in MS (Hesseltine et al., 2006; Freund 
et al., 2010; Raz et al., 2013). Furthermore, the spinal cord is frequently affected 
by MS at this level (Oppenheimer et al., 1978) and may therefore be 
representative of the cord in general. 
Lastly, the EDSS may be affected by MS involving systems other than spinal cord, 
e.g., brain stem and cerebellum. However, it remains a ‘gold standard’ in MS, and 
the importance of spinal cord GM involvement is reinforced by correlations of 
GM DTI measures with specific measures of pyramidal, sensory and sphincter 
function (Table 9.3). Notwithstanding, future studies could include more 
quantitative and sensitive measures of sensory and motor function (Oh et al., 
2013). 
9.4.4 Conclusions 
In this DT imaging study, marked microstructural abnormalities were found in 
the spinal cord GM in SPMS compared to RRMS. A combination of abnormal cord 
GM tissue microstructure and global cord tissue loss explained 77% of the 
variation in the widely used EDSS disability scale. GM pathology in the spinal 
cord may contribute to developing SPMS and irreversible disability. Future 
studies in MS should investigate longitudinal changes in spinal cord GM DTI 
measures and the relationship with evolving clinical status. 
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Chapter 10 - Summary 
This thesis uses in vivo MR imaging on a 3 Tesla scanner to explore the 
pathology of MS in the spinal cord as well as the relationship between spinal 
cord abnormalities and physical disability. The results demonstrate that both 
macro and micro-structural abnormalities may be visualised using high field MRI 
and have significant independent contributions to physical disability. Specific 
findings of the thesis will now be discussed in turn. 
 
10.1 Atrophy 
The relevance of spinal cord atrophy in long disease duration MS is explored in 
chapter four. Using a regression analysis spinal cord atrophy emerged as being 
significantly associated with the use of a walking aid (EDSS ≥ 6) and a higher 
EDSS score i.e. significantly higher levels of physical disability. These results 
emphasise the importance of using a combination of spinal cord and brain 
imaging in clinical trials, where MRI may be used as a primary or secondary 
endpoint.  
However, as the spinal cord is a small mobile structure with minimal discernible 
anatomical landmarks, the inclusion of cord atrophy as a potential endpoint to 
clinical trials poses numerous technical challenges. In chapter five alternative 
combinations of sequences and methodologies were investigated to determine a 
more reproducible method of cord area measurement to those currently 
available. In this chapter the semi-automated edge finding technique (Losseff et 
 
 
257 
al., 1996) was compared to the active surface model (ASM) (Horsfield et al., 
2010). The combination of the ASM with phase sensitive inversion recovery 
(PSIR) imaging proved to be the most reproducible method of cord area 
measurement (Reproducibility expressed as coefficient of variation [COV]: intra-
rater COV 0.002%, inter-rater COV 0.03%, scan re-scan COV 0.1%). 
To evaluate the possibility of using cord atrophy in a clinical trial in MS, sample 
sizes were calculated based on the between-subject mean standard deviation of 
the mean spinal cord cross-sectional area of 15 MS patients’ baseline scan. The 
combination of PSIR and ASM required the smallest sample size for a trial, using 
cord atrophy as an endpoint. These data suggest that it may be feasible to include 
this MRI parameter in future trials of neuroprotection in MS. 
10.2 Lesions 
As spinal cord lesions may also be visualised, as well as atrophy, on gross 
pathology (Opppenheimer 1979; Fog 1950), cord lesions were also investigated 
in this thesis. To identify high resolution axial sequences that could accurately 
identify the anatomical location of spinal cord lesions, a pilot study was 
performed firstly in a small group of people with MS. The results of this pilot 
study indicate that fast field echo (FFE) and phase sensitive inversion recovery 
(PSIR) images in combination may be useful in recording the presence and 
columnar involvement of spinal cord lesions. 
Having established the utility of these two sequences in the pilot study, these 
sequences were then employed in the upper cervical cord of the whole cohort of 
CIS and MS patients studied in this thesis. In order to accurately record the 
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differences in lesion morphology between relapsing remitting and progressive 
MS, a classification system of spinal cord lesions detected on axial images, is 
proposed in this chapter six. Furthermore, the presence of diffuse abnormalities 
was also recorded (not previously done in the pilot study). 
The results of this chapter suggest that larger, more extensive lesions, involving 
a greater number of WM columns, are more common in progressive MS 
compared to the relapsing remitting subtype. In agreement with the existing 
literature on spinal cord imaging (Lycklama à Nijeholt et al., 1998), diffuse 
abnormalities were found more commonly in progressive MS. The spinal cord 
columnar involvement was also found to be in agreement with early post mortem 
studies of the spinal cord (Opppenheimer 1979; Fog 1950) indicating that the 
lateral and posterior columns are frequently involved by spinal cord lesions.  
The results of this chapter suggest that spinal cord lesion morphology may be 
accurately characterised using high resolution axial imaging. However, it is 
important to emphasise the caveat that the scanning protocol implemented in 
this study would be too long to use in clinical practise. Therefore, a number of 
technical modifications would be required to reduce the scanning time 
(alternative sequences, higher field strength or different acquisition protocols) 
before this approach could be used more routinely. 
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -- - -- - - - - - - - - - - - - - - - - - - - - - - -  
Spinal cord pathology in MS results in a number of histopathological 
abnormalities including inflammation, gliosis, demyelination and axonal loss 
(Oppenheimer 1979; DeLuca et al., 2006; Tallantyre et al., 2009). Through the 
use of quantitative MRI, histopathological abnormalities were investigated in 
this thesis. 
10.3 Lesion load 
In part two of chapter six, spinal cord lesion morphology and location are 
investigated; however, this approach did not investigate the volume of the 
lesions seen. Therefore, the subsequent chapter seven, utilised a quantitative 
approach to measure spinal cord lesion load, analogous to that used in post 
mortem studies (Evangelou et al., 2005; DeLuca et al., 2006), by individually 
circumscribing all the lesions detected on the PSIR scan. In addition the 
magnetisation transfer ratio (MTR) was measured in both normal appearing and 
lesional spinal cord. 
The main result of this chapter is that spinal cord lesion load in the upper 
cervical cord was associated with physical disability independently from spinal 
cord atrophy. These two MRI parameters in combination explained 56% of the 
variance in EDSS in this cohort. These data also demonstrated modest 
associations between tissue integrity, measured by MTR and physical disability. 
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10.4 Meningeal and subpial abnormality (MTR) 
Chapter eight also used MTR imaging of the spinal cord. However, in this 
instance it was used to investigate a concept that has arisen in brain studies 
suggesting that meningeal inflammation is associated with subpial 
demyelination and progressive MS (Magliozzi et al., 2010; Lucchinetti et al., 
2011). Meningeal inflammation in the spinal cord has also been reported to be of 
importance in the pathophysiology of MS through its association with axonal loss 
(Androdias et al., 2010; DeLuca et al., 2013). However, these post mortem 
findings have not been previously investigated in vivo. 
High resolution axial imaging was acquired in the upper cervical cord and the 
outermost region of the cord (thought to contain the pia mater and subpial white 
matter) was extracted to compare MTR values in this and the deeper white and 
grey matter. Significant higher MTR was measured in the outer spinal cord 
compared with deeper white matter in healthy controls, suggesting that the 
outermost region of the cord may be composed of different tissue types to the 
white matter, possibly reflecting collagen in pia mater. The MTR values in the 
outermost region were significantly lower in all patient subtypes (including 
clinically isolated syndrome [CIS] and MS) compared to controls. As MTR values 
were lower in CIS, these data suggest that early inflammation/demyelination 
may occur in the outermost region of the spinal cord. 
The association between outer spinal cord inflammation and axonal loss was 
then explored via a regression analysis. A significant independent association 
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was seen between outer cord MTR (putative marker of meningeal inflammation 
and subpial demyelination) and cord atrophy (used as a marker of axonal loss), 
in agreement with previous pathology studies of the spinal cord (Androdias et al., 
2010; DeLuca et al., 2013). 
 
10.5 Grey matter (DTI) 
Pathological studies in progressive MS have also reported extensive grey matter 
pathology in the spinal cord (Gilmore et al., 2006; Gilmore et al., 2009). However, 
the functional effects of spinal cord grey matter involvement have not been fully 
elucidated. In chapter 9, diffusion tensor imaging (DTI) was used to investigate 
spinal cord grey matter abnormalities and their association with disability and 
secondary progressive MS. 
The DTI metrics investigated in the spinal cord grey matter (fractional 
anisotropy, mean diffusivity and radial diffusivity) displayed significantly more 
abnormalities in secondary progressive MS compared to relapsing remitting MS 
and CIS. Furthermore, radial diffusivity (RD) of the spinal cord grey matter was 
independently associated with a number of measures of physical disability. A 
combination of cord atrophy and grey matter RD explained 77% of the variation 
in EDSS. These results indicate the spinal cord grey mater pathology may be of 
importance in the development of secondary progressive MS and irreversible 
physical disability. 
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10.6 Future questions 
This thesis explores a number of facets of spinal cord involvement in MS. 
However, it also raises questions that would be of interest to address in future 
studies of the spinal cord. The cross-sectional nature of this study precluded 
observation of the temporal dynamics of the MRI abnormalities accrued in the 
spinal cord. A longitudinal study could potentially address the relationship 
between an increasing number of spinal cord abnormalities detected on MRI 
(such as an increase in lesion load) and an increase in fixed disability. It will be 
especially relevant to investigate whether abnormal outer cord MTR (suggesting 
meningeal inflammation) predicts subsequent atrophy (implying axonal loss). 
This thesis also implemented multi-modal imaging of the spinal cord with an 
overall scan time that would preclude implementation in its entirety in clinical 
practise to manage individual patients. Technological alterations, such as higher 
field strength or alterations in the scan acquisition could potentially shorten the 
scanning protocol or parts thereof, thereby facilitating its future implementation. 
The methods developed in this thesis could, however, already be applied in the 
setting of a clinical trial with a standardised and quality-controlled protocol, 
where they could provide outcome measures for investigating therapies aimed at 
preventing spinal pathology. 
The coverage of the spinal cord was restricted to the upper cervical spinal cord 
in this thesis, therefore, the functional effects of spinal cord abnormalities in 
lower segments of the cord were not investigated and it may be of interest to do 
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so e.g. a quantitative MRI study of the thoraco-lumbar spinal cord in order to 
investigate the relationship between bladder dysfunction and cord pathology. 
The measures of physical disability used were largely confined to the expanded 
disability status scale (EDSS) and MS functional composite (MSFC). Although the 
EDSS and MSFC scales confer the advantage of being familiar, from their 
implementation in clinical trials, neither scale is specific for spinal cord function. 
Previous quantitative MRI studies have implemented disability measures that 
were specific for spinal cord function, such as vibration sense and hip or foot 
flexion strength (Zackowski et al., 2009; Oh et al., 2013). Sensitive measures of 
spinal cord function, such as these, may provide additional valuable information 
in future studies. 
Lastly, this thesis was confined to in vivo imaging of the spinal cord and did not 
address the pathological correlates of the abnormalities identified. An ex vivo 
study could directly investigate the relationship between the MRI abnormalities 
detected and spinal cord pathology. 
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10.7 Conclusions 
The use of multi-modal imaging in the spinal cord in this thesis has provided 
insights into the pathology of MS in this clinically eloquent structure, as well as 
demonstrating the contribution of spinal cord abnormalities (both macro and 
micro) to physical disability. Through the use of different regression analyses, 
independent contributions of spinal cord abnormalities to commonly used 
measures of physical disability (such as EDSS) were identified. Overall, these 
results suggest an emerging and important potential role for in vivo spinal cord 
MRI in future clinical trials in MS where physical disability is used as a primary 
outcome measure. 
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